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Abstract 
 
CD8+ T cells play a vital role in the immune system by clearing pathogen-infected 
tissues, however self-reactive CD8+ T cells that escape thymic selection pose the 
danger of causing autoimmune disease. These self-reactive CD8+ T cells are 
controlled in the periphery by tolerance mechanisms, which inhibit their function 
(anergy) or induce apoptosis (deletion). However, the specific molecular pathways 
crucial for negatively regulating self-reactive CD8+ T cells are not well elucidated. A 
distinct form of negative regulation called “exhaustion” occurs within chronically 
stimulated effector CD8+ T cells during cancer and chronic infection. Due to the 
phenotypical similarities between CD8+ T cell tolerance and exhaustion, we aimed to 
understand if common underlying molecular pathways regulate these states.  
 
The pro-apoptotic protein BIM is important in deletion of self-reactive CD8+ T cells, 
however the transcriptional control of Bim induction has been unclear. In Chapter 2, 
we assessed the contribution of the transcription factor FOXO3 in deletion of self-
reactive CD8+ T cells given its role in Bim induction and cell death in effector and 
exhausted CD8+ T cells. While FOXO3 protein underwent activatory 
dephosphorylation during tolerance, FOXO3-deficient CD8+ T cells maintained the 
ability to induce BIM expression and undergo deletion. This result indicated that 
FOXO3 plays distinct roles in cell death of tolerant versus effector CD8+ T cells.  
 
To further characterise CD8+ T cell tolerance pathways, in Chapter 3, we 
investigated whether the ubiquitin ligase adaptor NDFIP1, which is crucially required 
for CD4+ T cell anergy, influences CD8+ T cell tolerance. In a model of peptide-
induced anergy, Ndfip1-deficient CD8+ T cells aberrantly expanded and 
differentiated into effector cells against high dose exogenous antigen, likely driven 
by increases in TCR signaling. In contrast, NDFIP1 was dispensable for peripheral 
deletion to low-dose exogenous antigen, and had little impact upon effector 
responses to acute infection.  These results showed the importance of NDFIP1 in 
regulating CD8+ T cell tolerance and indicated that CD8+ T cell deletion and anergy 
are molecularly separable checkpoints. 
  
 ix 
While CD8+ T cell exhaustion appears distinct from tolerance, the transcriptional 
regulator EGR2 is commonly expressed between these states. In Chapter 4, we 
showed that exhausted CD8+ T cells in chronic LCMV infection expressed elevated 
levels of EGR2 compared to functional effectors. Loss of Egr2 severely disrupted 
terminal CD8+ T cell exhaustion in a cell intrinsic manner, with RNA-Seq results 
indicating a global enrichment of the exhaustion “stem cell” gene set in Egr2-deficient 
cells. Strikingly, the genes regulated by Egr2 during exhaustion appeared distinct 
from those controlled by Egr2 during T cell tolerance, suggesting that EGR2 is 
repurposed during T cell exhaustion.  
 
These findings indicate that while there is molecular overlap between CD8+ T cell 
tolerance and exhaustion, shared proteins may differ in their mechanism of action. 
Such insight into the differences between tolerance and exhaustion checkpoints is 
important for refining future immunotherapies against cancer and autoimmune 
diseases. 
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CHAPTER 1: INTRODUCTION 
 
1.1: CD8+ T cell biology  
 
1.1.1: Overview of the immune system 
Living organisms have evolved to thrive in challenging external environments. A key 
factor for survival is the ability to protect oneself against pathogens or harmful 
microorganisms. Defense mechanisms collectively known as the organism's immune 
system have been evolving from the beginning of life. For successful protection, the 
immune system must be able to detect potential pathogens in the environment and 
mount an appropriate response against the pathogen. 
 
The immune response of multicellular animals is multilayered and broadly classified 
into two arms - the innate and the adaptive immune systems. Each system consists 
of a network of cell types, which coordinate to recognise and combat pathogens. At 
the molecular level, immune cells express receptors to recognise conserved 
pathogen-associated molecular structures, as well as molecular moieties called 
antigens. When activated against a pathogenic antigen, the immune system 
generates an effective response to eliminate the pathogen through diverse cytotoxic 
and neutralizing mechanisms.  
 
The immune system, however, can often be a double-edged sword, as dysregulated 
responses generated downstream of infection can also harm host tissues. Hence, 
regulation of immune responses through molecular checkpoints is crucial to generate 
a balanced and optimal response against the pathogen whilst limiting damage to host 
tissues due to excessive inflammation or inappropriate host-directed responses. If 
the response is unrestrained, this can harm the host in the form of immunopathology 
and autoimmune disease. On the other hand, excessive or prolonged dampening of 
the response can allow persistence of chronic infections and cancers. Therefore, 
understanding the molecular checkpoints that control this balancing act is important 
for the development of better therapeutics against immune-mediated diseases.   
 
 2 
The innate immune system 
In most organisms, the first line of defense includes physical barriers such as the skin 
and mucosal membranes, which limit entry of pathogens into the body. Upon breach 
of these barriers, multiple cell types forming the "innate immune system" such as the 
epithelium and phagocytes can be immediately activated due to their strategic 
location near these physical barriers. The innate immune system is crucial for rapid 
pathogen recognition and limiting pathogen spread. Phagocytes of the innate 
immune system comprise Dendritic Cells (DCs), macrophages and granulocytes, 
including neutrophils, eosinophils, and basophils. These cells are equipped with 
pattern recognition receptors (PRRs) to detect conserved pathogen-associated 
molecular patterns (PAMPs) such as bacterial cell wall components and viral nucleic 
acids (1). Activation of the PRRs leads to the generation of effector functions in the 
innate immune cells, such as the production of cytokines, degranulation of toxic 
molecules and phagocytosis. The latter allows the innate immune cells to ingest 
pathogens or infected cells with the aim to degrade the pathogen. This also enables 
"presentation" of pathogenic antigens on the surface of certain innate immune cells, 
which are classified as antigen presenting cells (APCs) (2). APCs are equipped with 
the task of processing pathogen-associated proteins in the phagosome and “present” 
pathogen-derived peptide fragments on their cell surface for recognition by cells of 
the adaptive immune system. Hence the innate immune system is vital for both quick 
responses to infection, and activation of the adaptive immune system through the 
production of cytokines and the presentation of antigen by APCs. However, it has 
multiple drawbacks, which necessitate the requirement for the adaptive immune 
system.  
 
First, while PRRs comprise of multiple receptor families recognizing many classes of 
pathogens, they cannot distinguish between the various strains of viruses, bacteria or 
parasites (1). This poses a disadvantage in the defense mechanisms as a similar 
response is generated against potentially diverse types of infections caused by 
different pathogen strains. The lack of specificity in the functioning of the innate 
immune system creates the need for a more sophisticated system of antigen 
recognition. The second drawback of the innate immune system lies in its limited 
ability to improve responses against previously encountered pathogens. While the 
rapid kinetics of the innate immune system is crucial in limiting the spread of the 
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infection, in most cases the level of response generated against previously 
encountered pathogens does not change. This is an evolutionary disadvantage in the 
arms race against rapidly evolving pathogens. These factors potentially contributed 
to the development of the adaptive immune system in vertebrates. 
 
The adaptive immune system 
The adaptive immune system responds to specific molecular antigens and, hence, 
can confer pathogen-specific life-long protection or “immunity”. Greek philosopher 
Thucydides was the first to observe and record the features of adaptive immunity in 
the Athens plague of 430 B.C. In The History of the Peloponnesian War, he 
commented, “the same man was never attacked twice - never at least fatally” (3). 
The adaptive immune system consists of cells called lymphocytes that possess 
highly specialized antigen recognition capacity.  
 
Macfarlane Burnet theorized about the nature of antigen recognition in lymphocytes 
in his clonal selection theory (4). He correctly hypothesized that lymphocytes carried 
highly varied receptors, allowing them to detect an unlimited range of antigen 
specificities. Each lymphocyte was proposed to be a unique “clone” that would carry 
a unique genetically encoded receptor sequence that could be inherited by all 
daughter cells of this clone. Burnet correctly postulated that the clones recognizing a 
certain antigen would be selected by specific antigen binding to undergo rapid 
proliferation and form a clonal army to combat that specific antigen. While the 
selection of the correct clone against an antigen requires many days due to the low 
frequency of lymphocyte receptors specific for a given antigen (5,6), the responses 
generated are highly specific towards the pathogen at hand. Furthermore, some of 
the activated lymphocyte clones have the ability to survive past pathogen clearance 
as memory cells that can reactivate rapidly upon reinfection, providing highly specific 
lifelong protection against the pathogen. Given these advantages, it is not surprising 
that the majority of pathogen infections that escape initial innate immune control are 
successfully eradicated by lymphocytes. The importance of these cells is highlighted 
in patients with Severe Combined Immunodeficiency (SCID) that lack lymphocytes 
and succumb to severe and persistent viral and bacterial infections (7). Hence, the 
adaptive immune system makes up for the drawbacks of the innate system through 
the highly specific and long lasting protection it endows on the host. However, this 
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specialised system has its own disadvantages.  
 
The nature of antigen recognition by the variable lymphocyte receptors is dependent 
on the chemical bonds formed between the antigen and the receptor, which 
determine the “affinity” of the interaction (8,9). Unlike the PRRs on innate immune 
cells, lymphocyte antigen receptors do not inherently recognise fixed molecular 
structures from bacterial cell walls or viral nucleic acids. This is because the unique 
lymphocyte receptor sequences are generated through randomized gene 
recombination events (10) as opposed to PRRs, which have conserved sequences. 
However, the diversity of lymphocyte receptor specificities thus generated can 
recognise any molecular moiety of a certain affinity regardless of whether they are 
host- or pathogen-derived, posing a risk of generating responses against self-tissues. 
Why does the immune system allow for the stochastic formation of lymphocyte 
receptors if it implies that the system has an equal chance of harming the host it has 
evolved to protect? The answer likely lies in the evolutionary advantage of a highly 
variable structure. The vast repertoire that randomized gene recombination provides 
outweighs the risk of generating self-specificities. Furthermore, the immune system 
employs multiple safeguards to mitigate the risk posed by self-reactive cells. First, 
the majority of lymphocytes bearing "self" specific receptors are either deleted from 
the repertoire, or functionally inactivated, via multiple immune "tolerance" processes 
(11) (described in the next section). Second, activation of adaptive immune cells 
typically requires signals from innate immune cells that are only produced upon 
innate immune recognition of an active infection, thus preventing the activation of 
self-reactive adaptive immune cells that may otherwise occur in the absence of 
infection (1). Lastly, the activation of lymphocytes is a multi-step process with each 
step stringently controlled by molecular networks acting as checkpoints to ensure 
lymphocytes are only activated against infectious stimulus (12,13). In this way, the 
immune system is able to usually keep any rogue self-reactive cells under control 
and limit their damage to the host. 
 
Lymphocyte subsets 
Lymphocytes of the adaptive immune system can be divided into two main subsets 
called B cells and T cells, which are armored with rearranged B Cell Receptors 
(BCRs) and T Cell Receptors (TCRs) respectively. While B cells and T cells are both 
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subjected to self-tolerance processes, their activation pathways are distinct due to 
differences in the structures of their lymphocyte receptors and hence the nature of 
the antigen that they recognize. B cells develop in the bone marrow and recognise 
native extracellular antigenic structures through their BCRs, such as repeating 
carbohydrates or intact proteins. Upon activation during an infection, pathogen-
specific B cells can secrete their BCR as soluble proteins, known as antibodies, 
which can bind to the pathogen and induce multiple downstream effector responses 
to promote pathogen clearance. Hence B cells are crucial in clearing pathogens from 
the host circulation, however they are less effective at targeting intracellular 
pathogens residing in the cytoplasm of infected cells. 
 
T cells detect and control intracellular infections through recognition of their specific 
antigens: small peptide fragments derived from proteins within the cell. In the 1970s, 
Doherty and Zinkernagel discovered that the TCR was in fact restricted to recognise 
antigen presented by the Major Histocompatibility Complex (MHC) molecules (14). 
Following this discovery, it was established that T cells carried either a CD4 or CD8 
co-receptor to stabilize their interactions with MHC Class II (“MHC II”) and MHC 
Class I (“MHC I”) molecules respectively (15,16). These MHC molecules differ in their 
expression patterns and the nature of the peptide antigen presented in their grove. 
MHC II is almost exclusively expressed on APCs and usually presents extracellular 
phagocytized peptide antigens of typically 10-12 amino acids (2). MHC I, on the other 
hand, is expressed on most of the body’s cells and typically presents peptide 
antigens of 8-10 amino acids from intracellular pathogens or proteins (17). This 
dichotomy reflects the different functions of the responding CD4+ and CD8+ T cells.  
CD4+ T cells, known as “helper T cells”, are a highly variable subset, which regulate 
the function of B cells and CD8+ T cells through secretion of cytokines and 
expression of immunoregulatory cell surface receptors. CD8+ T cells, or "killer T 
cells", are the primary responders against intracellular infections and have the ability 
to directly kill pathogen-infected cells. As CD8+ T cells comprise the subject of this 
thesis, the remainder of the introduction will focus on this cell type. 
 
The function of CD8+ T cells requires access to most body cell types that could be 
infected, and hence these cells have evolved to recognise the intracellular peptides 
presented on MHC I. MHC I constitutively presents peptides typically derived from 
 6 
self and foreign proteins processed by the proteasome within the cell. Thus, the 
continuous presentation of peptides on MHC I allows CD8+ T cells to survey the 
dynamic intracellular proteome within a target cell and scan for potential pathogen-
derived peptides. Upon activation, CD8+ T cells produce cytotoxic enzymes called 
granzymes and the pore-forming toxin perforin, which are both released upon antigen 
recognition on an infected target cell to initiate programmed cell death or apoptosis. 
This cytotoxic machinery, along with other factors such as cytokines and death 
receptors, allows the activated CD8+ T cells to directly kill pathogen-infected cells. 
For this reason, activated CD8+ T cells are known as Cytotoxic T lymphocytes (CTLs) 
(18).  
 
While CD8+ T cells are crucial in clearing intracellular pathogens, they can cause 
bystander tissue damage and also have the power to recognise endogenous self-
antigens presented on MHC I. Thus, if inappropriately activated, CD8+ T cells have 
the potential to cause high levels of damage to host tissue. For instance, self-reactive 
CD8+ T cells can cause autoimmune disease by inappropriately targeting uninfected 
self-tissue independent of the presence of infection (19). Additionally, pathogen-
specific CD8+ T cells can fatally damage whole organs during widely disseminated 
infections if their activity is not restrained (20–22).  Hence regulation of CD8+ T cell 
activation by molecular checkpoints is vital to ensure optimal responses are 
generated against infection with minimal damage to the host. Exploring these 
molecular checkpoints in CD8+ T cell biology is the central aim of this thesis. 
However, in order to understand the pathways that limit CD8+ T cell immunity, it is 
important to first delineate the molecular pathways involved in the activation and 
differentiation of a functional CTL response.  
 
1.1.2: CD8+ T cell activation and differentiation  
Prior to activation, the repertoire of CD8+ T cell clones continuously circulates 
between the blood and lymphoid organs in a "naïve" state. In this state, the cells are 
non-proliferative, metabolically quiescent, lack immune effector functions and cannot 
migrate into peripheral tissues. Instead, naïve cells are restricted to trafficking to the 
lymphoid organs through the expression of specific homing molecules, such as L-
Selectin (CD62L), which allows them to bind to the high endothelial venules in 
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lymphoid tissues (23). Naïve T cells receive homeostatic survival signals from 
frequent low avidity interactions with self-MHC and through the cytokine interleukin-7 
(IL-7), which binds to the IL-7R expressed by naïve cells (24,25). Naïve CD8+ T cells 
do not acquire effector functions by default, and in the case of an infection must be 
provided with the correct signals for their activation by innate immune cells. Complete 
activation of CD8+ T cells requires extrinsic signals from the innate immune system, 
which are then integrated intrinsically within the T cells to enable effector cell 
differentiation.   
 
T cell activation by DCs 
Activation of naïve CD8+ T cells first requires activation of innate immune cells by the 
invading pathogen. While B cells and macrophages can also act as APCs, it was 
shown in mixed leukocyte reactions that DCs are the most potent stimulators of T cell 
activation (26). Named after their characteristic dendrite-like projections, DCs are the 
key APC required for activation of naïve CD8+ T cells, as they provide context-
specific activation signals to CD8+ T cells. To understand the specific role of DCs in 
contributing to the CD8+ T cell response, many genetic models were created to 
deplete DC populations in vivo, either using mice lacking the Transcription Factor 
(TF) Batf3 (27,28) or genetically expressing Diptheria toxin receptor (DTR) under the 
CD11c (29), CD205 (30) BDCA2 (31), and Clec9A (32) promoters whereby delivery 
of the Diptheria toxin would result in selective loss of DC subsets expressing the 
above genes. The resulting loss of DCs (or specific DC subsets) in the above models 
led to a defective CTL response to a variety of infection and immune challenge 
models (27–32). The reliance on DCs for CD8+ T cell activation and effector 
differentiation is due to a number of reasons such as their efficient activation in most 
infections, the unique ability to “cross-present” antigen and acting as a non-
redundant source of key cytokines such as interferons (IFN).  
 
DCs are a heterogeneous population classified according to their ontogeny and 
function (33). DCs localize in the peripheral tissue and lymph nodes where they 
patrol for the presence of pathogens and hence have early access to invading 
pathogens within most body tissues. Tissue resident DCs constitutively sample 
antigen from their localised environment and migrate from the periphery to lymph 
nodes, thereby providing naïve T cells access to antigens derived from tissue-
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restricted pathogens. This steady state migration is especially important given that 
naïve CD8+ T cells do not have access to peripheral tissues.  
 
An important feature of the immune response is the ability to mount an efficient 
response tailored to the pathogen at hand. Along with providing information on the 
antigens present within a tissue, DCs are also able to provide the T cell with 
information on the type of pathogenic infection occurring in the peripheral site. The 
signals from the specific pathogenic infection result in the activation of the DCs, 
facilitating their transition into an “immunogenic state” capable of supporting effector 
T cell differentiation during infection (34,35). Immunogenic DCs, increase their 
migration to the nearest lymph nodes to activate the adaptive immune system, 
upregulate co-stimulatory molecules and cytokine production as well as activating 
other innate immune cells during infection. Costimulatory receptors, such as CD80 
and CD86 (36,37), are upregulated after PRR activation and these play important 
roles in sending positive differentiation signals to the T cells that they interact with. 
Along with PRR stimulation, inflammatory cytokines, such as Type I interferons (IFN), 
that are produced by other innate immune cells and infected tissues can also act on 
the DCs to further boost expression of co-stimulatory receptors (38). Depending on 
the type of infection and hence specific PRR activated, DCs produce cytokines that 
can inform the adaptive system about the infection at hand. In regards to intracellular 
pathogens, bacterial infections induce IL-12 production by DCs (39,40), while viral 
infections trigger production of IL-12 as well as IFNα/β (41) – both of these signals 
are crucial for appropriate CD8+ T cell activation in these respective infections. The 
activation and signaling of PRRs also enhances sampling and endocytosis of 
pathogenic antigen by DCs, leading to more efficient antigen presentation on MHC 
molecules to the naive T cell pool (42–44). Hence, given their presence throughout 
tissues, rapid activation in infection, and ability to provide the correct activation 
signals to T cells, DCs serve as excellent activators of the immune system. However, 
they are specifically crucial for CD8+ T cell activation due to their ability to “cross-
present” antigens.  
 
CD8+ T cells need to access intracellular antigens presented on MHC I, meaning that 
DCs need to present foreign antigens on MHC I in order to activate a CD8+ T cell 
response. However, if DCs are not directly infected with a pathogen and only 
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encounter pathogenic antigen by phagocytosis, they have no obvious way to present 
foreign antigen on MHC I and induce a response. To address this dilemma, certain 
subsets of DCs are uniquely endowed with the capacity to present exogenous 
antigen on MHC I in a process called “cross-presentation” (45). This deviation from 
the classical MHC presentation pathway is crucial for activation of CD8+ T cells 
against infections and tumor antigens, which are not intracellularly expressed within 
DCs (45–47). All CD8+ DCs with XCR1 expression (commonly referred to as the 
cDC1 cells) are able to cross-present antigen to CD8+ T cells (48–50). This subset 
stems from a common lineage controlled by the TF BATF3, which is crucial for the 
differentiation of cross-presenting DCs (27,51). Deletion of BATF3 in mouse models 
led to the crippling of the CTL response due to loss of the entire cross-presenting DC 
lineage (27). To specifically test the role of cross-presentation in the activation of 
CD8+ T cells, a recent study utilised mice with deficiency in the WDFY4 protein, a 
factor required for cross-presentation. In this model, despite the presence of the 
BATF3+ DC populations, the CD8+ T cell response to tumors and virus infection was 
defective due to the inability of DCs to cross-present antigen (52). Thus, DCs are 
uniquely specialised to license a naïve CD8+ T cell for effector differentiation within 
secondary lymphoid organs. 
 
A productive outcome of the DC-T cell cross talk in the lymph nodes requires both 
recognition of specific antigen by the TCR, and concomitant interactions with multiple 
cell surface receptors and cytokines (53). These interactions largely occur at an 
organized and polarized contact point between the DC and T cell known as the 
“immunological synapse” (54). DC-T cell cross talk is a complex process which 
occurs in multiple stages (55) and the stability and duration of the contact strongly 
determines downstream T cell activation (53,56). Studies using two-photon 
microscopy have shown the importance of adhesion molecules such as ICAM-1 (57) 
as well as the abundance of antigen presented on the DC (58) in contributing to 
synapse stability and T cell differentiation into functional effectors. After formation of 
a stable synapse, the nature of interactions between the T cell and DC determine the 
outcome of the crosstalk. Co-stimulatory receptors such as CD80 and CD86 on the 
DC bind to the CD28 ligand on the surface of T cells (59). While CD28 signaling is 
highly crucial in vitro, it is often not necessary in vivo as CD28-deficient mice were 
able to mount normal CD8+ T cell effector responses to viral infection (60). Along with 
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the CD28-CD80/86 interaction, CD8+ T cells are also activated by multiple redundant 
co-stimulatory pathways, such 4-1BB-41BBL (61) as well as CD27-CD70 (62). Thus, 
multiple redundant interactions are involved in CD8+ T cell activation; this 
redundancy likely evolved as a way to reduce possible immune evasion mechanisms 
by pathogens. In addition to co-stimulatory molecules, inflammatory cytokines such 
as IL-12 (63) or Type I IFN (64) released from DCs or other cell types, in addition to 
autocrine or paracrine IL-2 produced by the nascent effector T cell response (65), 
can directly act on the responding cells to enhance effector differentiation. The 
combination of cytokine and co-stimulatory signals encountered ultimately sum to 
both trigger effector differentiation of naive CD8+ T cells and determine the 
magnitude of the effector CD8+ T cell response (66). 
 
T cell signaling  
Productive CD8+ T cell activation ultimately hinges on the capacity of CD8+ T cells to 
convert the extracellular signals received (antigen, cytokines and co-stimulatory 
signals) into intracellular signaling events that direct effector differentiation. For this 
reason, insights into the signaling events engaged during effector differentiation have 
played a crucial role in shaping our understanding of the differentiation process. The 
TCR-antigen interaction, costimulatory receptor engagement and cytokine signals all 
engage both overlapping and independent signaling cascades in the T cell that 
culminate in the activation of transcription factors. Depending on the signals 
received, the respective transcription factors work together to cause the global gene 
changes required for the transition of naïve CD8+ T cells into functional CTLs 
appropriate for the infection context. While there are numerous complex signaling 
pathways involved in T cell activation, the most relevant ones, in addition to the 
broad principles underlying signaling in T cells, are discussed below and summarised 
in Figure 1.1. 
 
Upon formation of a stable TCR-MHC complex interaction, the signaling events 
downstream of the TCR are initiated by phosphorylation of the proximal CD3ζ chains 
by the kinase LCK (67). These phosphate groups then serve as docking and 
activation sites for further kinases resulting in a cascade of phosphorylation, serving 
to amplify the initial signal. The TCR signaling cascade results in the hydrolysis of the 
membrane protein lipid Phosphatidylinositol-3 phosphate (PIP3) to generate Inositol 
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triphosphate (IP3) and Diacylglycerol (DAG) molecules (68). IP3 induces calcium-
signaling which activates the key transcription factor NFAT (69,70). Many in vitro 
experiments use calcium ionophores to activate NFAT in T cells (68,71,72), 
illustrating the dependence of this transcription factor on calcium signaling. DAG 
produced from PIP3 hydrolysis is responsible for initiating numerous pathways, and 
its function varies depending on context. One of the key functions of DAG is to 
induce Ras activation (73) and, ultimately, phosphorylation of ERK, which is a 
hallmark of TCR signaling (74,75). Importantly, ERK signaling contributes to 
activation of the TF Fos, a key component of the AP-1 TF complex that plays 
important roles in T cell activation (76) (see below). Thus, antigen signaling from 
TCR results in the induction of NFAT and Fos activity, however these pathways 
alone are not sufficient to completely activate the T cells and turn on effector genes.  
 
Co-stimulatory and cytokine signals are equally important in the activation of T cells. 
This is a key point of regulation, as it ensures that CD8+ T cell activation will only 
optimally occur in the presence of an active infection. These signals critically 
contribute to T cell activation in a number of ways. Firstly, costimulatory signals, 
along with the TCR, are important for activating the JNK pathway, which is required 
for the activation of the JUN and FOS TFs that cooperatively make up AP-1 (77). AP-
1, in collaboration with NFAT, is important for activating many key effector genes, 
including cytokines (78). Furthermore, co-stimulatory interactions induce the 
Phosphoinositide 3 Kinase (PI3K) pathway, which in turn activates the kinase Akt, 
and the mammalian Target of Rapamycin (mTOR) (79). The Akt/mTOR axis plays 
essential roles in enhancing the metabolism of the T cell by, for example, augmenting 
protein translation (80,81). This is a particularly important function of this pathway, as 
profound metabolic shifts are required to support T cell differentiation. To convert a 
CD8+ T cell from its naïve resting state to an army of effector cells loaded with 
cytotoxic machinery requires drastic changes in CD8+ T cell physiology and changes 
in cellular respiration (82). mTOR activation is crucial in enabling a metabolic switch 
in activated CD8+ T cells from using oxidative phosphorylation to aerobic glycolysis - 
an oxygen independent process which allows for effector function in hypoxic tissue 
environments (83,84). Aerobic glycolysis involves production of glycolytic 
intermediates such as pyruvate, which are used to synthesise important molecules in 
anabolic reactions, such as amino acids, phospholipids and carbohydrates (85). 
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Figure 1.1: T cell signaling during effector differentiation: Productive activation 
of naïve CD8+ T cells into effector cells requires TCR signals, cytokine signals and 
co-stimulatory signals from the immunogenic APC. This figure summarises the 
downstream pathways triggered by the different signals and the final transcription 
factors induced downstream of the signaling pathways. 
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These factors can then fuel synthesis of key effector proteins, as well as support 
growth and proliferation (86). Furthermore, mTOR signaling increases surface 
expression of glucose and amino acid transporters, which in turn allow greater 
nutrient uptake into the cell to compensate for inefficient energy generation by 
aerobic glycolysis (86,79,87,88).  
 
While TCR and co-stimulatory signals are necessary for activation of naïve CD8+ T 
cells, inflammatory cytokines secreted by the DC (and surrounding innate immune 
cells) further aid T cell differentiation into effector cells (89). The presence of IL-12 
during infection can induce expression of the transcription factor T-BET in CD8+ T 
cells by binding to the IL-12R and signaling through STAT4 (90,91). T-BET is an 
important transcription factor that contributes to the effector function of CD8+ T 
cells(90,92) and is described in detail in the following sections. Additionally 
extracellular receptor interactions that likely occur during the T cell-DC interaction, 
such as Notch signaling, also affect acquisition of effector functions by CD8+ T cells 
by controlling downstream transcription factors (93,94).  
 
Thus, the signaling events triggered by the TCR, co-stimulatory, and cytokine 
pathways, in addition to other extracellular signals, converge to activate transcription 
factors, which in turn determine the fate of the T cell in a manner appropriate to the 
infection at hand. While most CD8+ T cells receiving these signals during an infection 
will differentiate into effector cells, a sub-population of cells persists beyond the 
clearance of infection and differentiates into memory cells. The bifurcation of cell fate 
between effector and memory cells begins early during activation and is controlled by 
various molecular factors discussed below.  
 
Effector and Memory CD8+ T cell differentiation 
The goal of the CD8+ T cell response is to firstly produce sufficient numbers of robust 
effector cells to clear the pathogen at hand, and to secondly form long-term memory 
to combat future invasion by the same pathogen. The typical CD8+ T cell response to 
an acute infection is categorized into three phases - expansion of effector cells, 
effector cell contraction and memory formation. The ideal features of effector cells 
include rapid expansion, the ability to produce cytotoxic molecules and the capacity 
to traffic to sites of infection. On the other hand, memory cells should ideally persist 
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and self-renew to maintain a stable population in the absence of antigen, and rapidly 
differentiate and re-expand upon pathogen re-encounter. Hence given that the 
cellular properties of effector and memory cells are distinct from each other, a highly 
regulated differentiation process ensures that the correct proportion of effector CD8+ 
T cells either undergo terminal differentiation or persist as memory cells. This 
decision to either form a short-lived effector cell or persist as a memory cell begins 
early during effector differentiation (95,96) , and is controlled by a suite of extensively 
studied molecular cues. This section will cover the molecular pathways that control 
effector cell expansion and persistence through to memory.  
 
Naïve CD8+ T cells undergo rapid proliferation following activation, with expansion 
capacity reaching up to 1000-fold over the initial naïve precursor frequency. 
However, not all T cell clones expand to similar levels, and proliferation is controlled 
by multiple factors including precursor frequency of clones specific for the antigen 
and pMHC affinity (6,97–99), as well as pathways downstream of TCR and co-
stimulatory receptors such as mTOR signaling, cytokine activation of STAT1/4 and 
potentially Notch signaling (100). Multiple TCRs can be specific for a given antigen at 
different affinities and, although CD8+ T cells of lower avidities are recruited into the 
effector program, they undergo less proliferation due to competition with the high-
affinity clones for the peptide-MHC complexes (101,102). This allows preferential 
expansion of the high-affinity TCR populations during effector differentiation in a 
process driven by the transcription factors IRF4 and BATF. IRF4 is induced 
downstream of NFAT and AP-1 activation in an antigen-dependent manner, with its 
expression directly proportional to the strength of TCR signaling (103). IRF4 enables 
high-affinity clones to undergo the metabolic switch to aerobic glycolysis and 
catabolic metabolism that is required to fuel effector cell expansion; this allows high 
affinity cells to become the dominant clonal population of effector cells (103). BATF is 
also induced downstream of TCR signalling, and it forms a complex with IRF4 and 
JUN proteins to initiate transcription of T-bet, Eomes and the cytokine receptor genes 
that control effector development (104).  
 
Along with expansion, the CTL clones acquire the capacity to migrate into infected 
peripheral tissues (105,106), and this is controlled by multiple selectin and integrin 
molecules. In particular, primed effector cells downregulate CD62L and up-regulate 
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both inflammatory chemokine receptors and specific integrins to enable homing to 
inflamed and infected tissues (23,107,108). Once they reach infected sites, they are 
able to mobilise effector functions upon target cell recognition. Downregulation of 
CD62L is linked to PI3K-mTOR activity, and this serves as a checkpoint ensuring that 
a cell’s migratory capacity and the metabolic changes required for effector function 
are acquired in parallel (109). PI3K-mTOR-dependent regulation of CD62L levels is 
achieved through PI3K dependent proteolytic shedding, and through suppression of 
the transcription factor KLF2. KLF2 induces expression of a number of receptors that 
promote recirculation (including CD62L), meaning that KLF2 inhibition facilitates 
CD8+ T cell migration into the tissue (110–112).  
 
In order to achieve rapid expansion, tissue migratory capacity and cytolytic function, 
effector CD8+ T cells undergo a unique transcriptional and epigenetic differentiation 
program that results in global changes in gene expression (100,113–117). This 
differentiation program allows CD8+ T cells to perform effector functions, including 
secretion of inflammatory cytokines such as Interferon γ (IFNγ), Tumour Necrosis 
Factor α (TNFα) and Interleukin-2 (IL-2) (118) . Effector cells also gain cytotoxic 
functions to enable target cell killing by apoptosis, including release of granzymes 
and perforin, and ligation of the FAS receptor on target cells via FASL (119,120). 
Many of these gene changes are initiated by transcription factors such as T-BET and 
EOMES, which induce the Ifng, Gzmb and Prf1 genes (121,122). In order to reinforce 
and stabilize effector differentiation, certain TFs create positive feedback loops. T-
BET provides an example of such a positive loop in effector CD8+ T cells. The 
expression, and thus function, of T-BET is controlled by the amount of inflammatory 
signals in the environment, specifically IL-12 (90). T-BET acts as a rheostat: 
measuring inflammation and driving the terminal differentiation of effector cells 
accordingly in a threshold dependent manner (90). T-BET promotes effector 
differentiation by inducing other TFs that reinforce the effector gene program. T-BET 
promotes effector function, in part, by inducing the transcription factor ZEB2, which 
allows CD8+ T cells to commit to the effector lineage and die after antigen clearance 
(123,124). T-BET also drives the expression of other TFs, such as BLIMP-1 (125), 
which prevents premature memory differentiation. BLIMP-1 contributes to 
transcription of Granzyme B (GZMB) in co-ordination with EOMES and T-BET (125). 
Finally, BLIMP-1 represses the transcriptional regulator ID3 (126), leading to 
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induction of a related factor, ID2 (127), and optimal expansion and effector 
differentiation. These examples illustrate how a single TF (T-BET) can trigger a 
cascade of positive feedback loops that reinforce CTL differentiation and expansion. 
 
Effector cells become terminally differentiated if they excessively proliferate and 
differentiate. Terminally differentiated cells have a poor capacity to persist (90), and 
once the infection is cleared, 90-95% of the effector CD8+ T cell population 
(predominantly comprising terminally differentiated cells) undergoes apoptotic cell 
death (128). The crucial factors responsible for cell death during contraction are the 
pro-apoptotic BH3-only Bcl2 family members BIM (129) and, to a lesser extent, 
PUMA (130). The pathways that trigger BIM-dependent death are still being 
characterised. Many studies have suggested that transcriptional induction of BIM 
expression by the transcription factor FOXO3 plays an important role in BIM-
dependent contraction. FOXO transcription factors are excluded from the nucleus 
and degraded upon phosphorylation by Akt (131). Conversely, upon loss of cytokine 
signaling, FOXO3 is dephosphorylated, leading to protein accumulation, nuclear 
translocation and access to target genes. In vitro experiments in several B and T cell 
lines (132,133) have indicated that FOXO3 directly binds to the Bim promoter, where 
it then induces expression of Bim mRNA (134) and subsequent death of the cells. In 
vivo models have confirmed a role for FOXO3 in contraction using mouse models 
with a T cell-intrinsic deficiency in FOXO3. These mice exhibited an accumulation of 
effector CD8+ T cells due to reduced apoptosis, and diminished Bim expression, 
during the T cell contraction phase in both LCMV and LM-OVA infections (135,136). 
However, it remains unclear whether FOXO3 directly controls Bim expression in vivo. 
Recent studies have presented contrasting evidence about the binding of FOXO3 to 
the BIM promoter (137), as mutation of the FOXO3 binding sites within the Bim 
promoter did not hinder BIM expression or apoptosis. Hence, other pathways, such 
as loss of Erk-mediated repression of BIM expression and protein levels (138–
140,75) upon pathogen clearance, could also contribute to BIM-dependent death 
during T cell contraction. 
 
Not all T cells undergo death during the contraction phase, with survival of CD8+ T 
cells beyond contraction linked to the degree of terminal differentiation that occurs 
during infection. The surface markers Killer-like Lectin Receptor G1 (KLRG1) 
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(141,142) and IL-7R (95,143) can help to identify these early populations of short-
lived effector cells and memory precursors, and these markers have enabled tracking 
of these populations in several infection models. While there are multiple hypotheses 
explaining how these T cell populations arise (100), the “decreasing potential” model 
is backed by multiple lines of evidence. The decreasing potential model claims that 
the differentiation of naïve CD8+ T cells into either effector or memory precursors is 
dependent on the balance in their expression of effector versus memory associated 
transcription factors. This model suggests that the more effector cells differentiate, 
the more they lose memory potential (100). This is postulated to occur due to 
increased expression of effector-specific TFs that specifically silence competing 
memory-associated TFs. However, the changes in TF expression are also 
compatible with other models of memory differentiation, such as binary fate 
determination by asymmetric cell division. There is likely a stochastic component to 
this differentiation process, with the small fraction of cells that are, by chance, 
exposed to less of the factors that promote terminal differentiation (such as 
inflammatory cytokines) retaining more memory potential. For example, CD8+ T cells 
exposed to high levels of IL-12 will up-regulate T-bet expression, while those clones 
that encounter less IL-12 will maintain expression of the opposing transcription factor, 
Eomes, aiding subsequent persistence and differentiation into memory cells (144). 
Multiple transcription factor pairs oppose each other to promote either a memory or 
short-lived effector fate. These pairs include Id2 and Id3 (126,127,145), Zeb1 and 
Zeb2 (123,124,146), T-bet and Eomes (144,147–149), Stat4 and Stat3 (150–152), 
and Blimp-1 and Bcl6 (125,150,153–157), with the former molecule involved in 
effector development and the latter in memory differentiation. The process of short-
lived effector and memory commitment is also controlled at the epigenetic level, with 
the memory genes being shut down in effector cells as they commit to that lineage 
(158). On the other hand, memory cells do not repress the effector genes but have 
bivalent modifications on the associated histones, allowing the cells to differentiate 
back into effector cells for subsequent infections (158,159). Hence the fate of effector 
and memory cells is tightly regulated by extrinsic factors, which control the intrinsic 
regulatory machinery. 
 
Following the contraction phase, the remaining CD8+ T cells form part of the memory 
compartment. Memory cells have unique properties that differentiate them from their 
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effector cell counterparts. First, they do not rely on antigen for their survival (160), but 
instead depend upon the homeostatic cytokines IL-7 (143,161) and IL-15 (162) for 
survival and self-renewal. Second, they produce greater amounts of IL-2 (163), and 
can rapidly give rise to effector cells upon antigen reencounter. In particular, memory 
cells undergo epigenetic changes that facilitate rapid re-expression of effector genes 
(114,115,164,165). Memory cells exhibit heterogeneity, with specialised subsets 
such as long-lived central memory cells (TCM), which reside in the lymphoid organs 
and exhibit greater proliferative capacity, and short-lived effector memory cells (TEM), 
which patrol tissues and can launch immediate responses to pathogen reinfection, 
but are less proliferative upon restimulation (163,166). TCM become enriched over 
time, likely largely due to preferential survival and homeostatic proliferation of the TCM 
population (98,167,168). Recently, a new subset of memory cells called tissue 
resident memory cells (TRM) was defined, with this subset restricted to the tissue site 
of primary infection; this subset plays non-redundant roles in protection against re-
infection at a specific tissue site (169,170). Each of these subsets is characterised by 
a unique combination of transcription factors, which drives their differentiation and 
maintains their identity and “stemness”. In general, long-lived circulating central 
memory CD8+ T cells are characterised by expression of multiple transcriptional 
regulators, including Eomes (149), Bcl6 (156), Id3 (126,145), Foxo1 (171,172), Tcf7 
(173) and Zeb1 (146). In contrast, recent data indicate that TRM appear to have a 
distinct transcriptional program from circulating memory cells (174–177). While 
decades of research have thoroughly characterised the network of transcription 
factors in effector-memory differentiation, the TF networks that dampen the CD8+ T 
cell response to chronic antigen are less well characterised. 
 
1.1.3: Negative regulation of CD8+ T cells  
While a highly coordinated effector and memory response is required to contain 
infection and prevent reinfection, a completely unrestrained CD8+ T cell response 
poses danger to the host. Hence, there is a need for negative regulation and 
checkpoints in CD8+ T cell activation. T cell clones that recognise self-antigen need 
to be suppressed to prevent inadvertent activation and acquisition of effector 
function. The regulation of self-reactive cells is collectively known as immunological 
tolerance, and this process is necessary to prevent autoimmune disease by self-
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reactive cells. Second, negative regulatory mechanisms are required during infection 
to protect the host against fatal collateral tissue damage. The negative regulatory 
pathways engaged to limit such immunopathology typically dampen the inflammatory 
function of chronically stimulated effector cells in a process often called T cell 
“exhaustion”. These two states of CD8+ T cell differentiation are driven by chronic 
antigen recognition, which induces negative regulatory pathways that suppress CD8+ 
T cell function to limit damage to host tissues. The pathways downstream of chronic 
antigen that cause exhaustion and tolerance are poorly characterised, and it is 
unclear whether the same or different pathways are utilized in both cases. A major 
theme of this thesis is to better define whether common regulatory pathways are 
engaged by chronic antigen in the context of both tolerance and exhaustion. 
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1.2: CD8+ T cell tolerance  
 
The vast diversity of lymphocyte receptor specificities in the adaptive immune system 
means an almost unlimited spectrum of antigens can be recognised, however this 
implies that B and T cells can also recognise self-antigens. This introduces a 
dilemma in the functioning of the adaptive immune system, as there is a possibility of 
generating cytotoxic responses against host tissues. To mitigate this risk, multiple 
layers of regulation, collectively referred to as immunological tolerance mechanisms, 
have evolved to control self-reactive lymphocytes. These mechanisms act in an 
antigen-specific manner, such that typically only T cells specific to self and steady-
state antigens are subjected to these tolerance processes. The tolerance 
mechanisms are usually subdivided into two main categories: central tolerance 
mechanisms, which purge self-reactive cells from the repertoire during lymphocyte 
development, and peripheral tolerance mechanisms, which restrain those self-
reactive cells that escape central tolerance. 
 
While tolerance processes are able to successfully control self-reactive B and T cells 
in the majority of individuals, roughly 5-7% of the population develops autoimmune 
diseases, indicating that these tolerance mechanisms can fail (178). Autoimmune 
diseases comprise of over 80 different conditions that are defined by the onset of 
immune responses against self-epitopes present in either specific organs, or 
expressed systemically throughout the body. Examples of organ-specific 
autoimmune diseases include Type I Diabetes (T1D), Multiple Sclerosis (MS), and 
Vitiligo; and systemic autoimmune conditions include Systemic Lupus Erythematosus 
(SLE) and Rheumatoid Arthritis (RA) (178). While determining the precise cause or 
triggers of autoimmune disease remains a holy grail in this research area, it is 
postulated that multiple genetic, environmental and cellular factors contribute to the 
eventual break in tolerance. Furthermore, current treatments for these diseases are 
limited to immunosuppressive drugs that non-specifically shut down all B and T cell 
responses, causing severe side effects that warrant the development of more specific 
treatments. Self-reactive CD8+ T cells are implicated in multiple organ-specific 
autoimmune diseases, and can cause significant organ damage through their 
cytotoxic function (19). Thus, understanding the cellular and molecular tolerance 
pathways that act as checkpoints for self-reactive CD8+ T cells is crucial, as these 
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pathways could become potential drug targets for the treatment of CD8+ T cell-
mediated autoimmune disease. 
 
1.2.1: Central Tolerance  
In his clonal selection theory, Macfarlane Burnet proposed that clones recognizing 
self-antigens would be purged from the repertoire before they entered the periphery 
(4). In subsequent decades, this hypothesis was validated with the identification of 
“central tolerance” pathways that delete self-reactive B cells and T cells during their 
development in bone marrow and thymus respectively. To ensure that the bulk of 
self-reactive cells are rapidly eliminated before they can pose a risk to the host, these 
pathways operate immediately after lymphocyte receptor rearrangement. In the case 
of T cells, TCR rearrangement occurs within the thymus after immature Pre-T cells 
formed in the bone marrow migrate to the thymus. Due to the stochastic nature of the 
TCR gene recombination process, a diverse lymphocyte receptor repertoire of up to 
1015 unique specificities is predicted to be generated in the thymus (179,180). While 
random receptor recombination can generate self-reactive clones, it can also 
generate useless clones that cannot interact with MHC. Thus, to ensure the TCRs 
are both functional and not self-reactive, the final receptor products need to be 
selected for their ability to interact with self-MHC molecules, and selected against 
recognition of self-antigens. For this reason, two selection processes have evolved 
within central tolerance: one to ensure that only T cells with TCRs capable of binding 
to MHC are retained (positive selection), and one to actively eliminate cells that are 
self-reactive (negative selection) (181). 
 
Positive and negative selection during thymic development is a two-step process, 
where selection is based on the affinity of the TCR for self-peptide-MHC complexes. 
Positive selection occurs in the outer cortex of the thymus, where the newly 
rearranged TCRs interact with the MHC II and MHC I molecules on cortical thymic 
epithelial cells (cTECs) (182). T cells that recognise MHC molecules with low affinity 
are provided with survival signals and proceed with thymic development. The 
selected T cells then undergo negative selection, where their TCRs are screened for 
affinity to self-antigens, and those exhibiting strong recognition of self-antigens are 
deleted from the repertoire. The APCs in the thymus responsible for inducing 
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negative selection include the medullary TECs (mTECs) and DCs, which present an 
array of self-antigens (183). While mTECs directly present self-antigens that they 
express, DCs have been shown to cross-present antigens to CD8+ T cell precursors 
(184,185). Negative selection can occur in both the medulla and the cortex regions of 
the thymus, and is manifested in two “waves” of selection. The first wave deletes 
immature thymocytes that can strongly recognise self-antigens presented in the 
thymus, and the second wave is important in generation of Tregs from mature CD4+ 
self-reactive thymocytes (186,187). While T cells are selected against ubiquitously 
expressed self-antigens within the thymus (188), it was initially hypothesized that T 
cells would not be tolerised against tissue restricted antigens (TRA) during thymic 
selection, and that peripheral tolerance mechanisms exclusively controlled T cells 
specific for TRAs. However, this dogma was challenged by multiple studies. Firstly, it 
was shown that DCs from the periphery could pick up antigen from peripheral tissues 
and migrate to the thymus for subsequent negative selection of TRA-specific CD8+ T 
cells (189). Secondly, early studies indicated promiscuous mRNA expression of 
TRAs in thymic mTECs, such as insulin, alpha-fetoprotein and myelin proteins (190–
192). The source of this promiscuous expression was eventually attributed to the 
transcription factor AIRE, which is responsible for a leaky expression system that 
turns on expression of different sets of tissue-restricted genes in each mTEC 
(193,194). While DCs do not express AIRE, they are able to cross-present AIRE-
dependent TRAs derived from mTECs and thereby participate in negative selection 
(184,195). AIRE is likely not responsible for controlling all of the observed 
promiscuous TRA expression, and recently the transcription factor FEZF2 (196) was 
also shown to contribute to promiscuous TRA expression within mTECs. The 
importance of these transcription factors in thymic negative selection and immune 
tolerance has been highlighted in AIRE deficient mice and humans, which succumb 
to multi-organ autoimmune diseases (193,197–199).  
 
The major goal of thymic negative selection is to purge cells reactive to TRAs and 
ubiquitous self-antigens from the T cell repertoire. This is achieved through induction 
of apoptosis in the self-reactive cells and is primarily mediated by the pro-apoptotic 
factor BIM. Loss of Bim resulted in defective thymic deletion, although the surviving 
self-reactive cells did not break tolerance as peripheral tolerance mechanisms 
appeared to keep these cells in check (200). Other apoptotic factors such as PUMA 
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also contribute to thymic deletion, as a lack of both Bim and Puma resulted in the 
onset of autoimmune disease, presumably by overwhelming peripheral tolerance 
processes (201).   
 
Despite the comprehensive negative selection process in the thymus, negative 
selection is “leaky” and self-reactive CD8+ T cells do escape into the periphery. Self-
reactive T cells have been observed in the peripheral blood of healthy individuals at 
comparable levels to patients with autoimmune disease (202–206). More recently, 
tetramer enrichment of self-antigen specific T cells revealed that male antigen H-Y 
specific CD8+ T cell numbers were present in both male and female adults despite 
the presence of H-Y as a self-antigen in males (207). The number of tetramer+ cells 
present in males was a third of the number found in females, indicating that thymic 
selection only purged ~70% of the repertoire specific for H-Y antigen. This finding 
suggested that, at least in the case of the H-Y antigen, thymic selection was 
incapable of deleting all self-reactive T cells from the repertoire. 
 
There are multiple reasons for the escape of potentially autoreactive T cells from the 
thymic selection process. First, the deletion of self-antigen specific TCRs during 
negative selection is biased towards high-affinity TCR-MHC interactions, and low 
avidity clones are often spared (208,209). Second, despite promiscuous TRA 
expression, not all peripheral tissue antigens are displayed on the mTECs and DCs 
during negative selection, allowing escape of T cells specific to those tissue antigens 
not presented in the thymus (210). Furthermore, expression of TRAs in the thymus 
does not necessarily guarantee deletion of the responding thymocytes (211). Third, 
and importantly, complete purging of self-specific T cells from the thymus would 
result in holes in the TCR repertoire. Self-antigen affinity of TCRs is a continuum, 
rather than an “all or nothing” process, and setting a too stringent threshold for 
selection would thus decrease repertoire diversity. This would be evolutionarily 
disadvantageous to the host, as it would leave the immune system vulnerable to 
evasion by pathogens mimicking the self-antigens against which T cells were 
excessively selected. Thus, as the threat of pathogenic infection is greater than the 
slow onset of autoimmune disease that may occur downstream of slightly leaky 
thymic selection, the escape of some self-reactive T cells into the periphery is likely 
tolerated by the immune system. Supporting this theory, the above-mentioned study 
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on tolerance of H-Y specific T cells in males also demonstrated the presence of 
unlimited TCR specificities in healthy controls against all possible mutagenic 
variations of a Hepatitis B viral peptide, emphasizing that a broad TCR repertoire was 
present in most individuals (207). Thus, to maintain this vast T cell repertoire in the 
periphery while simultaneously restraining the rogue self-reactive T cells that are an 
inevitable consequence of this diversity, the immune system has developed several 
“peripheral” tolerance mechanisms. 
 
1.2.2: Peripheral tolerance 
Peripheral tolerance mechanisms identify self-reactive T cells by selectively tolerising 
cells that recognise their cognate antigen in the steady state. This is based on the 
presumption that antigen encountered in the steady state (ie. in absence of 
inflammation or danger signals) is likely enriched for self-antigens, and hence any 
responding T cells are likely self-reactive. Furthermore, non-self antigens presented 
in the steady state are likely not harmful to the host, and an immune response 
against such steady-state persistent antigens could thus result in immunopathology 
and be detrimental to the host. As a result, antigen recognition by naïve peripheral 
CD8+ T cells in a non-inflammatory context typically fails to result in effector 
differentiation, and even if the responding cells do acquire effector characteristics, 
their functions are greatly muted compared to those adopted during the response to 
an active infection. These regulatory outcomes are imposed on the self-reactive 
CD8+ T cells through tolerogenic interactions with DCs, and suppression of activation 
by regulatory T cells (Tregs) (212,213). Similar peripheral tolerance mechanisms are 
responsible for limiting aberrant CD8+ T cell responses to benign foreign antigens 
derived from food (214), gut bacteria (215) and a growing fetus (216).  
 
Current understanding of tolerance mechanisms against peripheral self-antigens has 
stemmed from studies of transgenic animal models with tissue-restricted expression 
of model self-antigens. In particular, well-characterised model antigens derived from 
viral proteins such as Haemagglutinin (HA) from Influenza virus (217,218), 
Glycoprotein (GP) from the common mouse pathogen Lymphocytic Choriomeningitis 
Virus (LCMV) (219) or well defined animal proteins including chicken ovalbumin 
protein (OVA) (220–222) have been extensively used. These and other model 
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antigens were genetically engineered for transgenic expression under the control of 
tissue-specific promoters, such that they would be recognised by the immune system 
as surrogate “self-proteins” in their respective tissue of expression. The TCRs that 
recognised immunodominant epitopes within these model antigens were typically 
well characterised, with TCR transgenic mice often available for the specific model 
antigen of interest. These included CD8+ TCR transgenic mice specific for well 
characterised MHC I peptides, such as “Clone 4 (CL4)” mice bearing CD8+ T cells 
specific for the HA533–541 peptide (223), “P14” mice with T cells specific for the GP33-41 
peptide (224), and “OT-I” mice with cells specific for the OVA257-264 peptide (225). 
The focus on peripheral, tissue-restricted antigens within these models was because 
many of these mouse strains were generated prior to the discovery of AIRE; as such, 
tolerance against tissue-restricted antigens was thought to occur solely in the 
periphery. The Rat Insulin Promoter (RIP) was used in many transgenic mice as it 
limited expression of the model antigen to the insulin-producing islet β cells of the 
pancreas (220,226,227). If the responding T cells mounted an effector response 
against the model antigen, it would result in destruction of the islet β cells and 
induction of diabetes, which was easily measured through high glucose levels in the 
urine (219,228,229). This was a useful model to study CD8+ T cell tolerance in a 
disease-relevant context, as CD8+ T cells are one of the major drivers of autoimmune 
diabetes (230). Multiple other models have utilised tissue promoters to study CD8+ 
and CD4+ T cell tolerance by limiting expression of model antigens to locations such 
as enterocytes in the intestinal tissue (221), lung parenchyma (218) and CNS 
(231,232), allowing study of self-tolerance mechanisms in relevant disease areas of 
intestinal bowel disease, lung inflammation and MS. However, not all tissue 
promoters were restricted to peripheral expression in the targeted tissue. Some 
promoters, including RIP, also elicited ectopic expression of antigen in the thymus, 
which led to central tolerance and thymic deletion of the endogenous antigen-specific 
T cells (220). Hence, depending on the model system used, endogenous T cells 
specific for the peripheral model antigen were either present in the mice and could be 
studied directly, or TCR transgenic T cells were adoptively transferred into the 
periphery to generate a population of model self-reactive T cells for further study. The 
multiple factors determining the presence or absence of endogenous T cells specific 
for the various model antigens within each model will be explained in later sections. 
While the different transgenic models utilised the same fundamental genetic tools, 
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the tissue-specific promoter, model antigen and strength of antigen expression varied 
between mouse strains. These differences translated into different experimental 
outcomes, with the above studies often observing one of three different CD8+ T cell 
tolerance outcomes: ignorance, anergy or deletion (233,234). These tolerance 
outcomes are are largely guided by how T cells interact with steady-state DCs 
bearing self-antigen. 
 
Regulation of peripheral tolerance by dendritic cells 
Peripheral tolerance in CD8+ T cells is typically induced by presentation of self-
antigen by APCs in the absence of infection or pathology. In the steady state, DCs 
are in a quiescent state however they still continuously survey the environment for 
antigens. In particular, the CD8α+ subset of DCs actively captures apoptotic cells in 
the steady state and cross-presents captured proteins to self-reactive CD8+ T cells in 
the lymph nodes (235–237). The role of DCs in antigen cross-presentation has also 
been highlighted in transgenic tolerance models such as RIP-mOVA and RIP-OVAhi, 
where expression of membrane bound or soluble OVA respectively is limited to the 
pancreas, yet CD8+ T cells specific for OVA peptide are able to recognise antigen in 
the draining pancreatic lymph nodes due to cross-presentation by the CD8α+ DC 
subset (238). DCs are extremely crucial to steady state tolerance induction in CD8+ T 
cells, as several in vivo and in vitro experiments have shown loss of DCs through 
targeted depletion (239) or specific loss of cross-presentation capacity in the DCs 
results in loss of CD8+ T cell tolerance (237). The importance of DCs in inducing 
tolerance was further illustrated by the Ins-HA transgenic model, where the model 
antigen Haemaglutinnin (HA) from the Influenza virus is expressed under the RIP 
locus. Infection of adult mice with Influenza did not result in diabetes induction (240), 
as all HA-specific CD8+ T cells were tolerised by steady state DCs. However, when 
these experiments were carried out at 3 weeks of age, prior to the appearance of 
cross-presenting DCs within the pancreatic lymph nodes, Influenza infection led to 
diabetes induction due to the presence of endogenous HA specific CD8+ T cells 
(241). This experiment highlighted the crucial role of cross-presenting DCs in 
inducing peripheral tolerance in CD8+ T cells. Thus, DCs not only have the capacity 
to license T cells during infection, they also carry out the important process of 
inducing tolerance in naïve self-reactive T cells in the steady state.  
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How are DCs able to play critical roles in both peripheral tolerance and the priming of 
an effector T cell response to infection? This plasticity in DC function is due to the 
state, or “phenotype”, of DCs in these two contexts. During an active infection, the 
presence of inflammatory cytokines, PRR activation and DC conditioning by activated 
CD4+ T cells results in the transition of DCs into an immunogenic state, as described 
earlier. This state is characterised by upregulation of co-stimulatory receptors, 
cytokine production and, in the case of migratory DCs, enhanced migration to the 
lymph nodes for activation of CD8+ T cells. In contrast, in the steady state, DCs 
sampling apoptotic tissues are not activated by PRR or inflammatory signals and 
assume a default “tolerogenic” state, where they lack expression of factors required 
to prime effector differentiation. Early experiments on tolerance induction by DCs 
correlated tolerogenicity with DC “maturity”. Steady-state DCs often express lower 
levels of costimulation and MHC, which is termed an “immature” state, and PRR 
engagement triggers DC “maturation” through up-regulation of co-stimulation and 
MHC expression (35,242). Certain studies which showed that antigen targeted to 
immature DCs caused tolerance induction, lead to the assumption that the outcome 
of a DC-T cell interaction was linked to DC maturity (243,244). However, several 
publications have indicated that mature DCs are capable of tolerance induction 
(245,246), and recent transcriptomics studies found that an equal number of genes 
are differentially expressed after the maturation of both immunogenic and tolerogenic 
DCs in vivo (247). Upon “maturation”, DCs in both immunogenic and tolerogenic 
states upregulate antigen presentation pathways, migrate to the draining lymph 
nodes while simultaneously down-regulating further antigen processing and 
phagocytosis pathways. Collectively, these data challenge the assumption that DC 
maturation predicts immunogenicity. 
 
While the exact molecular features that define tolerogenic versus immunogenic DCs 
are still poorly characterised, there are a number of known features of a tolerogenic 
DC-T cell interaction. In particular, DC mediated tolerance induction is typically 
dependent on inhibitory receptors such as PD-1 and CTLA-4 (248–250). Expression 
of PD-L1 and other inhibitory receptors is not exclusive to the tolerogenic DCs, as 
immunogenic DCs likely upregulate these inhibitory receptors given their recently 
discovered roles in effector differentiation (251,252). However, it is likely the sum of 
the activatory and inhibitory interactions at the immunological synapse that determine 
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the outcome of interaction (66). Inhibitory receptors such as PD-1 and CTLA-4 
induce negative outcomes through several mechanisms including inhibition of 
downstream signaling in T cells (covered in later section), and competing with other 
co-stimulatory receptors. While some reports have indicated a role for PD-1 and 
CTLA-4 in reducing the stable interaction time between the T cell and tolerogenic DC 
(249,250), which could lead to tolerance induction, another study indicated equal 
interaction times of the DC-T cell synapse formed in immunity and tolerance 
induction in vivo (253). Thus, there is conflicting evidence of the role of these 
receptors in reducing dwell time between the T cell and DC interaction. Therefore, 
while the precise molecular pathways are still unclear, the differentiation status of 
DCs, the nature of their interactions with naïve T cells and a number of other extrinsic 
factors (covered in later sections) cumulatively determines whether antigen 
recognition leads to tolerance or immunity. When CD8+ T cells are tolerised, there 
are multiple differentiation paths that the responding self-reactive T cell can adopt, 
with the outcome primarily dependent on the amount of antigen presented by the 
tolerogenic DC. 
 
1.2.3: CD8+ T cell tolerance outcomes  
CD8+ T cell tolerance outcomes observed in most transgenic mouse models of 
tolerance can be classified into three groups – ignorance, anergy or deletion (Figure 
1.2). As discussed below, a large body of evidence suggests that the choice between 
these outcomes is determined by the dose of self-antigen presented by the DC. T cell 
“ignorance” occurs when self-reactive T cells remain in a naïve state due to self-
antigen presentation levels that lie below the activation threshold, while anergy and 
deletion occur when self-antigen is expressed at sufficient levels to provoke a 
response. When a response to tolerogenic self-antigen does occur, the self-reactive 
T cells undergo either anergy or deletion depending on whether high or low levels of 
self-antigen are encountered respectively. Examples of these three outcomes, their 
hallmarks and the experimental data supporting these conclusions are discussed 
below. 
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Ignorance of self-reactive CD8+ T cells 
“Ignorance” of self-reactive CD8+ T cells was a concept derived from experiments 
indicating that CD8+ T cells were not actively tolerised against their antigen in the 
steady state and, as a result, remained in a naïve or “ignorant” state. Ignorance was 
first observed in RIP-GP transgenic mice, which express LCMV GP as a neo-self-
antigen within pancreatic islet β cells and soluble GP protein could be detected by 
histology of the pancreas (219). In RIP-GP mice, neither the endogenous GP-specific 
T cells, nor transferred CD8+ MHC I-restricted TCR transgenic P14 cells, were 
tolerised against the GP antigen (219,254). Upon infection with LCMV, which lead to 
presentation of GP peptides in an inflammatory context, endogenously generated 
GP-specific effector CD8+ T cells formed from the naïve GP-specific population of 
cells attacked the pancreatic tissues expressing the viral protein, resulting in 
induction of diabetes (219,229). Similarly, the ODC-OVA model expressing OVA in 
the oligodendrocytes resulted in ignorance of the responding OVA-specific CD4+ and 
CD8+ T cells (231), and hence bystander LCMV-OVA or LM-OVA infections resulted 
in CNS immunopathology (255). These early studies suggested that self-tolerance is 
maintained through an inability of T cells to access antigens sequestered in tissues.  
 
Subsequent studies in other model systems challenged this paradigm. In particular, it 
was found that the model self-antigen OVA was constitutively presented to OVA-
specific OT-I T cells in the draining pancreatic lymph node within RIP-mOVA mice, 
which express a transmembrane form of OVA (220). Transferred OT-I cells were 
subsequently found to be deleted after activation in the draining pancreatic lymph 
nodes of RIP-mOVA mice (256). Similar observations were made around the same 
time in transgenic mice expressing the model antigen Tag under control of RIP, and 
Tag-specific CD4+ T cells were deleted within 2-3 weeks of activation (257). Thus, 
the results of these models were in stark contrast to that of the RIP-GP model. This 
discrepancy was subsequently explained through the study of two lines of RIP-OVA 
mice expressing different levels of soluble OVA antigen (258). The lines were named 
according to the levels of antigen expression, with RIP-OVAhi mice expressing high 
OVA levels, and RIP-OVAlo mice expression low OVA levels. Direct quantitation of 
OVA protein levels in the pancreatic tissue indicated at least a 33 fold difference in 
OVA expression between these two mouse lines, with RIP-OVAhi mice expressing 
~1ng OVA per µg pancreatic protein versus <0.03ng OVA/µg in RIP-OVAlo mice. 
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While OT-I cells in the RIP-OVAhi mice were activated in the pancreatic lymph nodes 
in the steady state and underwent deletion, OT-I cells in RIP-OVAlo mice remained in 
a naïve or ignorant state (259). An important point to note is that, while OVA 
expression in RIP-OVAlo mice was not sufficient for presentation in the draining LN, 
the protein expression level was sufficient to enable killing of islet cells and diabetes 
induction by in vitro activated OT-I CTL (259). As such, OVA expression in the 
pancreas of RIP-OVAlo mice was at a physiologically relevant level to enable CTL-
mediated autoimmunity, meaning that this model phenocopied the results obtained 
within the RIP-GP model. Thus, this result established the concept that antigen dose 
determines whether self-reactive CD8+ T cells ignore self-antigen, or respond in a 
manner that leads to deletion or anergy.  
 
Since ignorant cells are not anergised or deleted against their cognate antigen in the 
steady state, they can respond normally to their cognate antigen (or a foreign antigen 
that bears homology to their cognate antigen) if it is presented in an immunogenic 
context. While it possible that ignorant self-reactive cells are largely low affinity due to 
partial thymic selection, multiple studies have shown that low affinity self-reactive 
cells are capable of differentiating into pathogenic effector cells and have the 
potential to cause autoimmunity if they are inadvertently primed in the context of an 
infection (101,260). Therefore, self-reactive CD8+ T cells that are ignorant likely pose 
a risk to the host, as inadvertent activation of these cells by pathogen molecular 
mimicry of self-antigens, or by recognition of their self-antigen in an immunogenic 
context, could lead to autoimmunity. Nevertheless, pathways such as anergy and 
deletion do exist to inactivate self-reactive cells in the periphery, and these processes 
likely prevent the majority of self-reactive cells from participating in future immune 
responses. These processes will be discussed in detail within the following sections. 
 
Influence of antigen signals on tolerance outcomes within CD8+ T cells 
T cells that are actively tolerised in the periphery by antigen recognition on 
tolerogenic DCs undergo two different cell fates depending on the dose of antigen 
encountered.  High doses of self-antigen result in “anergy”, whereby the responding 
CD8+ T cells survive in a non-responsive state resistant to further stimulus. On the 
other hand, low doses of self-antigen result in apoptotic death of the responding T 
cells in a process termed “deletion”. While anergy and deletion have been observed 
Figure 1.2: Multiple fates of CD8+ T cell tolerance: Steady state tolerogenic DCs 
present self-antigen to naïve self-reactive T cells. This interaction, depending on the 
dose of self-antigen presented, can result in different fates for the responding CD8+ 
T cells. If the dose of self-antigen presented is too low for T cell engagement, then 
ignorance occurs, where the self-reactive T cells remain in a naïve state. If the 
antigen dose is high enough to engage a response, the cells will proliferate, and 
then can either undergo deletion by BIM-mediated apoptosis, or can persist in an 
anergic state, where the cell’s TCR signaling pathways become non-responsive to 
further stimulus. Deletion occurs when intermediate levels of self-antigen are 
presented, while anergy occurs when high antigen levels are encountered. 
Ignorance 
Deletion Anergy 
Self-Antigen 
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in multiple transgenic models, the importance of these processes in maintaining 
tolerance within endogenous self-reactive CD8+ T cells remains largely unknown.  
 
Antigen dose was initially shown to determine whether tolerance induction lead to 
anergy or deletion in early studies using transgenic CD8+ T cells specific for H-Y 
antigen (261). The response of H-Y specific T cells was studied in irradiated bone 
marrow chimeras reconstituted with varying ratios of male and female cells, thus 
altering the amount of H-Y male antigen present in the mice (261). As the amount of 
male antigen was increased, there was a proportional increase in the percentage of 
anergic H-Y specific cells while the amount of deletion was inversely proportional to 
the percentage of male antigen. This dependence on antigen dose has been 
confirmed in models of peptide-induced tolerance, where delivery of self-peptide 
without adjuvant resulted in either anergy or deletion of the responding T cells 
depending on the dose of peptide injected (262,263). Similar results were found 
when the antigen dose was kept constant, but the affinity for antigen was varied; in 
this context low affinity interactions lead to deletion over anergy (263). Collectively, 
these data suggest that the TCR signal strength encountered during tolerance 
induction determines whether T cells persist in an anergic state or are deleted by 
apoptosis. It is important to note that anergy and deletion are not mutually exclusive 
as some amount of deletion of responding T cells does occur in anergy models (264).  
 
Cells undergoing anergy and deletion share some hallmarks, including proliferation 
upon antigen recognition, a failure to acquire effector functions, and reliance on 
chronicity of self-antigen for optimal tolerance induction. Unlike their thymic 
counterparts, self-reactive T cells in the periphery typically undergo a few rounds of 
division within in vivo tolerance models before they undergo anergy or deletion 
(256,265). The level of proliferation is dependent on the amount of antigen 
encountered, although the number of cell divisions that a cell undergoes during 
tolerance induction does not affect the efficacy of the tolerance process (266,267). In 
both anergy and deletion, the proliferating cells fail to acquire effector functions. This 
occurs at the level of both cytokine production, where cells have a defect in their 
capacity to produce IFNγ upon restimulation (265), and cytotoxicity, where tolerant 
cells are unable to kill targets, likely due to a defect in GZMB up-regulation (265,268). 
Finally, cells undergoing anergy and deletion rely on continuous interactions with 
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presented self-antigen to maintain their tolerant states. After a period of rest in a host 
that lacks expression of their specific antigen, tolerised cells are able to regain 
function and proliferative capacity, meaning that continuous antigen presence is 
required to enforce the tolerant state. Adoptive transfer of anergic T cells into 
antigen-free hosts allowed these cells to be activated upon subsequent restimulation 
(269). Similar experiments conducted in the InsHA tolerance model showed that 
transfer of cells undergoing deletion into antigen-free hosts allowed the cells to both 
persist, and differentiate into effector cells upon infection with Influenza (270). 
Repeated injections of tolerogenic HA peptide antigen into the “antigen-free” 
recipients was required to achieve complete deletion of the transferred cells (270). 
Hence, tolerance is highly dependent on the chronicity of the antigen; this is likely an 
additional strategy for self/non-self discrimination, as a hallmark of a self-antigen will 
be sustained expression. Existence of tolerance processes in the steady-state imply 
that most self-reactive T cells present in the periphery would be tolerised against 
quiescent and chronic self-antigens before any potential bystander activation of these 
cells during a pathogenic infection. Thus, anergy and deletion likely play important 
roles in the maintenance of tolerance, and the features of these states are 
considered in more detail below. 
 
Anergy  
The classical definition of anergy was derived from in vitro experiments in the 1990’s, 
where culture of CD4+ T cells in the presence of anti-CD3 antibodies but without 
CD28 co-stimulatory signals resulted in the shut down of IL-2 production and 
proliferation upon restimulation due to the acquisition of specific deficiencies in ERK 
signaling (71,72,271,272). This traditional definition of anergy has been adapted over 
the years to describe non-responsiveness of CD4+ and CD8+ T cells in both in vitro 
and in vivo models (273). Early studies of CD8+ T cell anergy in vivo involved delivery 
of cognate peptides in the absence of adjuvant. Efforts to vaccinate the mice with 
GP33 peptide without adjuvant resulted in a deficiency in the endogenous response 
to LCMV infection, suggesting that the endogenous repertoire had been tolerised 
(274). Other in vivo anergy models were pioneered using peptides from model 
antigens such as OVA and HA (262,275) or super antigens (276). In vitro and in vivo 
models of CD8+ T cell anergy have also shown a “split anergy” phenotype, whereby 
cells are able to produce granzymes and perforin and kill targets, but lack cytokine 
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production capacity (221,277). One of the hallmark features of anergic self-reactive 
CD8+ T cells is diminished ERK phosphorylation (pERK), which is possibly due to the 
multiple negative regulatory pathways that are activated in anergic cells (71,72,272). 
Another hallmark of anergy is long-term persistence of cells, with anergy 
maintenance dependent upon continuous antigen encounter. The molecular 
pathways responsible for the establishment and maintenance of anergy will be 
discussed in the next section.  
 
Deletion  
Deletion of self-reactive CD8+ T cells was first documented in H-Y specific T cells in 
bone marrow chimera experiments expressing lower ratios of male bone marrow 
(261). Following this study, deletion of self-reactive CD8+ T cells has been observed 
in multiple transgenic models, such as the InsHA (240), RIP-mOVA (256) and RIP-
OVAhi (259) models. Antigen specific transgenic T cells transferred into these models 
undergo proliferation in the draining lymph node after encountering antigen, and 
upregulate the activation markers CD44 and CD69 (256,265,268). However, as 
noted above, the tolerised CD8+ T cells in RIP-mOVA and RIP-OVAhi failed to 
differentiate into effector cells and underwent apoptosis through BIM upregulation 
(278). Cells undergoing deletion also do not have a block in TCR signaling unlike 
their anergic counterparts, and maintain pERK levels upon restimulation (262,268). 
Cells undergoing deletion up-regulate many of the genes linked to anergy induction 
(268). The functional relevance of these similarities is unclear, but it suggests that 
deletion and anergy maybe molecularly similar despite differences in outcome. It is 
thus unknown whether anergy and deletion can be molecularly separated as 
differentiation states, or whether they are essentially the same process, with the cells 
merely kept alive by antigen in anergy models.  
 
1.2.4: Molecular regulation of CD8+ T cell tolerance 
Diverting CD8+ T cells down the fates of anergy or deletion requires unique molecular 
changes that limit T cell function, prevent effector differentiation and (in some cases) 
induce death. Although the majority of the studies on the molecular circuitry of 
tolerised T cells have focused on CD4+ T cell anergy, some of these pathways 
overlap with CD8+ T cell tolerance. In the following sections, several aspects of 
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molecular regulation in T cell tolerance are highlighted and their role in CD8+ T cell 
anergy and deletion discussed. 
 
Cell extrinsic regulators of tolerance 
Apart from DCs, which are crucial in the induction of tolerance in self-reactive CD8+ T 
cells, several other factors in the steady state environment can also contribute to the 
induction and maintenance of tolerance in CD8+ T cells. These include inhibitory 
receptor interactions, suppressive cytokines in the environment, lack of CD4+ T cell 
help and involvement of regulatory T cells. All of these factors collectively contribute 
to inducing and maintaining suppression of self-reactive CD8+ T cells.  
 
Inhibitory receptors  
The DC-T cell immunological synapse is dominated by inhibitory receptor 
interactions, which are important in inducing tolerance in the T cells. In particular, 
factors such as PD-1 (279,280), CTLA-4 (248,281), LAG3 (282) and TIM3 (283,284) 
have been implicated in T cell tolerance induction. PD-1 and CTLA-4 are both 
members of the B7 family of receptors, which includes CD28, however these 
receptors inhibit rather than activate T cells (285). Both CTLA-4 and PD-1 expression 
are induced on the T cell as part of a negative feedback circuit downstream of TCR 
signaling (286,287). While CTLA-4 inhibits activation by outcompeting CD28 for 
binding to CD80 and CD86 (288,289), PD-1 inhibits TCR and/or CD28 signaling upon 
binding separate ligands, PD-L1 (290) and PD-L2 (291), on the DCs and tissues 
(289,292). The importance of these pathways in the maintenance of self-tolerance 
has been observed in knockout mouse models; Pdcd1-/- (293,294) and Ctla4-/- (295) 
mice are characterised by severe widespread autoimmunity, inflammation and lupus-
like disease. Subsequent studies have suggested that these pathways directly 
control CD8+ T cell tolerance. OT-I cells lacking PD-1 were able to overcome 
deletional tolerance induction in RIP-OVAhi mice, differentiate into effector cells and 
induce diabetes (279). However, PD-1 only appears to be involved in the induction 
but not maintenance of tolerance as anergic cells were resistant to PD-L1 blockade 
at later time points (296). CTLA-4 on the other hand has crucial functions in CD4+ T 
cell tolerance (281,297) and Treg suppression (298,299), but was variably required in 
some CD8+ T cell tolerance models in vivo (248) and not others (249,300).  
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LAG3 is a CD4-related molecule that binds to MHC II, and its expression is 
upregulated after T cell activation (301). CD4+ T cells deficient in LAG3 exhibited 
reduced expansion to super antigen and peptide stimulation, although they displayed 
greater production of IL-2 and IFN-γ (302), indicating a regulatory role in T cell 
function. LAG3 deficient CD8+ T cells accumulated in the C3-HA transgenic mice, 
which express HA as a self-antigen in the lungs, and caused inflammation in the 
lungs, indicating that LAG3 was crucial for maintaining tolerance in CD8+ T cells in 
this model (282). TIM3 is important in regulating CD4+ T cell tolerance (283,284) and 
has been postulated to bind multiple ligands such as GALECTIN-9 (303) and 
CEACAM-1 (304). However it’s role in regulating CD8+ T cell tolerance has not been 
investigated.  
 
CD4+ T cells 
CD4+ T cells play an important role in the activation of effector CD8+ T cells through 
production of cytokines, and providing the “help” signal CD40L to “license” DCs for T 
cell activation (305,306). CD4+ T cells themselves are activated by presentation of 
antigens on MHC II of professional APCs and require similar activation signals to 
those described above for CD8+ T cell activation (307). Upon activation of CD4+ T 
cells, they are able to produce high levels of cytokines, such as IL-2 and IFNγ, which 
can directly influence CD8+ T cell activation (307). Importantly, though, CD4+ T cells 
can provide signals to DCs, such as CD40L, which binds to CD40 on DCs that can 
support activation of the DC into an immunogenic state (308,309). CD4+ T cell 
tolerance to self will mean that “help” for self-antigens is unlikely to normally occur. 
However, when CD4+ “help” is provided in tolerance models, it is often sufficient to 
cause a breach in CD8+ T cell tolerance. For example, provision of CD4+ T cell help 
to RIP-OVAhi mice led to a break in tolerance of OT-I cells and diabetes induction, 
which was partially mediated through CD40 signals (310). A similar break in CD8+ T 
cell tolerance was observed in experiments supplementing iFABP-OVA mice with 
CD40 antibody, which mimics the DC “licensing” signal provided by CD4+ T cells 
without the cytokine production (311). Hence, tolerance within the CD4+ T cell 
compartment helps to maintain CD8+ T cell self-tolerance.  
 
Tregs, a regulatory lineage of CD4+ T cells, play an equally important role in actively 
maintaining tolerance. Tregs enforce tolerance induction through a variety of 
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mechanisms, and the rapid autoimmune disease that ensues upon acute Treg 
depletion illustrates the importance of Tregs in the maintenance of self-tolerance 
(312–314). However, in terms of their role in CD8+ T cell tolerance, Tregs perform the 
opposite role to conventional CD4+ T cells by acting as a “sink” for IL-2. Through 
expression of the high affinity IL-2R, or CD25, Tregs “soak up” the IL-2 in the 
environment. Depletion of Tregs in the CD11c-OVA model, which constitutively 
expresses OVA in CD11c+ DCs, resulted in an IL-2-dependent breach in CD8+ T cell 
tolerance against self-antigen (315). Tregs also inhibit immune responses through 
actively inhibiting DC immunogenicity (316), and by producing inhibitory cytokines 
such as IL-10 and TGF-β (317–319). However, there is limited understanding of 
whether these mechanisms of immunosuppression directly contribute to the 
maintenance of CD8+ T cell tolerance. 
 
Cytokines  
T cell homeostasis and phenotype is highly dependent on cytokines in the 
environment. Naïve T cells require IL-7 signals for their survival, however IL-7R is 
downregulated by cells undergoing anergy and deletion meaning that this cytokine 
can no longer sustain these populations (234,268). While there is a lack of 
inflammatory cytokines in steady state, the presence of these cytokines can reverse 
tolerance in a non-antigen specific manner. In particular, exogenous IL-2 treatment 
disrupts CD8+ T cell tolerance and results in autoimmune disease (320). While a 
number of inhibitory cytokines exist, such as IL-10 and TGF-β, there is limited 
understanding of their roles in the CD8+ T cell tolerance process. 
 
Cell intrinsic regulators of tolerance 
The above extrinsic factors influence the intrinsic changes within CD8+ T cells, which 
ultimately affect the outcome of the immune response. This section considers the 
changes that occur within a T cell to enforce a tolerised state, including what is 
known about the similarity and differences between the intrinsic gene program 
triggered in deletion and anergy. 
 
T cell signaling  
A central characteristic of anergic cells is an inability to signal effectively via their 
TCR. While signaling deficiencies within in vitro anergy models are largely restricted 
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to blocks in pERK (71,72) and mTOR signaling (321,322) , the block in signaling 
appears more proximal and extensive within in vivo anergy models (262,323–325). 
These blocks in TCR signaling are achieved, at least in part, through up-regulation of 
phosphatases and ubiquitin ligases. Phosphatases are either transcriptionally up-
regulated, or recruited through inhibitory receptor signaling, and dampen TCR 
signaling by dephosphorylating key signaling molecules. For example, PTPN2, a 
constitituvely active phosphatase crucial for dampening TCR signaling through 
dephosphorylation of LCK, and FYN, was shown to play an important role in 
maintaining CD8+ T cells tolerance in the RIP-mOVA mice (326).  Furthermore, 
inhibitory receptor signaling through PD-1 and CTLA-4, which is variably required to 
enforce tolerance as discussed above, results in recruitment of phosphatases such 
as SHP-1, SHP-2 and PP2A to the immunological synapse and further dampens the 
T cell signaling process (327–330). Apart from phosphatases, kinases such as DAG 
kinases (DGK α and ζ) were shown to be upregulated specifically in tolerance and 
their absence allowed the CD4+ T cells to be resistant to anergy induction (331,332). 
DAG kinases phosphorylate DAG into phosphatic acid, which prevents induction of 
Ras signaling pathway and ERK phosphorylation downstream of TCR (332). As cells 
undergoing deletion maintain TCR signaling, it is also not clear what the potential role 
of Dgkz would be in deletional tolerance. While Dgkz was upregulated in CD8+ T 
cells undergoing deletion, it’s importance in the deletion process is unknown (268) 
and furthermore there has not been other studies confirming the role of this kinase in 
maintaining CD8+ T cell anergy. However, it’s role in other negatively regulated CD8+ 
T cell contexts such as in tumour-sepcific T cell responses has been elucidated in 
multiple studies showing tumour specific CD8+ T cells lacking DGK proteins resulted 
in enhanced tumour killing (333–335). Thus, DGK proteins have been defined as 
negative regulators of CD8+ T cell function in other contexts. In summary, inhibition of 
TCR signaling through phosphatase and kinase-mediated pathways likely plays an 
important role in limiting CD8+ T cell differentiation within tolerance models. 
 
Another mechanism by which suppression of T cell signaling, and hence impaired 
effector differentiation, is maintained, is through active targeting of signaling 
components for degradation by the proteasome. A group of proteins called ubiquitin 
ligases carry out this process by targeting specific signaling molecules for 
ubiquitination, a process where ubiquitin molecules are covalently attached 
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proteins to “tag” them for subsequent proteasomal degradation (336). The role of 
ubiquitin ligases in T cell tolerance was first revealed in microarray studies of anergic 
CD4+ T cells, where increased levels of the ubiquitin ligase Cbl-b, Itch and GRAIL 
during anergy enforced hyporesponsiveness through degradation of PLC-γ, an 
important component of the TCR signaling pathway and subsequent poor 
immunological synapse formation (337). CBL-B has been shown to be crucial in 
limiting proliferation of self-reactive CD8+ T cells in vivo against high dose self-
antigen (338). Multiple other ubiquitin ligases have been revealed as playing a crucial 
role in CD4+ T cell anergy and these include ITCH (339), GRAIL (340), and DELTEX 
(341). These factors degrade different signaling components downstream of TCR 
signaling, thus inhibiting further stimulation, however their role in CD8+ T cell 
tolerance is less well characterised. Ubiquitin ligases also rely on other proteins 
called adaptors for their function. One such adaptor molecule called NDFIP1 was 
shown to bind and control the function of both NEDD4 and ITCH. Mice with mutations 
in NDFIP1 developed severe dermatitis due to aberrant expansion of CD4+ T cells 
(342). Ndfip1 deficient CD4+ T cells are resistant to in vitro anergy (343), and, within 
in vivo tolerance models, failed to undergo cell cycle exit and aberrantly differentiated 
into Th2 cells (344). While extensive CD8+ T cell activation is also seen in Ndfip1 
deficient mice, this phenotype appears cell extrinsic, and it is thus not known whether 
NDFIP1 also intrinsically contributes to CD8+ T cell tolerance.  
 
Transcriptional control of tolerance  
While it was evident within in vitro anergy models that cells stably up-regulated 
factors that limited TCR signaling and differentiation, the transcriptional basis of this 
process was not well understood until a pioneering study demonstrating that the TF 
NFAT is critically required for in vitro anergy induction (345). In support of the critical 
role of NFAT in programming an anergic state, induction of calcium signaling alone 
by ionomycin treatment is sufficient to induce anergy (71,72,346).  It was 
subsequently found that, in the absence of AP-1 activation downstream of MAPK 
signaling, NFAT adopts an inhibitory role and activates a unique gene network that 
leads to suppression of TCR signaling (337,345,347).  In early efforts to characterise 
the molecular profile of cells undergoing anergy, in vitro generated anergic CD4+ T 
cells were compared to in vitro generated effector CD4+ T cells. The microarray 
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results revealed the presence of NFAT and upregulation of a unique transcriptional 
network driven by NFAT (337).  
 
NFAT activation in the absence of AP-1 causes formation of NFAT homodimers that 
target different genes to suppress T cell function (345,347). NFAT interacts 
preferentially with AP-1 over itself, but in the absence of AP-1 forms inhibitory 
homodimers. While NFAT directly binds to the promoters of key anergy associated 
genes (345), much of the NFAT-mediated anergy program occurs indirectly, through 
induction of the TFs Egr2 and Egr3. EGR2 and EGR3 have been described as 
master regulators of tolerance, with both Egr2-/- and Egr3-/- cells unable to become 
anergic, in part due to deficiencies in Cblb and Dgka expression (348,349). While the 
roles of Egr2 and Egr3 have not been directly validated in CD8+ T cell anergy or 
deletion, a microarray analysis of OT-I cells undergoing deletion in RIP-OVAhi mice 
(268) revealed upregulation of both Egr2 and Egr3 along with its key target genes 
(Cblb, Dgkz) during deletional tolerance.  
 
Survival and death  
One of the key differences between CD8+ T cells undergoing anergy and deletion is 
differential survival, and it is unclear which pathways in these cells control the 
decision between survival and death. Key anergy-linked factors are up-regulated 
during deletion (268), and although there is some degree of contraction observed in 
cells undergoing anergy, most of them are able to persist for long periods of time 
while cells undergoing deletion undergo cell death. While the molecular basis of this 
differential survival is unclear, it is known that death during deletion is dependent on 
the pro-apoptotic protein BIM. Bim transcripts are induced to greater levels during 
tolerance relative to cells undergoing effector differentiation (268), and genetic loss of 
Bim in OT-I cells led to a block in cell deletion in RIP-mOVA and RIP-OVAhi models 
of tolerance, although the cells did not cause diabetes suggesting that effector 
differentiation was not rescued (278). These data are consistent with results from 
CD4+ T cell tolerance models, in which blocking deletion lead to anergy within the 
surviving cells (350). 
 
Given that death during both peripheral deletion and effector cell contraction is Bim 
dependent (129,278), it is unknown whether the pathways that induce Bim-
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dependent death are similar or distinct in tolerance versus contracting effectors. 
While transcriptional induction of Bim occurs after OT-I cells receive tolerogenic 
signals in RIP-OVAhi mice (268,278), it is not known which TFs are responsible for 
this gene induction process, and whether they differ from the factors required for 
BIM-dependent death of effector cells. More insight into the transcriptional pathways 
controlling Bim induction during deletion is required to understand why cells are 
either deleted or survive to persist as anergic cells. Furthermore, understanding the 
differences in death induction in tolerance versus immunity may provide therapeutic 
approaches to target self-reactive CD8+ T cells without causing widespread 
immunosuppression by also affecting the effector-memory response to infection.  
 
In summary, the current understanding of CD8+ T cell tolerance has been built from 
studies in several transgenic animal models, whereby the cells can undergo different 
fates of ignorance, anergy or deletion. Further work is required to thoroughly 
characterise the molecular regulation of CD8+ T cell tolerance and determine whether 
anergy and deletion are molecularly separable states.  
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1.3: CD8+ T cell exhaustion  
 
1.3.1: Overview of CD8+ T cell exhaustion 
As outlined in Section 1.1, the primary aim of the CD8+ T cell response is to clear 
intracellular pathogens from host tissue. This is successfully achieved in most 
instances through differentiation of naïve pathogen specific CD8+ T cells into potent 
cytotoxic effector cells, and formation of antigen-independent memory cells for 
combating future reinfection by the pathogen. However, the CD8+ T cell response 
against chronic pathogenic infections or cancers does not follow the effector-memory 
differentiation pathway observed in response to acute infection. Persistence of 
antigen and inflammatory signals drive the CD8+ T cell response to become 
“exhausted”, a process characterised by a gradual loss of effector functions and 
defective antigen-independent memory cell formation. The blunted T cell responses 
triggered by chronic stimulation contribute to disease progression, and are thus an 
area of intense interest. Studies over the last few decades have thoroughly 
characterised the cellular and molecular features of exhaustion, revealing that 
exhaustion is a unique differentiation state governed by altered expression of surface 
receptors, and distinct transcriptional and epigenetic programs.  
 
CD8+ T cell exhaustion was first described in mice chronically infected with the 
natural mouse pathogen LCMV (351,352). The long-term viremia in chronically 
infected mice was accompanied by blunted responses within the effector CD8+ T 
cells, which lost cytokine production capacity over time and were in some cases 
completely deleted from the repertoire (351–353). Subsequently, similar functional 
deficiencies in CD8+ T cell responses were observed in several human chronic 
infections, such as during HIV (354,355), Hepatitis B (356) and C (357,358) viral 
infections, as well as within cancers (359–361). Research efforts to study the 
underlying molecular and cellular factors driving exhaustion have led to both a 
greater understanding of the exhaustion process, and the discovery of drug targets 
for reversing exhaustion, such as the inhibitory receptors PD-1 (20) and CTLA-4 
(362). Blockade of PD-1 and CTLA-4 on exhausted CD8+ T cells can rescue effector 
CD8+ T cell function and reduce disease burden in both pre-clinical animal models of 
SIV (363) and HIV (364,365) infection, and within cancer patients in the clinic (366–
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368). These results imply that exhausted cells do not irreversibly lose function, but 
instead can be revived by selectively targeting certain molecular pathways. Hence, a 
better understanding of the factors that contribute to exhaustion is critical to not only 
delineating the basic biology of this process, but also in the development of more 
efficacious therapeutic strategies for the treatment of cancer and chronic infection.  
 
Much of the current molecular and cellular understanding of exhausted cells has 
been derived from studies in the chronic LCMV mouse model of infection, with 
validation often followed in human disease settings (369). Along with the benefits of 
animal work, a primary reason for the continued use of the LCMV infection model has 
been the ability to directly compare CD8+ T cell exhaustion during infection with 
chronic strains of LCMV versus CD8+ T cell effector and memory differentiation in 
mice infected with acute LCMV strains. Of the existing chronic and acute strains of 
LCMV, the most commonly used have been acute Armstrong (Arm) strain and 
chronic Clone 13 (Cl13) strain. The chronic Cl13 strain was isolated as a 
spontaneously arising genetic variant of the acute Arm strain (370). The Cl13 strain 
only differs from the Arm strain by two point mutations, which lead to single amino 
acid changes in the LCMV polymerase gene and the LCMV glycoprotein gene 
(371,372). These two amino acid changes allow Cl13 to sustain high viral titres over 
time and establish chronic infection (371–373). Fortunately, these amino acid 
changes do not affect the known T cell peptide epitopes within the virus (371–373), 
and hence CD8+ T cell responses to the same viral antigens can be assessed in both 
chronic Cl13 and acute Arm infection. For this reason, the LCMV model has been 
extensively used to characterise the exhaustion process, as within this system the 
molecular and cellular features of the exhausted T cell response can be compared 
against effector cells from acute infection specific for the same viral antigen. This 
section of the introduction will describe the features of CD8+ T cell exhaustion and 
the various factors that contribute to this differentiation state, with a primary focus on 
studies from the chronic LCMV model, and references to human conditions where 
appropriate. 
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1.3.2: Phenotype of exhausted CD8+ T cells 
Exhausted CD8+ T cells display multiple unique hallmarks that distinguish them from 
other states of T cell differentiation. Notably, global gene expression profiling 
comparing virus-specific CD8+ T cells from LCMV Cl13 infection to their effector-
memory counterparts in LCMV Arm infection, revealed that multiple gene sets, 
including transcription factors, inhibitory receptors and metabolic factors, were 
uniquely regulated within exhausted cells (374). However, the alteration in cellular 
and molecular function of exhausted cells occurs in a slow, hierarchical manner over 
time and is driven by multiple factors. Hence, exhaustion is a progressive 
differentiation process in which cells lose function and become terminally exhausted 
as they differentiate. Some of the major features of exhaustion are described below 
and summarised in Figure 1.3.  
 
Alterations in T cell function 
Fully functional effector CD8+ T cells co-produce multiple cytokines, and express 
cytotoxic molecules that can be mobilized to kill target cells. During exhaustion, 
cytokine function is lost in a hierarchical manner, with the cells first losing the ability 
to produce the cytokine IL-2, followed by losses in TNFα and IFNγ production 
respectively (353). Loss of inflammatory cytokine production is associated with a gain 
in production of the immunosuppressive cytokine IL-10, which can feedback and 
further inhibit the immune response (375). As cells differentiate further towards an 
exhausted state, they eventually die and are deleted from the repertoire (353). Along 
with loss of cytokine function, exhausted CD8+ T cells can display deficiencies in in 
vitro cytotoxicity against target cells (352,353), although other groups have reported 
comparable in vivo cytotoxicity within exhausted cells relative to functional effectors 
(376), as well as stable expression of Gzmb and Perforin in exhausted CD8+ T cells  
within tumours (377). This discrepancy may be due to differences between in vitro 
and in vivo killing assays, and could also be explained by the heterogeneous nature 
of the exhausted population as described later. Thus the ability to kill target cells is 
variably maintained in exhausted cells as opposed to their effector counterparts.  
 
Expression of inhibitory receptors 
A characteristic feature of exhausted cells is the expression of multiple inhibitory 
receptors, and elevated expression of these receptors plays a direct role in 
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dampening CD8+ T cell function. As opposed to fully functional effector cells, which 
transiently express some of these receptors upon activation, exhausted cells exhibit 
sustained and elevated expression of multiple inhibitory receptors, which belong to 
different receptor families and hence likely act in a non-redundant manner (378). 
These receptors, including PD-1 (20,378–381), TIM3 (378,380–383), CTLA-4 
(362,384), LAG3 (385,386), CD160 (378), 2B4 (378,387), TIGIT (388) and 
CD39(389–391), are frequently highly expressed on exhausted CD8+ T cells from 
Cl13 infected mice, and HIV and cancer patients, and often actively inhibit effector 
function. Inhibitory receptors limit T cell function in exhaustion via a number of 
mechanisms, including competition with, and restriction of, co-stimulatory receptor 
interactions, recruitment of inhibitory signaling pathways and alteration of 
transcription factor biology (280,383,392–395). Several transcription factors and 
epigenetic regulators have been shown to induce the expression of certain receptors 
such as PD-1 (347,396–398) and TIM3 (399,400). However, the factors responsible 
for inducing the expression of most inhibitory receptors are not clear.   
 
PD-1 is one of the most highly expressed and well-studied inhibitory receptors in 
exhaustion. PD-1 was identified as one of the most highly induced genes in a 
microarray screen of LCMV-derived exhausted versus effector CD8+ T cells (20,374). 
PD-1 is a member of the B7 family of receptors consisting of CD28 and CTLA-4 (285) 
and contains an Immuno Tyrosine Inhibitory Motifs (ITIM) in its cytoplasmic domain.  
Upon binding to its ligands PD-L1 or PD-L2, PD-1 can signal to recruit phosphatases 
and dampen the TCR signaling cascade (328,330,401). However, these experiments 
were mostly performed in vitro with activated CD8+ T cells and may not represent the 
signaling pathways utilised by PD-1 in exhausted cells in vivo. Indeed, recent in vitro 
biochemical and matching in vivo data indicate that PD-1 may predominantly operate 
by inhibiting CD28 co-stimulatory signaling rather than TCR signaling (394,395). 
Along with increased expression of PD-1 on CD8+ T cells during exhaustion (20,378), 
the ligand PD-L1 is also upregulated on several cell types such as DCs, CD4+ T cells 
and B cells as well as other infected cells (402,403) during chronic infection. Elevated 
PD-L1 expression during infection likely occurs as PD-L1 is induced on cells 
(including tumour cells) by IFNγ signaling (404), providing a mechanism by which 
inflammation may reinforce this regulatory circuit. Thus, elevated PD-1 and PD-L1 
expression during chronic infection and within tumours is an important regulatory axis 
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during exhaustion. The importance of PD-1 signaling in exhaustion is best illustrated 
by studies where PD-1 function was blocked. PD-1 blockade during chronic LCMV 
infection leads to expansion of exhausted cells, restoration of their effector function, 
and enhanced viral control (20,379,402) and these findings extend to SIV (363), in 
vitro HIV cells (379,405,406), humanised mouse models of HIV (364,365) and cancer 
patients (366–368). 
 
The number of inhibitory receptors co-expressed by exhausted cells is typically 
inversely associated with cytokine function (378). Although independent blockade of 
many inhibitory receptors has little influence on exhaustion, their combined 
suppressive effect is significant (378). Consistent with this idea, a number of studies 
have shown synergy with combined blockade of PD-1 and TIM3 (375), PD-1 and 
LAG3 (378) and blockade of PD-1 with activation of 4-1BB costimulatory receptor 
(407). Furthermore, combined blockade of PD-1 and CTLA4 in the clinic substantially 
boosts the efficacy of cancer immunotherapy (408). Hence, inhibitory receptors 
synergistically limited exhausted CD8+ T cell function, although the complexities of 
receptor interactions are still being uncovered.  
 
Altered metabolism 
As described in Section 1, cellular metabolism is crucial for effector CD8+ T cell 
function and memory formation (82). In exhausted cells, multiple studies have 
confirmed that the mTOR pathway is compromised, resulting in deficiencies in 
metabolic pathways and mitochondrial energetics (393,409,410). Much of the 
metabolic dysfunction in exhausted cells is driven by inhibitory receptors, such as 
PD-1 and CTLA-4, which limit mTOR signaling by restraining CD28 signaling 
(394,395,411). Limited mTOR signaling likely contributes to metabolic deficiencies 
through restraining activity of the transcription factor HIF1α. During normal effector 
differentiation, mTOR induces HIF1α, which subsequently induces genes that lead to 
the switch to anaerobic glycolysis required for growth and differentiation (412). 
Consistent with the idea that mTOR inhibition restrains HIF-mediated regulation of 
metabolism, Cl13 infection of mice lacking Vhl1, a negative regulator of HIF1α and 
HIF2α, results in both a gain of effector function, and induction of factors associated 
with glycolysis, in exhausted CD8+ T cells within both chronic infection and cancer 
models (413). Beyond alterations in mTOR signaling, other factors contribute to 
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metabolic changes during exhaustion such as sustained and elevated expression of 
the transcription factor IRF4. While IRF4 promotes glycolytic metabolism of effector 
cells (103), in the context of exhaustion IRF4 instead promotes metabolic dysfunction 
of the CD8+ T cells (396). As alluded to above, exhaustion is also associated with 
defects in mitochondrial metabolism, and rescuing these defects can rescue T cell 
function (409). Thus, metabolic deficiencies during exhaustion appear to contribute to 
diminished effector function, suggesting that therapeutic targeting of metabolism may 
have potential in immunotherapy.  
 
Population homeostasis and response to cytokines  
The long-lived memory CD8+ T cells that develop after resolution of an infection 
depend on the homeostatic cytokines IL-7 and IL-15 for their maintenance in the 
circulation and tissues. In contrast, exhausted cells are not typically maintained by IL-
15 and IL-7. Studies of viral specific CD8+ T cells in Cl13 infection showed lack of IL-
7R (CD127) expression, and antibody blockade of IL-7R signaling also did not affect 
survival of these cells (414), although treatment of Cl13 infected mice with 
supraphysiological levels of exogenous IL-7 increased T cell numbers, restored T cell 
function and led to viral control (415). Similarly, exhausted CD8+ T cells do not rely 
on IL-15 signals for long term survival (414,416). Thus, exhausted CD8+ T cells have 
distinct requirements for population homeostasis and maintenance in comparison to 
memory CD8+ T cells. While homeostatic cytokines are dispensable for exhausted 
cell maintenance, exhausted cells do rely on the presence of chronic antigen for long 
term survival, and hence have often been called “antigen addicted” (414,417,418). 
Transfer of LCMV-derived exhausted CD8+ T cells into recipients infected with a 
mutant virus lacking the immunodominant GP33-41 epitope (419) lead to maintenance 
deficiencies within GP33-41 specific CD8+ T cells (414). Notably, the transferred cells 
failed to exhibit the extensive constitutive proliferation typically seen in exhausted 
cells, arguing that antigen engagement maintains exhausted cells in part through 
driving proliferation (414). As the transferred cells were still exposed to constitutive 
inflammation, this also argues that inflammation alone cannot sustain exhausted 
cells. Thus, chronic antigen plays a crucial role in exhausted cell maintenance.  
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Figure 1.3: Progressive differentiation towards an exhausted state: CD8+ T 
cells undergo exhaustion in chronic infection and cancer. Exhaustion is a slow and 
progressive differentiation process, characterised by a loss of effector functions, and 
alterations in metabolism. Exhaustion is programmed by chronic antigen 
engagement and various inhibitory factors (such as IL-10). The loss of cytokine 
production occurs in a hierarchical manner, with IL-2 loss occurring first, followed by 
loss of TNFα and then loss of IFN-γ before cells undergo apoptosis. There is a 
parallel increase in the expression of inhibitory receptors as cells progress through 
exhaustion. Multiple transcription factors drive the exhaustion process, and these 
are summarised in the graded boxes.   
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1.3.3: Evolutionary basis of exhaustion  
Exhaustion most likely evolved as a mechanism to limit the potentially fatal 
immunopathology and organ damage that can be a natural consequence of a robust 
inflammatory T cell response. This has been best illustrated in the LCMV infection 
model, where infection of mice with an intermediate dose of virus that does not 
replicate to sufficient levels to induce exhaustion, but is also not cleared by the initial 
T cell response, can trigger fatal immunopathology (22). Mice that lack the inhibitory 
receptor PD-1 (20), and hence have deficiencies in the exhaustion process, similarly 
succumb to immunopathology. It is important point to note that “exhaustion” of CD8+ 
T cells does not imply a complete abrogation of T cell function. Exhausted CD8+ T 
cell still retain some function and this is crucial in containing infections and cancers. 
This was demonstrated through multiple studies where depletion of CD8+ T cells from 
virally infected primate hosts led to an increase in viremia during chronic SIV 
infection (420,421). Hence, rather than complete eradication of infection, the immune 
system establishes a new equilibrium with the chronic pathogen by actively 
containing infection while limiting damage to the host.  
 
1.3.4: Factors driving CD8+ T cell exhaustion  
Exhaustion of effector CD8+ T cells is programmed by multiple extrinsic and intrinsic 
factors. While these factors can vary between infection types and cancers, there are 
still a number of conserved antigen and environment-derived signals that are crucial 
in driving the exhausted state.  
 
Chronic Antigen  
Persistence of antigen in chronic infection and cancers plays a prominent role in 
inducing exhaustion of responding CD8+ T cells. The potential effect of antigen load 
on exhaustion was first observed when examining the immunodominance hierarchy 
in chronic versus acute LCMV infection. Some T cell specificities normally abundant 
in acute Arm infection are lost in the context of chronic Cl13 infection, while other 
specificities are either maintained or occasionally selectively expanded during Cl13 
infection (353). These differences appeared to be associated with antigen load, with 
the degree of deletion or persistence correlating with the abundance of the specific 
antigen recognised. Consistent with this idea, vaccination strategies have proven to 
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be ineffective for chronic infection, as the cells are only further exhausted by 
additional antigen from the vaccine (422). Conversely, adoptive transfer of P14 cells 
from Cl13 infected mice into infection-matched Arm mice at early time points post 
infection resulted in rescue of effector function in the virus-free recipients (423). 
Furthermore, mice engineered to prevent CD8+ T cell viral antigen recognition on 
non-haematopoeitic cells exhibited an early increase in cytokine function and a 
delayed development of exhaustion (424). Studies in chronic Influenza virus models 
have also confirmed that chronic antigen alone is sufficient to induce exhaustion 
(425). Finally, as noted earlier in this section, exhausted cells are addicted to antigen 
for their survival (414). Chronic antigen recognition drives numerous aspects of 
exhausted cell biology, including expression of inhibitory receptors and key 
transcriptional changes. In particular, loss of antigen recognition during chronic 
LCMV infection by epitope escape leads to loss of PD-1 expression selectively within 
the epitope specific CD8+ T cell population (418). Chronic antigen recognition also 
engages a number of key transcriptional circuits responsible for programming the 
exhausted state, and these factors will be considered in detail in a later section. 
 
Cellular and soluble mediators  
Along with persistent antigen, the prolonged presence of chronic pathogen or cancer 
also has effects on other components of the immune system, which in turn affect the 
development of the CD8+ T cell response and maintenance of exhaustion. APCs and 
CD4+ T cells are the prime regulators of CD8+ T cell exhaustion, although NK cells 
(426) and infected tissues (427) can also play an indirect role in contributing to the 
immunosuppressive environment (428). A number of key cytokines and soluble 
factors produced by these cells influence CD8+ T cell exhaustion, although 
exhaustion can also be regulated by environmental factors such as cholesterol (429) 
and potassium levels (430).  
 
DCs are the key APC cell type responsible for activation of naïve CD8+ T cells 
against pathogens. However, during chronic infection with LCMV Cl13, DCs are more 
susceptible to direct viral infection, which alters their phenotype and function (431). 
Chronic infection can also alter the DC response to TLR stimulation (432). Notably, 
there is an inhibitory APC subset, which arises and expresses multiple inhibitory 
receptors along with IL-10 cytokine production (433). As IL-10 levels are increased in 
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chronic LCMV infection, and IL-10 aids in enforcement of the exhausted phenotype 
(434,435), DC-derived IL-10 may contribute to exhaustion. DCs also produce Type I 
IFN (436,437) throughout chronic infection, which can directly induce CD8+ T cell 
exhaustion (438,439). Thus, DCs affect the T cell response by presentation of 
antigen, inhibitory receptor ligands and inhibitory cytokines. Other APCs, including 
MDSCs and inhibitory macrophages, also affect CD8+ T cell exhaustion (438,440). 
Notably, recent work suggests that macrophages are a more important source of IL-
10 than DCs (441). Additionally, T cell-derived TNFα can trigger production of 
immunosuppressive PGE2 by macrophages, which can then feedback and inhibit 
exhausted T cell function (442). 
 
Apart from APCs, CD4+ T cells play a crucial role in maintenance of the exhausted 
CD8+ T cells response. Mice depleted of CD4+ T cells were unable to clear Cl13 
infection, resulting in lifelong viremia and severe exhaustion of viral-specific CD8+ T 
cells (443). CD4+ T are the primary in vivo source of cytokines IL-2 and IL-21, and 
either IL-21 loss (444–446), or inhibition of IL-2 signaling within exhausted CD8+ T 
cells (447), compromises CD8+ T cells maintenance and function during chronic 
infection. Conversely, supplementing Cl13 infected mice with recombinant IL-2 
protein resulted in increased numbers of virus-specific CD8+ T cells and reduced viral 
titres (448).  
 
CD4+ T cells also produce factors that limit exhausted CD8+ T cell function. Chronic 
stimulation of virus-specific CD4+ T cells leads to IL-10 production that plays 
important roles in limiting CD8+ T cell function (441,449). Along with helper CD4+ T 
cells, Tregs also influence the exhaustion process. Treg numbers increase in chronic 
infection and depletion of these cells at later time points of infection can restore the 
CD8+ T cell function (450). Tregs can produce IL-10, TGF-β and IL-35, which can 
drive T cell exhaustion (451,452).   
 
Population heterogeneity 
Commitment to an exhausted fate is time and antigen dependent. Transfer of virus-
specific CD8+ T cells from Cl13 infected mice into antigen-free hosts at earlier time 
points post infection results in revival of effector function, but this recovery fails to 
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occur at later time points post infection. Thus, cells progressively, and ultimately 
irreversibly, commit to an exhausted fate (423,453).  
 
A detailed examination of the exhausted T cell population at any given point in time 
reveals substantial heterogeneity that is likely reflective of cells at different points of 
the exhaustion differentiation program. One of the earliest examples of heterogeneity 
was variability in PD-1 expression, with evidence of PD-1 intermediate (PD-1int) and 
PD-1 high (PD-1hi) sub-populations. Notably, these sub-populations have different 
functional characteristics. In particular, while the PD-1int population expands in the 
response to PD-1 blockade, the PD-1hi population fails to respond (454). This 
suggests that PD-1hi population is likely more irreversibly committed to an exhausted 
fate. Subsequent work using transcription factor deficient mice that lacked either of 
these subsets (see next section) illustrated that both of these subsets are required for 
optimal viral control (455). Thus, exhaustion triggers a continuum of differentiation 
states that cooperatively play important roles in infection control. 
 
While equivalents of the PD-1int and PD-1hi subsets were found in several human 
disease models of HIV and cancer (361,405), subsequent studies revealed an 
alternative set of markers to identify less differentiated “stem cell-like”, and terminally 
differentiated exhausted sub-populations. A number of papers using the Cl13 model 
system, with validation studies in HIV infection, revealed that the transcription factor 
TCF1 marks the exhausted stem cell population (456–459). The TCF1+ population 
also expressed CXCR5, which enabled the cells to reside in the follicular space in the 
lymphoid organs where there is less viral infection, and upon antigen encounter 
these cells proliferated and gave rise to terminally differentiated TIM3+ and PD-1hi 
progeny (456–459). As with the PD-1int cells, the TCF1+ cells are also the main 
exhausted cell sub-population that responds to PD-1 blockade (456–459). Thus, 
there are two main subsets of cells in exhaustion – a stem cell-like population, which 
is less differentiated and maintains proliferative potential, and the terminally 
differentiated progeny of these stem-like cells, which express more cytolytic 
granzymes, inhibitory markers and produce less cytokines. These subsets have been 
validated in human chronic infection and cancer (360,377,460,461), and so appear to 
be a conserved feature of the exhaustion process. Importantly, as with the PD-1int 
and PD-1hi subsets, both of these subsets appear important in infection and cancer 
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control (377). Understanding the differences in these subsets is crucial in guiding 
future immunotherapeutic strategies aimed at disrupting exhaustion, since the TCF1+ 
subset is both crucial for maintenance of the exhausted population, and for the 
response to checkpoint blockade. 
 
Transcriptional drivers  
Transcriptional programs controlling effector and memory differentiation are crucial in 
determining the extent of cellular function and population numbers. CD8+ T cell 
exhaustion is a unique differentiation state with a distinct transcriptional signature 
(374). The exhaustion process is governed by multiple transcription factors, which 
control the dynamics of exhausted sub-populations and the exhaustion differentiation 
process. TFs in exhaustion are differentially expressed in comparison to 
effector/memory differentiation and, in some cases, repurposed in their function in 
functional effector/memory differentiation (462). In particular, network analysis during 
exhaustion revealed vastly different TF interactions and networks in effector versus 
exhausted T cells (462). Multiple gene knockout studies have since been employed 
to understand the contribution of individual transcription factors to the exhaustion 
process.  
 
The T-box transcription factors EOMES and T-BET play important roles in effector 
and memory differentiation, and are typically inversely expressed. Intriguingly, these 
TFs are also inversely expressed in exhaustion, but their roles in differentiation are 
swapped from that seen in their effector-memory counterparts. T-BET functions as a 
rheostat to IL-12 and inflammatory signals in effector cells during acute infection, and 
drives cells towards terminal differentiation (90). However in chronic infection, loss of 
T-BET led to increased viral titres, and augmented terminal differentiation of 
exhausted CD8+ T cells in LCMV CL13 infection, with cells displaying increased 
levels of inhibitory receptors and reduced cytokine production (463,455). 
Furthermore, virus-specific cells were not able to persist in the absence of T-BET, 
and additional functional studies found that T-BET dampens PD-1 expression by 
direct binding to the PD-1 promoter (463). EOMES on the other hand is responsible 
for driving terminal differentiation of exhausted cells (399,455). The cell extrinsic 
factors that control expression of these two TFs remain unclear, however FOXO1 
does appear to play a role in the induction of terminally exhausted EOMEShi T-BETlo 
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cells (393). PD-1-mediated mTOR inhibition induces FOXO1 nuclear translocation, 
resulting in a positive feedback loop whereby FOXO1 induces further PD-1 
expression and formation of the EOMEShi T-BETlo population (393).  
 
The transcriptional repressor BLIMP-1 is another TF re-purposed to promote 
exhaustion. In the context of acute infection, BLIMP-1 promotes terminal 
differentiation of functional effector cells (125,155), while in the context of chronic 
infection BLIMP-1 appears to promote terminal exhaustion. Loss of BLIMP-1 in Cl13 
infection led to increased numbers of virus-specific CD8+ T cells (464), and also 
enhanced the expression of memory/stem-like markers (such as CD62L and CD127) 
while lowering the expression of inhibitory receptors (464). The cells also exhibited 
increased IL-2 production diminished GZMB expression. Overall, this suggested that 
BLIMP-1 deletion prevents terminal exhaustion. In the context of acute infection, 
BLIMP-1 in part limits memory potential and promotes terminal differentiation through 
antagonizing expression of BCL6. Given that BCL6 deletion during exhaustion also 
leads to loss of the TCF1+ stem-cell like population (457) (ie. the opposite phenotype 
to that seen in BLIMP-1 deficient mice), it is likely that a similar mutually antagonistic 
gene program operates in exhaustion. Hence, there are some parallels in BLIMP-1 
and BCL6 function between chronic and acute LCMV infection. Again, the 
extracellular signals that lead to BCL6 loss and BLIMP-1 induction during terminal 
differentiation remain unclear. 
 
The transcription factor TCF1 is not merely a marker of stem cell-like exhausted 
cells, but also plays important functional roles in maintaining this population. In the 
context of acute infection, TCF1 is involved in the formation and maintenance of 
central memory CD8+ T cells (173). In exhausted cells, TCF1 is important for the 
maintenance of the stem cell-like exhausted sub-population (456–459), which does 
bear some similarities to central memory cells. TCF1 functions by blocking IFN 
signals, suppressing expression of TIM3 and other exhaustion related genes, and 
also inducing BCL6 (400). Importantly, many studies in both animal models and 
patients have now confirmed that this population responds to PD-1 blockade in both 
chronic infection and cancer, and that TCF1 loss abrogates the response to therapy 
(360,377,456,458–461). Notably, the presence or absence of this TCF1+ sub-
population can predict melanoma patient responders to PD-1 blockade (360). Thus, 
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there is currently substantial interest in the role of TCF1 in exhaustion, although 
relatively little is known about the factors that trigger TCF1 down-regulation during 
the terminal exhaustion process. 
 
As described in detail above, T cell exhaustion is driven by chronic antigen 
recognition. Multiple transcription factors downstream of the TCR are important in 
promoting the exhaustion gene program. Firstly, NFAT is activated in exhausted cells 
by chronic TCR signalling and promotes expression of PD-1, as well as a number of 
other key genes in the exhaustion gene signature (376). NFAT appears to function 
differently in exhaustion relative to functional effector cells by forming homodimers as 
in tolerance (347). These homodimers bind a unique set of exhaustion-associated 
genes (347), and induced a number of downstream TFs that reinforce the exhaustion 
process. BATF was originally identified in vitro as a gene induced by PD-1 ligation 
that limited T cell function in HIV samples (392), however subsequent studies 
identified BATF as an NFAT target (396). TCR-induced NFAT signaling also induces 
elevated expression of the TF IRF4 during exhaustion, and IRF4 appears to promote 
exhaustion by binding to the same gene loci as that of NFAT and BATF (396). 
Collectively, these results suggest that chronic NFAT engagement induces a 
transcriptional complex consisting of NFAT, IFR4 and BATF that promotes terminal 
exhaustion. NFAT was recently also shown to induce expression of the transcription 
factor NR4A1 and its family members (465,466), and deletion of these factors also 
abrogated exhaustion. Thus, antigen-induced NFAT triggers a positive feedback loop 
that promotes exhaustion via a range of mechanisms.  
 
Epigenetic drivers  
Epigenetic changes that influence DNA accessibility within chromatin are a crucial 
component of gene regulation and cellular differentiation. A number of studies have 
now indicated that epigenetic regulation plays an important role in programming the 
exhausted state. Early studies of the Pdcd1 locus encoding the PD-1 inhibitory 
receptor revealed differential methylation of the Pdcd1 gene regulatory regions in 
exhausted vs effector or memory cells (397). The Pdcd1 locus was demethylated in 
effector cells during acute infection to promote chromatin accessibility and gene 
expression, however it was remethylated as cells transitioned to a memory 
phenotype (397). On the other hand, exhausted cells maintained the demethylation 
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of the Pdcd1 locus even after antigen clearance or transfer of cells into antigen-free 
hosts. Additionally, a recent study also showed that there was a uniquely accessible 
enhancer region in exhausted cells, which was required for high PD-1 expression in 
exhausted cells (398). This result indicated that the epigenetic signature of 
exhausted cells was unique from effector cells. This study further compared the open 
chromatin regions of exhausted and functional effector cells in LCMV Cl13 and Arm 
infection and demonstrated that exhausted cells contained ~6000 unique accessible 
chromatin regions that were not present in their effector or memory cell counterparts 
(398). This result reinforces gene expression studies showing that exhausted cells 
are a unique lineage, distinct from functional effector or memory cells. A subsequent 
study conducted in tumours showed similar unique chromatin changes within 
exhausted tumour infiltrating CD8+ T cells (467). The DNMT3 DNA methylase has 
been indicated as a crucial factor that regulates epigenetic state during exhaustion. 
Notably, DNMT3 deletion resulted in reversal of exhaustion-specific DNA methylation 
marks and a revival of cell function, particularly in response to PD-1 blockade therapy 
(468). As many of the exhaustion-specific chromatin changes are not fundamentally 
reversed by PD-1 blockade (469), it is likely that therapeutic targeting of epigenetic 
pathways in combination with PD-1 blockade will likely be needed for durable 
therapeutic disruption of exhaustion. Indeed, treating exhausted cells with a DNA 
demethylating agent augmented their response to PD-1 blockade (468).  
 
Overall, these data collectively demonstrate that exhaustion is a unique 
differentiation state programmed by distinct transcriptional and epigenetic programs. 
A greater understanding of the pathways that regulate this differentiation processes 
is critical if we are to develop more efficacious immunotherapy approaches targeting 
exhaustion. 
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1.4: Comparing tolerance and exhaustion 
 
CD8+ T cell tolerance and exhaustion occur in different immune contexts, however 
both serve to limit the CD8+ T cell response for the purpose of host protection. CD8+ 
T cell tolerance pathways are enforced on self-reactive naïve T cells in steady state 
conditions (234), while exhaustion is a slow progressive process that targets 
pathogen-specific activated effector cells in chronic infection and cancer to reduce 
function (470).  
 
The obvious major difference between tolerance and exhaustion is that exhaustion 
acts upon established effector cells later in the immune response, whereas tolerance 
acts upon cells that have undergone minimal or no effector differentiation (221,268). 
Nevertheless, several similarities are evident in the phenotypes, and pathways 
employed, during tolerance and exhaustion. CD8+ T cells are increasingly being 
harnessed for immunotherapy in cancer, but autoimmune side effects are an 
emerging problem. While this could be because exhaustion is known to limit 
established autoimmune disease (471), this could additionally be because current 
therapies (PD-1 and CTLA4 blockade) target pathways that are also employed in 
peripheral tolerance induction (248,279). Refining immunotherapies to limit 
autoimmune side effects while retaining anti-tumour responses is thus not possible 
unless we better understand the similarities and differences between tolerance and 
exhaustion. The shared molecular pathways in tolerance and exhaustion are 
described below and summarised in Figure 1.4.  
 
Loss of cytokine function 
At a gross phenotypic level, both tolerant and exhausted CD8+ T cells have similar 
deficiencies in effector function. For example, in both states, cells make transcripts 
for Ifng, but fail to make IFNγ protein due to a block in translation (265,268,472). 
Exhausted cells also have deficiencies in IL-2 and TNFα production (353), and 
similar deficiencies can be seen in tolerant CD8+ T cells (I.A. Parish, unpublished 
observations). Interestingly, though, as discussed in the previous section exhausted 
cells retain expression of GZMB as well as cytotoxic capacity. This is in contrast to 
tolerant cells, which are often deficient in killing capacity and GZMB expression 
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(265,268), although tolerance models do exist where killing capacity is observed 
(221). 
 
Chronic antigen  
T cells undergoing tolerance generally recognise self- or non-dangerous antigen 
signals in the absence of infection/inflammation, leading to tolerance induction and 
deficiencies in effector function. However multiple studies have shown that different 
forms of tolerance, such as anergy and deletion, are dependent on persistent antigen 
recognition for their maintenance (270,273). Similarly, as discussed in the previous 
section, chronic antigen is a key driver of exhaustion (414,456). Notably, the key 
regulatory transcriptional pathways downstream of chronic antigen, such as NFAT-
dependent pathways, are also shared between tolerance and exhaustion (345,347). 
In particular, key functionally important NFAT gene targets, such as NR4A family TFs 
(465,466) and the ubiquitin ligase CBLB (338,473), share similar roles in both 
tolerance and exhaustion. Additional NFAT induced TFs (347), such as Egr2, Ikzf2 
(encoding HELIOS) and Tox, are upregulated in both exhausted (374,462) and 
tolerant (268) CD8+ T cells. Up-regulation of EGR2 in particular is notable as this TF 
is a master regulator of T cell anergy (348,349). This suggests that a common 
antigen-induced NFAT-dependent gene program operates in both exhaustion and 
tolerance. Consistent with this idea, there is a small but significant overlap in the 
gene expression profiles of tolerant and exhausted cells (268), with the degree of 
overlap more pronounced in some tolerance models (474). Nevertheless, certain 
functionally important NFAT-induced TFs, such as IRF4 and BATF (392,396), have 
not been investigated in tolerance, and there is only limited induction of these genes 
within some tolerance models (I.A. Parish, unpublished observations). Thus, further 
studies are needed to determine the degree to which antigen-induced negative 
regulatory pathways are shared in tolerance and exhaustion. 
 
Inhibitory receptors  
As described in earlier sections, certain inhibitory receptor interactions between T 
cells and DCs or other cell types can limit T cell function. Notably, a number of 
inhibitory receptors, such as PD-1, CTLA-4, TIM3 and LAG3, contribute to both 
tolerance (248,279,282,283) and exhaustion (378,470). While exhausted cells 
accumulate these receptors over time, where they constitutively limit function (378), 
Figure 1.4: Comparison of molecular pathways in CD8+ T cell tolerance and 
exhaustion: CD8+ T cell tolerance and exhaustion are driven by chronic antigen 
signals and inhibitory receptors. Antigen engagement triggers the activity of the 
transcription factor NFAT in both tolerance and exhaustion, leading to induction of 
common downstream immunoregulatory factors such upregulation of inhibitory 
receptors. Signaling through IL-2R can result in rescue of tolerance and exhaustion, 
and cells in both states are chracterised by a block in cytokine translation and 
undergo BIM-dependent apoptotic death. 
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these receptors are often only required in the induction phase of tolerance (296,474). 
Relatively little is understood of the overlap and differences in the regulatory 
pathways engaged by these receptors in the context of exhaustion and tolerance. 
Further work on this topic is thus needed if refined immunotherapy approaches that 
spare peripheral tolerance are to be developed. 
 
IL-2 signalling 
As discussed in earlier sections, exogenous IL-2 treatment can rescue CD8+ T cell 
function in both exhaustion (447,448) and tolerance (320). Thus, both differentiation 
states likely depend on development in an IL-2 depleted environment. In the case of 
tolerance, low levels of IL-2 are expected, as the lack of T cell activation in the 
steady-state means sparse amounts of free IL-2 will be available. This, coupled with 
deficiencies in expression of the high affinity IL-2 receptor CD25 (320), means that 
tolerant cells are normally starved of IL-2 signals. While abundant IL-2 is likely 
encountered by cells during chronic infection early during the immune response, IL-2 
levels naturally drop as infection progresses due to loss of IL-2 producing capacity 
within chronically stimulated CD4+ and CD8+ T cells (353,423,475) It remains 
unclear, however, whether common pathways of IL-2-dependent immune activation 
are engaged in both tolerance and exhaustion. 
 
Bim mediated death  
Deletional tolerance and exhaustion both result in death of cells through apoptotic 
death. The apoptotic mechanisms responsible for cell death appear at least partially 
overlapping. While apoptotic death is almost completely BIM-dependent in the 
context of deletional tolerance, death of some exhausted CD8+ T cell specificities is 
partially controlled by BIM (278,476). It is unknown whether similar transcriptional 
pathways upregulate BIM expression in tolerance and exhaustion, and/or if other 
overlapping apoptotic factors play a role in cell death.  
 
Thus, given the overlapping phenotypic features of CD8+ T cells undergoing 
tolerance and exhaustion, it is important to decipher whether these states are 
transcriptionally linked.    
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1.5: Research questions  
 
The focus of this thesis was to expand the molecular understanding of CD8+ T cell 
tolerance, and investigate any molecular overlap between CD8+ T cell tolerance and 
exhaustion. Chapters 2 and 3 investigate the role of the TF FOXO3, and ubiquitin 
ligase adaptor NDFIP1, in CD8+ T cell tolerance respectively. Chapter 4 investigates 
the role of the tolerance-associated TF EGR2 in CD8+ T cell exhaustion. Collectively, 
these chapters address a number of key fundamental questions within the tolerance 
field, with each chapter focused on one of the following broad research questions. 
 
1.5.1. Does the same transcription factor control BIM-dependent death in 
tolerant versus effector cells? 
Tolerant CD8+ T cells undergo BIM-mediated apoptosis, however it is not known 
whether similar transcriptional pathways trigger Bim expression in tolerance as 
during effector differentiation. FOXO3 has been postulated to trigger BIM dependent 
death in effector and exhausted cells (135,477). Chapter 2 investigates the role of the 
transcription factor FOXO3 in CD8+ T cell deletion through use of the FOXO3 mutant 
mice and the RIP-OVAhi model of tolerance. These data reveal that BIM induction 
pathways are likely distinct in effector versus tolerant cells. 
 
1.5.2. Are similar molecular pathways engaged to enforce CD8+ T cell anergy 
versus deletion? 
During tolerance induction, cells either die by apoptosis or persist in a hypofunctional 
anergic state. It remains unclear whether similar pathways are employed to program 
both states. Chapter 3 explores the role of the ubiquitin ligase adaptor molecule 
NDFIP1, previously implicated in maintaining CD4+ T cell anergy (344), within CD8+ 
T cell tolerance models. By examining the effect of NDFIP1 deletion on CD8+ T cell 
tolerance induction in a range of models, we reveal that CD8+ T cell tolerance and 
anergy are molecularly separable. 
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1.5.3. Are the same transcriptional regulatory pathways engaged downstream 
of TCR signaling during tolerance and exhaustion? 
Chronic antigen is a common signal responsible for induction of both tolerance and 
exhaustion, and common transcriptional pathways are induced downstream of TCR 
in both states. As noted above, the master transcriptional regulator of anergy, EGR2, 
is induced during exhaustion, but its role in the exhaustion process is unclear. In 
Chapter 4, we examine whether EGR2-dependent induction of the anergy gene 
program contributes to CD8+ T cell exhaustion. Using conditional deletion of Egr2, 
and the chronic LCMV model of exhaustion, we find that EGR2 does promote 
terminal exhaustion, but appears to do so by engaging a fundamentally different 
gene program to that seen during anergy. 
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CHAPTER 2: FOXO3 is differentially required for 
CD8+ T cell death during tolerance versus immunity 
 
 
 
Wagle M V, Parish IA. FOXO3 is differentially required for CD8+ T-cell death during 
tolerance versus immunity. Immunol Cell Biol. 2016; 94 (9):895–9. 
 
 
The online publication in Immunology and Cell Biology can be accessed through the 
following DOI: https://doi.org/10.1038/icb.2016.53 
 
 
The following manuscript included in the thesis has been modified to fit the thesis 
layout and may differ from the original manuscript submitted to the journal in the 
following ways. In this version of the manuscript, the methods section is placed 
between the introduction and results sections. The result figures are incorporated into 
the results section 2.4 and the figure numbers have been modified to include the 
chapter number in the prefix, for example from Figure 1 to Figure 2.1.  
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2.1: Abstract 
 
Peripheral tolerance mechanisms limit autoimmunity by constitutively eliminating self-
reactive CD8+ T cells from the periphery in a process called deletion. Previous work 
has demonstrated that this deletion process is mediated by BIM-dependent apoptotic 
death due to transcriptional induction of the Bim gene. Currently, the transcriptional 
pathways responsible for Bim induction during peripheral deletion remain unclear. 
We speculated that the transcriptional regulator FOXO3 may induce BIM-dependent 
death during peripheral deletion, as it has been implicated in Bim induction and cell 
death during effector CD8+ T cell differentiation. Despite observing less Akt-
dependent inactivation of FOXO transcription factors in tolerised cells relative to 
effector cells, we demonstrate that FOXO3 deficient CD8+ T cells induce Bim and die 
normally during peripheral deletion. These data thus demonstrate that BIM-
dependent death during CD8+ T cell deletion is FOXO3 independent. Furthermore, 
these data provide the first evidence that the pathways responsible for Bim induction 
and cell death during effector differentiation versus tolerance of CD8+ T cells are 
molecularly distinct. 
 
 
2.2: Introduction 
 
The random recombination events that give rise to T cell receptors inevitably 
generate self-reactive T cells. While the majority of self-reactive T cells are 
eliminated during thymic selection, this process is imperfect and rogue self-reactive 
cells escape into the periphery1. Peripheral tolerance mechanisms have thus evolved 
to restrain these self-reactive cells and prevent autoimmune disease. As peripheral 
tolerance mechanisms must be subverted in order for autoimmunity to occur, a better 
understanding of this process is essential for understanding autoimmune 
progression. In particular, there is a need to resolve the mechanisms guiding 
individual antigen-activated T cells into either functional effector cells that mediate 
immunity versus non-functional tolerised cells. 
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One of the main mechanisms responsible for peripheral T cell tolerance is peripheral 
deletion. Self-antigens expressed at low levels or in a tissue-specific manner are 
constitutively presented by tolerogenic dendritic cells (DCs) in the steady-state, and 
low level self-antigen recognition on such DCs results in the proliferation and 
apoptotic death of any responding self-reactive T cells1-6. Importantly, the responding 
T cells fail to develop into effectors prior to death7, meaning that the proliferating self-
reactive T cells are unable to cause pathology and are ultimately purged from the 
repertoire. 
 
Apoptotic death during peripheral T cell deletion is dependent on transcriptional 
induction of the pro-apoptotic BH3-only protein BIM8,9, however the transcriptional 
pathways responsible for Bim induction during peripheral deletion are not known. 
Interestingly, BIM is also responsible for effector T cell death at the cessation of an 
immune response to infection10, but it remains unclear whether the same 
transcriptional pathways control BIM-dependent death during tolerance versus 
immunity. 
 
FOXO3 is a member of the FOXO transcription factor family that regulates Bim 
induction upon growth factor withdrawal11,12. Importantly, FOXO3 regulates cell death 
and Bim induction within T cells in vitro11, 12, and FOXO3 was recently shown to play 
roles in effector CD8+ T cell death during expansion, contraction and/or memory cell 
formation in vivo13-15. Notably, enhanced survival of FOXO3-deficient effector CD8+ T 
cells was associated with diminished BIM expression14,15. However, the role of 
FOXO3 in peripheral T cell deletion is not known. 
 
The evidence above would predict that FOXO3 is responsible for elevated Bim 
induction during peripheral deletion relative to a productive immune response. One of 
the main pathways responsible for FOXO3 inactivation is the Akt pathway, as Akt 
phosphorylated FOXO3 is exported from the nucleus thereby inhibiting FOXO3 
mediated gene induction16. IL-2 treatment and PD-1 blockade both disrupt peripheral 
deletion17,18, and one of the main effects of both of these treatments is induction of 
Akt signaling. Thus, a more specific prediction is that a lack of Akt signaling during 
peripheral deletion causes Bim induction via accumulated nuclear 
(unphosphorylated) FOXO3. In contrast, effector cells will likely receive Akt-
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dependent signals from infection-associated inflammation and IL-2 early during an 
immune response, leading to FOXO3 inactivation and diminished Bim expression 
relative to tolerance. 
 
Consistent with this idea we observe more FOXO protein phosphorylation in CD8+ T 
cell immunity compared to tolerance at early stages of the immune response. 
However, despite being partially resistant to contraction during a productive immune 
response, we find that FOXO3 deficient CD8+ T cells exhibit normal BIM induction 
and cell death during peripheral deletion. Collectively these data suggest that 
molecularly distinct transcriptional pathways may regulate BIM induction and T cell 
death during tolerance compared to immunity. 
 
 
2.3: Methods 
 
2.3.1: Mice and mouse infection 
C57BL/6, OT-I and B6.SJL-PtprcaPep3b/BoyJ (CD45.1) mice were purchased from 
the Australian Phenomics Facility, ANU, Australia. RIP-OVAhi 19 and MommeR120 
mice have been previously described. For Listeria infections, mice were infected with 
5×104 c.f.u. LM-OVA21 intravenously. All animals used in this study were cared for 
and used in accordance with protocols approved by the Australian National 
University Animal Experimentation Ethics Committee and the current guidelines from 
the Australian Code of Practice for the Care and Use of Animals for Scientific 
Purposes. 
 
2.3.2: T cell preparation for adoptive transfer 
Naïve CD8+ CD45.1+ OT-I cells were enriched from spleen and lymph nodes by 
generating single cell suspensions and incubating the cells with rat monoclonal Abs 
against Mac-1 (M1/70), macrophages (F4/80), red blood cells (Ter119), Gr1 (RB6-
8C5), MHC class II (M5/114), CD44 (IM7) and CD4 (GK1.5) on ice for 30 min. The 
rat Ab-labelled cells were removed by anti-rat IgG-coupled magnetic beads 
(Polysciences Inc.). CTV labelling was performed by labelling cells in RPMI (Life 
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Technologies) containing 10% Foetal Calf Serum with 10 µM CTV (Invitrogen, CA, 
USA) at room temperature for 5 min. 
 
2.3.3: Flow cytometric analysis 
Single cell suspensions were stained in PBS containing 2.5% Foetal Calf Serum and 
0.1% Azide. For surface staining, cells were stained for CD8, CD45.1 and CD45.2 
(Biolegend). For intracellular BIM staining, cells were fixed with Fixation buffer 
(Biolegend) and permeabilised with Permeabilisation Buffer (BD Biosciences) 
according to manufacturer’s instructions, and stained with unconjugated BIM 
antibody (Cell Signalling Technology) followed by a Goat anti-Rabbit A488 secondary 
antibody (Life Technologies). 
 
Ex vivo phosphoflow analysis was conducted as described previously22. Briefly, 
spleens and LNs were dissociated into a single cell suspension within RPMI 
containing 1% paraformaldehyde (Sigma) upon harvest. Cells were counted, 
aliquoted into tubes and fixed in ice-cold methanol. Cells were then either treated 
with 1000U l-phosphatase (New England Biolabs) or left untreated in Tris Buffered 
Saline (TBS) at 37oC for 15 min, and subsequently treated with FcBlock (BD 
Biosciences) in TBS containing 1% Bovine Serum Albumin (BSA) (Sigma) and 0.05% 
Azide. Cells were then stained for pFOXO1 (T24)/pFOXO3 (T32) using an 
unconjugated antibody (Cell Signalling Technology) followed by a Goat anti-Rabbit 
A488 secondary antibody (Life Technologies). Samples were collected on a BD 
LSRII or Fortessa flow cytometer (BD Biosciences), with data analysed using FlowJo 
Software (Tree Star). 
 
2.3.4: Statistical analysis 
Data analysis was conducted using Prism Software (GraphPad). Data were either 
analysed using a Two-way ANOVA with a Bonferroni post test (Figures 2.1b, 2.2a), 
or a One-way ANOVA with a Tukey’s Multiple Comparison test (Figure 2.2d). 
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2.4: Results 
 
2.4.1: Elevated phosphorylation of FOXO proteins within CD8+ T cells in 
immunity versus tolerance 
To test whether there is elevated Akt-dependent phosphorylation of FOXO proteins in 
CD8+ T cells during immunity relative to tolerance, we examined ex vivo 
phosphorylation of FOXO proteins via flow cytometry. To track T cells during 
peripheral tolerance, the well-established RIP-OVAhi tolerance model was employed. 
RIP-OVAhi transgenic mice express soluble ovalbumin (OVA) selectively within 
insulin-producing pancreatic islet b-cells19. Transfer of OVA-specific OT-I CD8+ T cell 
receptor transgenic cells into RIP-OVAhi mice leads to proliferation in the draining 
pancreatic lymph nodes (PLNs) that triggers peripheral deletion by BIM-dependent 
death8,23. To track matched cohorts of T cells during an immune response that 
generates effector cells, OT-I cells were transferred into mice infected with OVA-
transgenic Listeria monocytogenes (LM-OVA)21. In both cases, the transferred OT-I 
cells were labeled with the cell division dye Cell Trace Violet (CTV) to allow 
measurement of division-dependent changes in phosphorylation. 
 
Elevated Bim expression is first evident within OT-I cells at sixty hours post-transfer 
into RIP-OVAhi mice9. OT-I cells were thus isolated after sixty hours from the draining 
PLNs or spleen of RIP-OVAhi or LM-OVA infected C57BL/6 (B6) mice respectively. 
Cells were immediately fixed upon isolation, and stained directly ex vivo using an 
antibody that recognises the Akt phosphorylated forms of FOXO1 and FOXO3. To 
control for background staining, cells that had been stripped of phosphorylated 
residues by phosphatase treatment were stained in parallel. Consistent with 
increased Akt-dependent signaling during immunity, OT-I cells from LM-OVA infected 
mice displayed elevated FOXO phosphorylation at later cell divisions relative to OT-I 
cells in RIP-OVAhi mice (Figure 2.1a,b). Interestingly, lower levels of phosphorylation 
were observed in earlier cell divisions during LM-OVA infection, although the small 
number of cells recovered from these divisions means that these results may not be 
reliable. Thus, CD8+ T cells in later cell divisions display less Akt-dependent FOXO 
inactivation during peripheral tolerance than during effector cell formation, at a 
timepoint when Bim expression is elevated during tolerance. 
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Figure 2.1. Akt-dependent FOXO phosphorylation is elevated in effector versus 
tolerised OT-I cells. 2×106 CTV labeled CD45.1+ OT-I cells were transferred i.v. into 
either RIP-OVAhi mice, or B6 mice simultaneously infected with LM-OVA. Sixty hours 
after transfer the spleen (LM-OVA) or PLNs (RIP-OVAhi) were harvested and OT-I 
cells were analysed for ex vivo Akt-dependent FOXO phosphorylation (pFOXO). As a 
background staining control, cells were also stripped of phosphate by l-phosphatase 
treatment and analysed in parallel. (a) Representative flow cytometry contour plots 
showing OT-I pFOXO staining against cell division (CTV) for LM-OVA (red) or RIP-
OVAhi (blue) mice. Left and middle plot show staining relative to the relevant 
phosphatase background control (black), while right plot overlays OT-I cells from LM-
OVA and RIP-OVAhi mice. (b) Pooled quantified Mean Fluorescence data with 
phosphatase background MFI subtracted. Graph shows average MFI per OT-I 
division, with MFIs normalised to undivided cells during tolerance. Representative 
and pooled data from two independent experiments (n=7) are shown. Error bars 
represent SEM, ** = p<0.01, *** = p<0.001. 
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2.4.2: Foxo3MmR1/MmR1 mutant effector OT-I cells are partially resistant to T cell 
contraction 
We next tested whether a failure to inactivate FOXO proteins in CD8+ T cells leads to 
FOXO3-dependent Bim induction. Using a previously reported mutant mouse strain 
(MommeR1), OT-I cells were generated that bore a homozygous inactivating 
mutation in the Foxo3 gene22. We first confirmed that the MommeR1 mutant OT-I 
cells (OT-I.Foxo3MmR1/MmR1) were able to phenocopy the resistance to contraction 
seen in OT-I.Foxo3-/- cells after LM-OVA infection14. Equal proportions of 
congenically marked OT-I.Foxo3MmR1/+ or OT-I.Foxo3MmR1/MmR1 were transferred into 
B6 mice that were subsequently infected with LM-OVA. The relative proportions of 
mutant and control OT-I cells were measured in the blood at day 8 and day 20 post- 
infection. The mutant OT-I cells almost exactly phenocopied the reported OT-I.Foxo3-
/- phenotype14, with OT-I proportions initial comparable at day 8 prior to an 
enrichment of mutant cells at day 20 (Figure 2.2a). Thus, OT-I.Foxo3MmR1/MmR1 cells 
display a partial resistance to contraction after infection comparable to that seen in 
OT-I.Foxo3-/- cells. 
 
2.4.3: FOXO3 is dispensable for BIM induction and cell death during peripheral 
CD8+ T cell tolerance 
To test whether FOXO3 mediates Bim induction during peripheral deletion, CTV-
labelled OT-I.Foxo3MmR1/MmR1 cells were transferred in RIP-OVAhi mice. Sixty hours 
post-transfer, BIM protein induction was compared by flow cytometry between mutant 
cells and their wild-type counterparts. As a positive control for BIM down-regulation 
during a productive immune response, wild-type OT-I cells isolated from LM-OVA 
infected mice were also analysed for BIM expression. Consistent with previous 
results9, effector OT-I cells displayed diminished BIM expression at later cell divisions 
(Figure 2.2b,c), with diminished BIM expression correlating with increased FOXO 
phosphorylation (Figure 2.1a,b). However, OT-I.Foxo3MmR1/MmR1 cells displayed 
normal BIM induction in RIP-OVAhi mice, suggesting that FOXO3 is dispensable for 
BIM induction during CD8+ T cell peripheral deletion. OT-I.Bim-/- cells resist deletion 
in RIP-OVAhi mice8. To further test whether Foxo3 loss similarly protected cells from 
death during peripheral deletion, OT-I.Foxo3MmR1/MmR1 or OT-I.Foxo3MmR1/+ cells were  
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Figure 2.2. FOXO3 is dispensable for BIM induction and cell death during OT-I 
peripheral deletion. (a) 104 CD45.1/CD45.2 OT-I.Foxo3MmR1/+ cells were mixed with 
104 CD45.1/CD45.1 OT-I.Foxo3MmR1/MmR1 cells, and injected i.v. into B6 mice 
subsequently infected with LM-OVA. The relative proportion of wild-type and mutant 
OT-I cells was assessed within the blood at days 8 and 20 post-infection. Graph 
depicts the percentages of wild-type (black circle) or mutant (open square) cells 
within the CD45.1+CD8+ population at each time-point. Pooled data from two 
independent experiments (n=9) are shown. (b,c) 2×106 CTV labeled CD45.1+ OT-
I.Foxo3MmR1/+ or OT-I.Foxo3MmR1/MmR1 cells were transferred i.v. into RIP-OVAhi mice, 
with CD45.1+ OT-I.Foxo3MmR1/+ cells also transferred into LM-OVA infected B6 mice 
as a control. Sixty hours after transfer the spleen (LM-OVA) or PLNs (RIP-OVAhi) 
were harvested and OT-I cells analysed for BIM expression. Both representative 
contour plots (b) and pooled data (c) are shown from 3 independent experiments 
(n=9-10). (d) 2×106 CTV labeled CD45.1+ OT-I.Foxo3MmR1/+ or OT-I.Foxo3MmR1/MmR1 
cells were transferred i.v. into RIP-OVAhi mice or antigen-free B6 mice. The OT-I 
cells remaining were assessed 6 weeks post-transfer in either the B6 (white circles) 
or RIP-OVAhi (black circles) mice. Pooled data from 2 independent experiments (n=6-
8) are shown. Error bars represent SEM, ** = p<0.01, *** = p<0.001, ns = non-
significant. 
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transferred into RIP-OVAhi mice and then examined for survival at 6 weeks post-
transfer. As a control for naïve OT-I survival in the absence of antigen, cells were 
also transferred into B6 mice. Interestingly, naïve OT-I.Foxo3MmR1/MmR1 cells did 
exhibit slightly elevated survival within antigen-free B6 mice, however mutant cells 
were deleted normally in RIP-OVAhi mice (Figure 2.2d). Thus, Foxo3 loss fails to 
protect OT-I cells from death during peripheral deletion. Collectively, these data, 
coupled with previously published results13-15, suggest that FOXO3 is differentially 
required for both BIM induction and cell death during CD8+ T cell immunity versus 
tolerance. 
 
 
2.5: Discussion 
 
The experiments above reveal an unexpected separation between the pathways 
controlling cell death during CD8+ T cell tolerance and immunity. Prior evidence that 
FOXO3 controls BIM induction in T cells11-15 leads to the logical extrapolation that 
FOXO3 is responsible for BIM induction and cell death during peripheral T cell 
tolerance by deletion. This hypothesis was based upon the assumption that tolerant 
CD8+ T cells that recognise antigen in the steady-state would lack the Akt-dependent 
survival signals typically received by effector cells during infection, leading to an 
accumulation of unphosphorylated, transcriptionally active FOXO3. Furthermore, 
treatments that activate the Akt signaling pathway (IL-2 treatment & PD-1 blockade) 
can break CD8+ T cell tolerance in the RIP-OVA tolerance model17,18. Consistent with 
this idea, we found that tolerant CD8+ T cells exhibited lower levels of Akt-
phosphorylated FOXO3 than effector cells. However, despite enabling augmented 
effector cell survival during contraction, FOXO3 loss failed to alter both BIM induction 
and cell survival during peripheral deletion.  
 
The reasons for differential FOXO3-dependent BIM regulation during tolerance and 
immunity remain unclear, however it is not due to lower FOXO3 expression during 
tolerance as our previous microarray studies indicated comparable high levels of 
FOXO3 expression during both CD8+ T cell tolerance and immunity9 (I.A.P., 
unpublished observations). One possibility is that other post-translational 
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modifications during tolerance inactivate FOXO3 function, as FOXO proteins are 
subject to a diverse array of modifications that differentially alter their function24. 
Alternatively, the FOXO3 binding sites within the Bim promoter may be packed into 
heterochromatin and inaccessible within tolerant cells. However, a more likely 
possibility is that FOXO3 does not directly induce Bim expression, with the elevated 
Bim expression seen in Foxo3-/- effector cells instead due to indirect effects of 
FOXO3. Mice in which the putative FOXO3 binding sites within the Bim promoter are 
mutated fail to phenocopy Foxo3-/- mice in terms of haematopoeitic cell survival25.  
 
Thus, the influence of FOXO3 on Bim expression and cell survival within effector 
cells may be by an indirect and potentially complex pathway that is not operable 
within tolerant cells. It should be noted that the Foxo3-/- CD8+ effector T cell 
phenotype is not as dramatic as the Bim-/- phenotype, suggesting that other pathways 
also contribute to BIM-dependent effector cell death. It should also be noted that we 
have not measured Bim mRNA levels during tolerance in the absence of FOXO3, 
which may be altered despite normal BIM protein induction. Nevertheless, the failure 
of FOXO3 deficiency to alter BIM protein induction and cell death during peripheral 
deletion provides the first evidence that the pathways controlling cell death during 
CD8+ T cell tolerance and immunity are molecularly separable. 
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CHAPTER 3: The ubiquitin ligase adaptor NDFIP1 
selectively enforces a CD8+ T cell tolerance 
checkpoint to high dose antigen 
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layout and may differ from the original manuscript submitted in the following ways. In 
this manuscript, the methods section is placed between the introduction and results 
sections, the methods included in the original manuscript and supplementary 
information are pooled together in section 3.3. The result figures are incorporated 
into the results section 3.4 and supplementary figures and tables are included after 
the references section 3.9. The figure numbers have been modified to include the 
chapter number in the prefix, for example from Figure 1 to Figure 3.1.  
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3.1: Abstract 
 
Escape from peripheral tolerance checkpoints that control cytotoxic CD8+ T cells is 
important for cancer immunotherapy and autoimmunity, but pathways enforcing 
these checkpoints are mostly uncharted. We reveal that the HECT-type ubiquitin 
ligase activator, NDFIP1, enforces a cell intrinsic CD8+ T cell checkpoint that 
desensitises TCR signaling during in vivo exposure to high antigen levels. Ndfip1-
deficient OT-I CD8+ T cells responding to high exogenous tolerogenic antigen doses 
that normally induce anergy aberrantly expanded and differentiated into effector cells 
that could precipitate autoimmune diabetes in RIP-OVAhi mice. In contrast, NDFIP1 
was dispensable for peripheral deletion to low-dose exogenous or pancreatic islet-
derived antigen, and had little impact upon effector responses to Listeria or acute 
LCMV infection. These data provide evidence that NDFIP1 mediates a CD8+ T cell 
tolerance checkpoint, with a different mechanism to CD4+ T cells, and indicate that 
CD8+ T cell deletion and anergy are molecularly separable checkpoints. 
 
 
3.2: Introduction 
 
Activated CD8+ T lymphocytes are key effector cells of the adaptive immune system 
that produce inflammatory cytokines and lytic granule proteins to kill infected or 
neoplastic cells. However, potentially pathogenic self-reactive CD8+ T cells escape 
thymic selection, and peripheral tolerance checkpoints have thus evolved to control 
these cells and to enable tolerance to food, commensal microbiota, and fetal 
antigens. These peripheral checkpoints must respond to a wide range of antigen 
levels, due to variation in antigen amount released by different tissues. Malignant 
cancer cells can exploit these checkpoints to prevent immune recognition of mutated 
neo-antigens, and checkpoint inhibitors have emerged as a third pillar of cancer 
treatment alongside chemotherapy and radiotherapy. 
 
Peripheral CD8+ T cells undergo deletion or anergy when resting naïve T cells 
encounter antigen in the absence of infection or inflammation. In this context, the 
responding T cells do not become cytotoxic effectors and adopt a transcriptional 
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profile that is distinct from other differentiation states (Hernandez et al., 2001; Parish 
et al., 2009). CD8+ T cell deletion occurs when cells undergo BIM-dependent 
apoptosis but largely retain T cell receptor (TCR) signaling capacity (Davey et al., 
2002; Parish et al., 2009; Redmond et al., 2005; Wagle and Parish, 2016), whereas 
CD8+ T cell anergy is characterised by persistence of cells with diminished TCR 
signaling, with tolerogenic antigen levels thought to determine outcome (Redmond et 
al., 2005). The molecular pathways that enforce CD8+ T cell anergy in vivo are poorly 
defined, and it is unknown if anergy checkpoint disruption interferes with CD8+ T cell 
deletion, or if the two processes are molecularly distinct. 
 
NDFIP1, a Golgi and intracellular vesicle localized transmembrane protein, plays a 
selective checkpoint role within CD4+ T cells (Altin et al., 2014; Oliver et al., 2006). 
NDFIP1 binds to and activates HECT-type E3 ubiquitin ligases (Mund and Pelham, 
2009; Riling et al., 2015), thereby triggering ubiquitin-mediated degradation of key T 
cell differentiation regulators, including JUNB, RORgt and JAK1 (Layman et al., 
2017b; O'Leary et al., 2016; Oliver et al., 2006). In T cells, NDFIP1 primarily recruits 
and activates the HECT-type E3 ligase ITCH (Oliver et al., 2006). Ndfip1 deficient 
CD4+ T cells resist both in vitro anti-CD3 induced anergy, and in vivo tolerance to low 
or high antigen levels, due to excessive IL-2 production, a failure to exit cell cycle and 
aberrant differentiation into Th2 or Th17 cells (Altin et al., 2014; Layman et al., 
2017b; Oliver et al., 2006; Ramos-Hernandez et al., 2013). Mice lacking NDFIP1 
develop a fatal T cell-mediated inflammatory disease associated with T cell 
activation, regulatory T cell dysfunction and Th2-mediated organ pathology (Altin et 
al., 2014; Beal et al., 2011; Layman et al., 2017a; Oliver et al., 2006). NDFIP1 likely 
plays similar roles in humans, as NDFIP1 polymorphisms and ITCH deficiency are 
associated with inflammatory and autoimmune diseases (Ferreira et al., 2011; 
Franke et al., 2010; Hu et al., 2011; International Multiple Sclerosis Genetics et al., 
2011; Lohr et al., 2010; Ramon et al., 2011). 
 
Despite elevated activated effector CD8+ T cells in Ndfip1-/- mice, and high Ndfip1 
expression in CD8+ T cells (Altin et al., 2014), CD8+ T cell activation in Ndfip1-/- mice 
is largely an indirect consequence of excessive IL-4 production by Ndfip1-mutant 
CD4+ T cells (Altin et al., 2014; Kurzweil et al., 2014). However, excessive bystander 
inflammation in Ndfip1-/- mice may mask a CD8+ T cell intrinsic role for NDFIP1. Here 
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we circumvent these complications by transferring Ndfip1-mutant and wild-type OT-I 
TCR transgenic CD8+ T cells and tracing their response. We reveal that NDFIP1 is a 
critical checkpoint against CD8+ T cell expansion and effector formation during 
chronic exposure to high tolerogenic antigen levels. 
 
 
3.3: Experimental procedures 
 
3.3.1: Mice 
C57BL/6, OT-I, B6.129S7-Rag1tm1Mom/J (Rag1-/-) and B6.SJL-PtprcaPep3b/BoyJ 
(CD45.1) mice were purchased from the Australian Phenomics Facility, ANU, 
Australia. RIP-OVAhi (Kurts et al., 1998), Ndfip1kru/kru (Altin et al., 2014), GzmB-cre 
(Jacob and Baltimore, 1999) and Ndfip1f/f (Howitt et al., 2012) mice have been 
previously described. All animal work was in accordance with protocols approved by 
the ANU Animal Experimentation Ethics Committee and current guidelines from the 
Australian Code of Practice for the Care and Use of Animals for Scientific Purposes. 
 
3.3.2: Peptide injections, rapamycin treatment and mouse infection 
SIINFEKL peptide (Biomolecular Resource Facility, ANU) was injected intravenously 
in PBS, while rapamycin was injected intraperitoneally at a dose of 600µg/kg (diluted 
in PBS from a concentrated stock in DMSO). For Listeria infections, mice were 
infected with 105 c.f.u. LM-OVA (Pope et al., 2001) intravenously. For LCMV-
Armstrong infections, mice were injected intraperitoneally with 2x105 p.f.u. of virus. 
Diabetes monitoring was conducted by urine glucose measurements using Diastix 
(Bayer). 
 
3.3.3: T cell preparation for adoptive transfer 
Naïve CD8+ CD45.1+ OT-I cells were enriched from spleen and lymph nodes by 
incubating single cell suspensions with rat monoclonal antibodies against Mac-1 
(M1/70), macrophages (F4/80), red blood cells (Ter119), Gr1 (RB6-8C5), MHC class 
II (M5/114), CD44 (IM7) and CD4 (GK1.5) on ice for 30 min. The rat antibody-
labelled cells were removed by anti-rat IgG-coupled magnetic beads (Polysciences 
 83 
Inc.). Cells were CTV labelled in RPMI (Life Technologies) containing 10% Foetal 
Calf Serum with 10 µM CTV (Invitrogen) at room temperature for 5 min. Ratios of OT-
I cells in the anergy group were normalised to the naïve ratio in the PBS treatment 
group by dividing the % population of each subset in anergy group by the % in PBS 
group. Cell enrichment after low OT-I cell number transfer experiments (Fig S2F,G) 
was conducted exactly as described previously (Hataye et al., 2006), except that a 
CD45.2-PE antibody was used to enrich the transferred cells. 
 
3.3.4: EdU treatment and staining 
Mice were injected i.p. with 0.25mg of EdU on days 4 and 5 of the experiment, after 
which splenocytes were stained using the indicated antibodies and the Click-iT EdU 
Alexa Fluor 647 Flow Cytometry Assay Kit (Life Technologies) followed according to 
manufacturer’s instructions. 
 
3.3.5: Flow cytometric analysis 
Cell suspensions were stained in PBS containing 2.5% Foetal Calf Serum and 0.1% 
Azide. Intracellular staining was conducted using the Foxp3 Transcription Factor 
Staining Buffer Set (eBioscience) according to manufacturer’s instructions. Samples 
were collected on a BD LSRII, Fortessa or X20 flow cytometer (BD Biosciences). The 
following antibodies/reagents were used for staining (purchased from Biolegend 
unless otherwise stated): CD8a (clone 53-6.7), CD44 (clone IM7), KLRG1 (clone 
2F1), CD107a (clone 1D4B), IFN-g (clone XMG1.2), TNF-a (clone MP6-XT22), IL-2 
(clone JES6-5H4), CD127 (clone A7R34), CD45.1 (clone A20), CD45.2 (clone 104), 
CD62L (clone MEL14), CD25 (clone PC61), GzmB (clone GB11; ThermoFisher 
Scientific), Ki67 (clone B56; BD Biosciences), JunB (clone C37F9; Cell Signaling 
Technology), Bim (Cat. No. 2819; Cell Signaling Technology), Bcl2 (3F11; BD 
Biosciences), ppErk1/2 (clone 197G2; Cell Signaling Technologies), pS6 (clone 
D57.2.2E; Cell Signaling Technologies), Annexin V, 7AAD and Zombie Aqua Fixable 
Viability Kit. Annexin V staining was conducted in Annexin V Binding Buffer 
(Biolegend). MHCI LCMV tetramers were purchased from the Biomolecular Resource 
Facility, JCSMR, ANU. 
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3.3.6: Phosphoflow and cytokine staining experiments  
For phosphoflow analysis of OT-I cells, cells were restimulated with 0.1µg/ml 
SIINFEKL peptide for 15 minutes. Cells were then fixed and permeabilised using the 
BD Phosflow Fix Buffer I and Perm Buffer III according to manufacturer’s instructions. 
Cells were stained with the appropriate surface and phosphoflow antibodies for 1 
hour at room temperature in PBS containing 2.5% Foetal Calf Serum and 0.1% 
Azide. For cytokine staining, OT-I cells or LCMV-specific cells were restimulated with 
0.1µg/ml OVA SIINFEKL, LCMV GP33-41 or LCMV NP396-404 peptide in the presence 
of 3µg/ml Brefeldin A (eBioscience) and CD107a antibody for 5-6 hours, prior to 
surface staining then fixation with Biolegend Fixation Buffer, and intracellular cytokine 
staining in eBioscience Permeabilisation Buffer according to manufacturer’s 
instructions. In order to normalize the MFI to the PBS group (or WT group in Figures 
3.5 and 3.S5), the MFI in each of the subsets was divided by the MFI of the marker in 
the Ndfip1+/+ OT-I cells in the PBS group, or corresponding cells from the WT group. 
 
3.3.7:In vivo cytotoxicity assay 
For the in vivo cytotoxicity assay (Oehen and Brduscha-Riem, 1998), pooled lymph 
nodes and spleens were harvested from CD45.1 mice, and red blood cells were 
lysed in 0.83% NH4Cl. Cells were split in half, with half the cells pulsed in 0.3µg/ml 
SIINFEKL peptide at 37oC for 1 hr, and the other half mock treated. Peptide pulsed 
cells were then labeled with a high concentration of CTV (5µM) while unpulsed cells 
were labeled with a low concentration of CTV (0.5µM) using the labeling protocol 
described above. Once labeled, cells were mixed together again, and 107 cells were 
injected per mouse. The ratios of CD45.1+ CTVhi and CTVlo cells were then 
assessed within the spleen by flow cytometry. % lysis was calculated as follows: [1 – 
(r unprimed/r primed)] x 100, where “r”= %CTVhi / %CTVlo. 
 
3.3.8: Histology 
H&E and GAF stains were performed on pancreata fixed in Neutral Buffered 
Formalin by the MCRF, JCSMR, ANU. Sections were visualised using a Olympus IX 
71 microscope and DP 70 controller software (version 1.2.1.108). 
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3.3.9: Statistical analysis 
Data analysis was conducted using Prism Software (GraphPad). Data were analysed 
using paired or unpaired T tests, or a Two-way ANOVA with a Bonferroni post-test 
(Fig. 3.S5A-C). 
 
 
3.4: Results 
 
3.4.1: Ndfip1 is dispensable for CD8+ T cell deletional tolerance to a pancreatic 
self-antigen 
Bystander CD8+ T cell activation confounds analysis of any CD8+ T cell intrinsic role 
of NDFIP1 in Ndfip1kru/kru mice homozygous for an NDFIP1-truncating null mutation 
(Altin et al., 2014). Activated/effector CD44hi CD8+ T cell accumulation was reduced 
in Ndfip1kru/kru mice bearing a rearranged TCR transgene encoding OT-I, an 
ovalbumin (OVA)-specific MHC I-restricted TCR, and was completely abolished in 
Rag1-/- OT-I Ndfip1kru/kru mice where no other TCRs can be expressed (Fig. 3.S1A). 
Thus Rag1-/- Ndfip1kru/kru OT-I mice provided a homogeneous source of naïve Ndfip1-
deficient CD8+ T cells. 
 
We first tested a peripheral CD8+ T cell deletion checkpoint triggered by low self-
antigen from pancreatic islet b cells, as NDFIP1 loss disrupts a similar CD4+ T cell 
checkpoint (Altin et al., 2014). A 50:50 mix of Ndfip1kru/kru (CD45.1/CD45.2) and 
Ndfip1+/+ (CD45.1/CD45.1) Rag1-/- OT-I CD8+ T cells was labeled with the cell 
division dye Cell Trace Violet (CTV). The cells were injected into CD45.2/CD45.2 
Ndfip1+/+ Rag1+/+ recipients bearing the RIP-OVAhi transgene, or non-transgenic (B6) 
controls (Fig. 3.S1B). In RIP-OVAhi mice, soluble OVA expressed in insulin secreting 
pancreatic islet β cells is constitutively cross-presented by dendritic cells in the 
draining pancreatic lymph nodes. Transferred OT-I cells divide in response to cross-
presented OVA, but do not form cytotoxic effector cells and undergo BIM-dependent 
apoptotic death (Davey et al., 2002; Parish et al., 2009; Wagle and Parish, 2016). 
However, co-transferred Ndfip1kru/kru and Ndfip1+/+ OT-I cells proliferated comparably 
as assessed by cell ratios, numbers and CTV dilution (Fig. 3.S1C-E) and failed to 
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Figure 3.1. NDFIP1 limits autoimmune pathology after high antigen dose 
stimulation. 2x106 Ndfip1+/+ or Ndfip1kru/kru OT-I cells were injected into RIP-OVAhi 
mice that did or did not receive 10µg OVA peptide on days -1,1,2 as in (A). (B) 
Diabetes incidence in the treatment groups (n=17 mice/group from 2 experiments). 
(C) Representative day 9 islet histology sections from peptide or PBS treated RIP-
OVAhi mice in (B) that received Ndfip1kru/kru OT-I cells. (D,E) Representative (D) and 
pooled data (E; Error bars are SEM) showing Ndfip1kru/kru OT-I numbers at day 9 in 
the draining sacral and pancreatic lymph nodes of peptide treated RIP-OVAhi versus 
PBS treated control mice (pooled B6 and RIP-OVAhi mice) (n=7 mice/group from 2 
experiments). *** = p<0.001 
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differentiate into effector cells (data not shown) in RIP-OVAhi recipients. RIP-OVAhi 
mice given either Ndfip1kru/kru or Ndfip1+/+ OT-I cells also did not develop diabetes, 
with both wild-type and mutant cells deleted normally by 6 weeks post-transfer (Fig. 
3.S1F-H). Thus, in contrast to CD4+ T cells, Ndfip1 is dispensable for a peripheral 
CD8+ T cell deletion checkpoint to a tissue-restricted self-antigen. 
 
3.4.2: Ndfip1-deficiency disrupts CD8+ T cell tolerance to a pancreatic self-
antigen in the context of higher antigen doses 
Islet-specific Ndfip1-mutant CD4+ T cells do not cause diabetes unless 
simultaneously exposed to a large, systemic bolus of tolerogenic antigen (Altin et al., 
2014). To test if a similar NDFIP1-dependent checkpoint exists in CD8+ T cells, RIP-
OVAhi mice injected with Ndfip1 mutant or wild-type OT-I cells as in Fig. 3.S1F (day 
0) were given either a high dose (10µg) of OVA-peptide (SIINFEKL) or saline (PBS) 
on days -1, 1 and 2 (Fig. 3.1A). As in Fig. 3.S1G, neither wild-type nor mutant cells 
caused diabetes without peptide treatment (Fig. 3.1B). Peptide treated wild-type OT-I 
cells also did not cause diabetes (Fig. 3.1B). However, 84% of RIP-OVAhi mice given 
mutant OT-I cells and systemic OVA-peptide developed diabetes associated with 
pancreatic islet infiltration and destruction (Fig. 3.1B,C), with peptide treatment 
augmenting mutant cell numbers (Fig. 3.1D,E). Thus, NDFIP1 cell autonomously 
restrains effector CD8+ T cell accumulation and target tissue cell destruction, but only 
in response to high systemic tolerogen levels. 
 
3.4.3: Tolerogen concentration governs Ndfip1 restraint of CD8+ T cell 
expansion and differentiation 
Low tolerogen doses induce peripheral CD8+ T cell deletion, whereas higher doses 
cause CD8+ T cell persistence in an anergic state (Redmond et al., 2005). To test if 
NDFIP1 is important for the CD8+ T cell anergy but not low dose deletion checkpoint, 
we co-transferred a 50:50 mix of CD45-marked Ndfip1kru/kru and Ndfip1+/+ OT-I cells 
into wild-type B6 mice as before (day -1, Fig. 3.2A). Recipient mice were then given 
daily i.v. injections of either PBS or a low (1µg) or high (10µg) dose of OVA-peptide, 
on days 0, 1 and 2. The mutant and wild-type OT-I cell numbers increased 
comparably in the spleen by day 3 after the first peptide injection (Fig. 3.2B-D).  
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Figure 3.2. Ndfip1 mutant OT-I cells resist tolerance to high antigen doses. B6 
mice were injected with 2x106 OT-I cells that were a 50:50 mix of Ndfip1+/+ and 
Ndfip1kru/kru cells, then peptide treated and analysed as in (A). (B-D) Representative 
plots and pooled data showing the ratio (B,D) and number (C) of Ndfip1+/+ 
(CD45.1/CD45.1) and Ndfip1kru/kru (CD45.1/CD45.2) OT-I cells after low and high 
dose OVA peptide treatment (n=6-19 mice/group from 3-5 experiments). (E) The % 
Ki67+ Ndfip1+/+ and Ndfip1kru/kru OT-I cells after high dose peptide treatment on the 
indicated days (n=7-10 mice/group from 3-4 experiments). Histogram shows data at 
day 6. (F) EdU incorporation into Ndfip1+/+ and Ndfip1kru/kru OT-I cells at day 6 after 
high dose peptide treatment (n=7-8 mice/group from 2 experiments). Histogram 
shows data at day 6. (G) The percent live (7AAD-AxV-), early apoptotic (7AAD-AxV+) 
and late apoptotic/necrotic (7AAD+) Ndfip1+/+ and Ndfip1kru/kru OT-I cells at day 6 
after high dose peptide (n=6 mice/group from 2 experiments). (H) The % and number 
of Granzyme B+ CD62L+ Ndfip1+/+ and Ndfip1kru/kru OT-I cells at days 3 and 6 after 
high dose peptide (n=8-9 mice/group from 4 experiments). Contour plot shows data 
at day 6. (I) B6 mice given 2x106 Ndfip1+/+ or Ndfip1kru/kru OT-I cells were treated with 
high dose OVA-peptide or PBS as in (A). At day 6, mice (including “Control” 
untreated B6 mice) were injected with a 50:50 mix of OVA-peptide coated CTVhi and 
untreated CTVlo CTL target cells, and splenic target cell lysis was measured after 4 
hours. Representative histograms and the % lysis are shown (n=8 mice/group from 2 
experiments, error bars are SEM). * = p<0.05, ** = p<0.01, *** = p<0.001 
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However, a striking increase in Ndfip1kru/kru relative to Ndfip1+/+ OT-I cells occurred by 
day 6 after high dose peptide, with mutant cells making up 86% of cells (Fig. 3.2B-D). 
By contrast, mutant cell ratios and numbers exhibited little difference at day 6 after  
low dose peptide (Fig. 3.2C,D). Thus, NDFIP1 acts cell autonomously to inhibit CD8+ 
T cell expansion to high systemic tolerogen levels. 
 
In CD4+ T cells, NDFIP1 promotes cell cycle exit as measured by Ki67 loss in T cells 
responding to low or high tolerising antigen doses (Altin et al., 2014). By contrast, the 
fraction of Ki67+ OT-I cells induced by high dose peptide was comparable in mutant 
and wild-type cells (Fig. 3.2E). We next measured the replication rate of responding 
OT-I cells on days 4 and 5 through incorporation of the thymidine analogue 5-
Ethynyl-2´-deoxyuridine (EdU), and a higher percentage of Ndfip1kru/kru OT-I cells had 
incorporated EdU by day 6 (Fig. 3.2F). By contrast, the pro-apoptotic protein BIM, 
which mediates CD8+ T cell death in tolerance models (Davey et al., 2002), was 
comparably expressed in mutant and wild-type OT-I cells (Fig. 3.S2A). Paradoxically, 
the pro-survival BCL2 protein was down regulated in Ndfip1-mutant T cells (Fig. 
3.S2B), but this likely reflects greater effector differentiation (see below). However, 
when mutant and wild-type OT-I cell death was analysed with the cell viability dye 
7AAD and Annexin V (AxV), there was a small decrease in early apoptotic 
(AxV+7AAD-) mutant OT-I cells, with a corresponding increase in AxV-7AAD- live 
cells (and no change in late apoptotic/necrotic 7AAD+ cells) (Fig. 3.2G). Thus, 
NDFIP1 restrains both CD8+ T cell replication rate and survival in response to high 
tolerogen doses. 
 
We next tested if Ndfip1-mutant OT-I cells aberrantly became effectors, since CD8+ T 
cell peripheral tolerance checkpoints normally inhibit cytotoxic effector cell 
differentiation by limiting cytolytic protease granzyme B (GzmB) expression and 
cytokine production (Hernandez et al., 2001; Parish et al., 2009). In response to high 
dose peptide, a higher percentage and number of GzmB+ CD62L- Ndfip1-mutant OT-
I cells were seen on day 6 (Fig. 3.2H). To assess if this translated into increased 
target killing by mutant cells, we conducted an in vivo cytotoxicity assay on day 6. 
After 4 hours, we observed significantly more killing by splenic mutant versus wild-
type OT-I cells (Figure 3.2I). As the assay was saturated in the mutant condition (ie. 
all peptide-pulsed targets were killed), this likely underestimates mutant OT-I cell 
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killing. In contrast, mutant cells did not exhibit elevated cytokine production at any 
time point (Fig. 3.S2C). OT-I cells variably maintained the capacity to degranulate (as 
assessed by surface CD107a expression), but mutant and wild-type degranulation 
was similar (Fig. 3.S2D). Elevated GzmB+ CD62L- Ndfip1-mutant OT-I cells were 
also seen at low peptide doses, although this was less pronounced than at high 
peptide doses (Fig. 3.S2E) and no GzmB+ CD62L- mutant OT-I cells were seen in 
RIP-OVAhi mice not treated with peptide (data not shown). Thus, in addition to 
increased expansion, NDFIP1-deficient CD8+ T cells aberrantly form cytolytic 
effectors. 
 
As naïve precursor frequency can affect CD8+ T cell differentiation, we next 
examined if Ndfip1-mutant OT-I cells aberrantly expanded and differentiated at low 
precursor frequencies. While more variability was observed at lower precursor 
frequencies, we still observed augmented expansion and effector differentiation of 
mutant OT-I cells (Fig. 3.S2F,G) suggesting that the mutant phenotype is largely 
independent of precursor frequency. 
 
3.4.4: Ndfip1 limits TCR signaling in anergic CD8+ T cells 
We next asked if exaggerated effector cell formation in Ndfip1 deficient OT-I cells 
was via the same mechanism as in CD4+ T cells. In Ndfip1-/- CD4+ T cells, 
exaggerated Th2 differentiation is accompanied by greater levels of the Th2 
transcription factor, JUNB, which is a direct target of ITCH (Altin et al., 2014; Oliver et 
al., 2006). Ndfip1-/- CD4+ T cells also produce more IL-2 and express more of the 
high affinity IL-2 receptor (CD25) (Ramos-Hernandez et al., 2013). By contrast, there 
was no increase in IL-2, CD25 or JUNB in NDFIP1-deficient OT-I cells responding to 
high peptide doses (Fig. 3.S2C, Fig. 3.S3A,B). Thus, the NDFIP1-mediated CD8+ T 
cell checkpoint is distinct from the checkpoint mechanism in CD4+ T cells. 
 
We next examined if NDFIP1 restrains TCR signaling in CD8+ T cells, since the ITCH 
ubiquitin ligase inhibits TCR signaling during in vitro ionomycin-induced CD4+ T cell 
anergy (Heissmeyer et al., 2004), and TCR-induced ERK phosphorylation is inhibited 
in CD8+ T cells exposed to high tolerogen doses (Redmond et al., 2005). After in vitro 
peptide restimulation, 76% of control OT-I cells from PBS-treated mice 
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Figure 3.3. NDFIP1 restrains OT-I TCR signaling after high dose peptide 
treatment. OT-I cells subjected to high dose OVA peptide treatment in Fig. 3.2 were 
analysed for ppERK and pS6 upon 15 min in vitro peptide restimulation (A,B; n=7-11 
mice/group from 3 experiments), or forward and side scatter (C,D; n=8-16 
mice/group from 4 experiments), at the indicated time points. ** = p<0.01, *** = 
p<0.001 
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phosphorylated ERK (denoted ppERK; PBS group, Fig. 3.3A). By contrast, on day 3, 
only 15% of OT-I cells treated with high dose peptide were ppERK+ after 
restimulation, regardless of Ndfip1 genotype. However, on day 4, in vitro 
restimulation induced ppERK in 30% of OT-I cells, with a significantly more ppERK+ 
Ndfip1-deficient versus wild-type cells (Fig. 3.3A). By day 6, ERK signaling in mutant 
and wild-type cells had recovered comparably. Recovery of function upon antigen 
withdrawal within peptide anergy models has been observed previously (Pape et al., 
1998; Redmond et al., 2005). 
 
TCR-induced mTOR signaling is impaired during CD4+ T cell anergy (Zheng et al., 
2007), and this was also seen in OT-I cells exposed to 10µg OVA peptide. 79% of 
restimulated OT-I cells from PBS-treated mice phosphorylated ribosomal protein S6 
(pS6), an mTOR target, compared to only 37% of wild-type OT-I cells on day 3 (Fig. 
3.3B). Ndfip1-deficient OT-I cells again had a partial rescue in signaling, with 
significantly greater pS6 responses at this timepoint and on days 4 and 6 (Fig. 3.3B).  
 
Since ERK and mTOR signaling promote anabolic growth, we compared forward 
scatter as a measure of cell size in Ndfip1-deficient and wildtype OT-I cells before 
restimulation. Forward and side scatter were significantly increased in Ndfip1 mutant 
versus wild-type OT-I cells on day 4 (Fig. 3.3C,D). Thus, an inability to fully dampen 
TCR signaling in Ndfip1 mutant OT-I cells may explain their exaggerated expansion 
and effector differentiation. 
 
To test if augmented mTOR signaling causes the Ndfip1 mutant OT-I cell phenotype, 
mice containing peptide stimulated wild-type and mutant OT-I cells were treated with 
rapamycin from days 3-5 of the experiment. While rapamycin treatment reduced 
overall OT-I expansion and effector differentiation (Fig. 3.S3C,D), augmented 
expansion and differentiation of mutant relative to wild-type OT-I cells was still 
observed (Fig. 3.S3E,F). Thus, elevated mTOR signaling alone cannot explain the 
mutant phenotype. 
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3.4.5: Ndfip1 restrains CD8+ T cell expansion and effector differentiation during 
continuous antigen exposure 
NDFIP1-deficient CD8+ T cells underwent exaggerated expansion and effector 
differentiation after the last peptide injection. We thus asked if NDFIP1 loss would 
disrupt this CD8+ T cell checkpoint in the face of sustained antigen by continuing the 
high dose peptide injections for the duration of the experiment (Fig. 3.4A). Ndfip1 
mutant OT-I cells exposed to sustained antigen still expanded to much higher 
numbers than co-transferred wild-type cells (Fig. 3.4B) and formed more GzmB+ 
CD62L- effector cells (Fig. 3.4C). As with transient peptide treatment, the NDFIP1-
deficient cells retained higher TCR-induced ppERK and pS6 (Fig. 3.4D,E), and 
displayed an increase in forward and side scatter (Fig. 3.4F,G).  
 
3.4.6: Ndfip1 does not limit CD8+ T cell expansion and differentiation during 
infection 
To test if NDFIP1 also repressed effector T cell expansion and differentiation during 
an acute infection, Ndfip1 mutant or wild-type OT-I cells were transferred into B6 
mice that were then infected with Listeria monocytogenes, using a strain that 
transgenically expresses OVA (Fig. 3.S4A). Wild-type and mutant OT-I cell 
expansion was similar at day 10 post-infection (Fig. 3.S4B). mTOR signaling 
promotes effector CD8+ T cell terminal differentiation (Araki et al., 2009), but we did 
not see an increase in terminal effectors (KLRG1hiCD127lo) or loss of memory 
precursors (KLRG1loCD127hi) in mutant cells, suggesting no functionally relevant 
increase in mTOR signaling (Fig. 3.S4C). Thus, Ndfip1 loss does not influence 
effector CD8+ T cell differentiation and expansion during Listeria infection. 
 
To better delineate effector and memory differentiation of Ndfip1-/- CD8+ T cells, we 
examined the response to acute lymphocytic choriomeningitis virus Armstrong strain 
(LCMV-Arm) infection. To avoid bystander autoimmunity in Ndfip1kru/kru mice, we 
used mice bearing a floxed Ndfip1 allele (Ndfip1f/f) and a GranzymeB-cre (GzmB-cre) 
transgene. GzmB-cre mice delete floxed alleles in activated effector CD8+ T cells 
during LCMV infection, but only minimally flox genes in activated CD4+ T cells 
(Rutishauser et al., 2009). Consistent with minimal gene deletion in CD4+ T cells, no 
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Figure 3.4. NDFIP1 controls OT-I anergy to sustained antigen. A high dose 
peptide anergy experiment was conducted as in Fig. 3.2, except OVA peptide (or 
PBS) treatment was sustained as in (A). The ratio of wild-type to mutant cells (B), 
Granzyme B and CD62L expression (C), ppERK and pS6 after in vitro peptide 
restimulation (D,E) and forward and side scatter (F,G) are shown (n=10-11 
mice/group from 2 experiments). *** = p<0.001 
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dermatitis or fatal autoimmune disease was seen in GzmB-cre+ Ndfip1f/f mice up to 3-
4 months of age and, unlike Ndfip1-/- mice, there was no accumulation of activated T 
cells in the blood of 8 week old mice (data not shown). GzmB-cre+ Ndfip1f/f 
(conditional KO, or cKO) mice, or GzmB-cre+ Ndfip1+/+ littermate (WT) controls, were 
infected with LCMV-Arm, and the CD8+ T cell response tracked in the blood to an 
early memory time-point (day 42) after which splenic memory T cell number, 
phenotype and function was assessed. There was no change in expansion, 
contraction and persistence of tetramer+ CD8+ T cells specific for the 
immunodominant LCMV GP33-41 or NP396-404 peptides in cKO versus WT mice (Fig. 
3.S5A,B). While the proportion of KLRG1hi and KLRG1loCD127hi cells was also 
unchanged at the peak of expansion (day 8), a significant decrease in 
KLRG1loCD127hi cells was seen within GP33-41 and (to a lesser extent) NP396-404-
specific cells (Fig. 3.S5B and data not shown), although accumulation of CD62Lhi 
central memory cells was normal (Fig. 3.S5C). Similar trends were observed within 
splenic memory cells (Fig. 3.S5D-F). However, memory T cell function was 
unchanged. The same number of IFNγ-producing cells was recovered in WT and 
cKO mice (Fig. 3.S5G), with no alteration in IFNγ produced per cell or the proportions 
of IFNγ+TNFα+ and IFNγ+TNFα+IL-2+ cells (Fig. 3.S5H). Thus, Ndfip1 loss 
minimally impacts the CD8+ T cell response to an acute systemic infection. 
 
 
3.5: Discussion 
 
In this study, we reveal a CD8+ T cell intrinsic, highly context dependent NDFIP1-
mediated tolerance checkpoint. Ndfip1-deficiency dysregulates CD8+ T cells by a 
different mechanism than in CD4+ T cells. Ndfip1-/- CD4+ T cell hyper-proliferation is 
due to elevated IL-2 production and an inability to exit cell cycle (Altin et al., 2014; 
Ramos-Hernandez et al., 2013), and is accompanied by excessive IL-4 production 
and Th2 differentiation due to JUNB accumulation (Oliver et al., 2006). By contrast, 
IL-2 production and JUNB was not increased in Ndfip1 deficient OT-I cells, and 
augmented expansion was via more rapid proliferation and diminished death rather 
than cell-cycle exit deficiencies. Elevated GzmB expression in Ndfip1 deficient CD8+ 
T cells demonstrates that NDFIP1 can inhibit Type 1 immune responses, in contrast 
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to CD4+ T cells where NDFIP1 loss has little effect on Th1 differentiation (Layman et 
al., 2017b; Oliver et al., 2006). 
 
The primary biochemical effect of NDFIP1 deficiency in high-zone CD8+ T cell 
tolerance was partial recovery of TCR signaling. Other mechanisms, such as the 
ubiquitin ligase CBLB (Heissmeyer et al., 2004; Jeon et al., 2004) or diacylglycerol 
kinase alpha (Olenchock et al., 2006), must also contribute to TCR desensitization, 
since signaling in NDFIP1-deficient CD8+ T cells remained lower than non-tolerized 
control T cells. NDFIP1 may directly target mTOR signaling pathway components, 
and increased mTOR signaling was proposed to augment Ndfip1-/- Treg proliferation 
and differentiation (Layman et al., 2017a), however our data suggest that elevated 
mTOR signaling alone cannot explain the mutant CD8+ T cell phenotype. Our data 
also do not rule out a role for pathways beyond partially rescued TCR signaling in the 
Ndfip1 mutant cell phenotype, and further work is required to pinpoint the 
mechanism. 
 
Current studies on CD8+ T cell checkpoints largely focus on exhaustion, where 
established effector cells lose inflammatory function when chronically stimulated. By 
contrast, in vivo tolerance checkpoints that regulate initial CD8+ T cell activation are 
poorly defined in molecular terms. Our findings provide evidence that molecularly 
distinct tolerance pathways operate in the context of high and low tolerogen doses. 
As high and low antigen doses favour anergy and deletion respectively (Redmond et 
al., 2005), and only high-zone tolerance depends on NDFIP1, these data imply that 
deletion and anergy are molecularly separable states. This difference may be due to 
the 6 day delay in Ndfip1 mutant OT-I cell phenotype; responding cells may die in 
deletion models before a phenotype can manifest. Alternatively, as Ndfip1 is TCR-
induced, it may only enforce tolerance during strong TCR engagement. However, 
there may be a delay in the kinetics of peripheral deletion that was missed in our 
study. Moreover, as a hallmark of anergy is cell persistence, the long-term 
persistence of Ndfip1 deficient anergic cells needs to be examined. 
 
The NDFIP1-mediated tolerance checkpoint may maintain CD8+ T cell tolerance to 
abundant environmental antigens (eg. commensal and food antigens), fetal antigens 
once the fetus has increased in mass, or abundant peripheral self-antigens not 
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efficiently expressed in the thymus. Thus, dysregulated CD8+ T cell tolerance could 
contribute to the autoimmune and inflammatory diseases seen in patients with 
NDFIP1 polymorphisms. NDFIP1 may also limit CD8+ T cell priming against high 
burden tumours, and could have utility in cancer immunotherapy. Finally, although 
Ndfip1 loss has little effect on the effector T cell response to acute infection, our data 
do not rule out a role for Ndfip1 in effector CD8+ T cell exhaustion during chronic 
stimulation within tumours or persistent viral infection. Future work is needed to 
evaluate these possibilities. 
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Figure 3.S1. Ndfip1 is dispensable for peripheral tolerance in RIP-OVAhi mice. 
Related to Figure 3.1. (A) The percentage of CD44hi cells within Ndfip1+/+ or 
Ndfip1kru/kru OT-I cells on either a Rag1+/- or Rag1-/- background (n=4-18 mice per 
group). Error bars depict SEM. (B) Experimental outline; CD45.2/CD45.2 Ndfip1+/+ 
Rag1+/+ B6 or RIP-OVAhi mice were i.v. injected with 2x106 CTV labeled OT-I cells 
that were a 50:50 mix of Ndfip1+/+ and Ndfip1kru/kru cells, and the cells within the 
draining sacral and pancreatic lymph nodes were analysed at the indicated time 
points post-injection. The ratio and numbers (C,D), and CTV dilution (E), of Ndfip1+/+ 
(CD45.1/CD45.2) and Ndfip1kru/kru (CD45.1/CD45.1) OT-I cells at the indicated time 
points are shown (data is pooled with 5-13 mice per group from 3-5 independent 
experiments). Representative plots are from day 6 (C) and day 3 (E). (F-H) B6 or 
RIP-OVAhi mice were i.v. injected with 2x106 Ndfip1+/+ or Ndfip1kru/kru CD45.1+ OT-I 
cells and monitored as illustrated in (F). (G) Diabetes incidence measured daily for 
21 days within RIP-OVAhi mice by urine glucose testing. (H) Ndfip1+/+ or Ndfip1kru/kru 
OT-I cell numbers within B6 or RIP-OVAhi mice 42 days after cell transfer. Pooled 
data with 11-16 mice per group from 5 independent experiments are shown, error 
bars depict SEM. ** = p<0.01, *** = p<0.001 
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Figure 3.S2: Expression of apoptosis regulators and cytokines by Ndfip1 
mutant OT-I cells. Related to Figure 3.2. The Ndfip1+/+ and Ndfip1kru/kru OT-I cells 
treated with high dose (10µg) OVA-peptide from Figure 3.2 were analysed on the 
indicated days for Bim (A) and Bcl2 (B) expression, or cytokine production (C; error 
bars depict SEM) and degranulation (CD107a) (D) upon peptide restimulation, at the 
indicated time points. Representative plots are from day 6, and grey histograms 
indicate expression levels in PBS control naïve OT-I cells. Pooled data with 6-12 
mice per group from 2-5 independent experiments are shown. (E) Ndfip1+/+ and 
Ndfip1kru/kru OT-I cells treated with low dose (1µg) OVA-peptide as in Figure 3.2C,D 
were analysed for Granzyme B and CD62L expression at day 6. Pooled data with 5-
11 mice per group from 3 independent experiments are shown. (F,G) CD45.1 B6 
mice were injected with 5x104 OT-I cells that were a 50:50 mix of Ndfip1+/+ 
(CD45.2/CD45.2) and Ndfip1kru/kru (CD45.1/CD45.2) cells. Mice were then treated 
with PBS or a high dose (10µg) of OVA-peptide as in Figure 3.2A. At day 6, CD45.2+ 
cells were enriched from pooled lymph nodes and spleen of each mouse, and the 
ratio (F) and Granzyme B and CD62L expression (G) of wild-type and mutant cells 
was assessed. Pooled data with 8 mice per group from 2 independent experiments 
are shown. * = p<0.05, ** = p<0.01, *** = p<0.001 
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Figure 3.S3. JUNB and CD25 expression levels are unchanged by Ndfip1 loss. 
Related to Figure 3.3. The Ndfip1+/+ and Ndfip1kru/kru OT-I cells treated with high 
dose (10µg) OVA-peptide from Figure 3.2 were analysed on the indicated days for 
CD25 (A) and JUNB (B) expression. Representative plots are from day 6, and grey 
histograms indicate expression levels in PBS control naïve OT-I cells. Pooled data 
with 8-10 mice per group from 3 independent experiments are shown. (C-F) B6 mice 
given 2x106 OT-I cells that were a 50:50 mix of Ndfip1+/+ and Ndfip1kru/kru cells were 
treated with high dose (10µg) OVA-peptide as in Figure 3.2A, except mice were then 
treated with 600µg/kg of rapamycin or vehicle from days 3-5 of the experiment. The 
total number of OT-I cells (ie. the combination of both genotypes) recovered as well 
as total Granzyme B and CD62L expression (C,D; error bars depict SEM), as well as 
the ratio (E) and Granzyme B and CD62L expression (F) of wild-type and mutant 
cells was assessed at day 6 of the experiment. Pooled data with 6 mice per group 
from 2 independent experiments are shown. * = p<0.05, ** = p<0.01 
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Figure 3.S4. Ndfip1 loss does not affect OT-I expansion and differentiation 
during acute Listeria infection. Related to Figure 3.4. B6 mice were i.v. injected 
with 5x104 CD45.1+ Ndfip1+/+ or Ndfip1kru/kru OT-I cells and subsequently i.v. infected 
with 105 cfu of OVA transgenic Listeria monocytogenes (LM-OVA) as illustrated in 
(A). OT-I expansion (B) and terminal differentiation as assessed by KLRG1 and 
CD127 expression (C) was assessed at day 10 post-infection. Pooled data with 5-9 
mice per group from 2 independent experiments are shown. Error bars depict SEM. 
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Figure 3.S5. NDFIP1 loss has little effect on CD8+ T cell effector and memory 
differentiation during acute LCMV infection. Related to Figure 3.4. GzmB-cre+ 
Ndfip1f/f (cKO) or GzmB-cre+ Ndfip1+/+ (WT) mice were infected with LCMV-Arm, and 
the CD8+ T cell response tracked in the blood (A-C) until day 42 post-infection when 
the splenic T cells were isolated and phenotyped (D-H). (A) The percentage of live 
WT or cKO blood cells that were CD8+ and stained for the LCMV GP33-41 or NP396-404 
tetramers. (B,C) The percentage of KLRG1hi, KLRG1loCD127hi or CD62Lhi CD8+GP33-
41
+ blood cells. (D) Number of splenic CD8+GP33-41+ or CD8+NP396-404+ cells. (E,F) The 
percentage of KLRG1hi, KLRG1loCD127hi or CD62Lhi CD8+GP33-41+ splenocytes. (G) 
The number of CD8+IFNγ+ splenocytes after GP33-41 or NP396-404 peptide 
restimulation. (H) IFNγ MFI, %TNFα+ and %TNFα+IL-2+ within CD8+IFNγ+ cells after 
GP33-41 peptide restimulation. n=6-8 mice per group from 2 experiments, error bars 
are SEM. * = p<0.05, ** = p<0.01 
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The following manuscript included in the thesis has been modified to fit the thesis 
layout and may differ from the final manuscript to be submitted for publication. The 
result figures are incorporated into the results section 4.4 and supplementary figures 
and tables are included after the references section 4.8. The figure and table 
numbers have been modified to include the chapter number in the prefix, for example 
from Figure 1 to Figure 4.1 and Table S1 to Table 4.S1.  
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4.1: Abstract 
 
Negative regulatory processes, such as anergy and exhaustion, cause active 
suppression of CD8+ T cell effector functions. A longstanding question has been to 
what extent the same molecular pathways control exhaustion and anergy. We have 
addressed this question by examining the role of a transcriptional master regulator of 
anergy, EGR2, within the CD8+ T cell exhaustion process. We demonstrate that 
EGR2 expression is elevated in an antigen-dependent manner within exhausted cells 
relative to functional effectors in the LCMV model of exhaustion. EGR2 loss triggered 
a block in terminal exhaustion, with evidence of direct EGR2-dependent regulation of 
key genes such as Pdcd1, Tigit, Bcl6, Bach2 and Tcf7. Strikingly, the suite of genes 
directly regulated by EGR2 in the context of exhaustion minimally overlapped with 
previously characterised direct targets of EGR2 during anergy. Collectively, these 
data suggest that exhausted cells “re-purpose” a TCR-induced, anergy-associated 
transcription factor to promote terminal exhaustion. 
 
 
 
4.2: Introduction 
 
Chronic antigen encounter by CD8+ T cells typically triggers diminished effector 
functions by engaging an array of regulatory pathways. Depending on the point 
during the T cell response at which persistent TCR signals are encountered, different 
outcomes can occur. Persistent stimulation of effector T cells during both chronic 
viral infection and tumour growth leads to a progressive loss of inflammatory cytokine 
production and survival capacity, in part due to up-regulation of inhibitory receptors 
that limit function (Wherry and Kurachi, 2015). This process is termed T cell 
exhaustion, and it represents a transcriptionally and epigenetically distinct 
differentiation state (Doering et al., 2012; Ghoneim et al., 2017; Man et al., 2017; Sen 
et al., 2016; Wherry et al., 2007). The regulatory pathways engaged within CD8+ T 
cells during exhaustion impair immune control of tumours and infection, and thus 
rescuing the function of exhausted cells through inhibitory receptor blockade often 
demonstrates clinical efficacy in these contexts (Pauken and Wherry, 2015). 
Nevertheless, exhausted cells retain some inflammatory function and contribute to 
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immune control of infection (Jin et al., 1999; Schmitz et al., 1999), suggesting that 
exhaustion has evolved to enable T cells to contain an infection without causing 
deleterious immunopathology (Barber et al., 2006; Cornberg et al., 2013; Frebel et 
al., 2012). In contrast, persistent recognition of steady-state self-antigens by naïve T 
cells leads to peripheral tolerance induction (Redmond et al., 2003), a process that 
likely evolved to purge self-reactive T cells from the repertoire and thereby limit the 
risk of autoimmune disease (Parish and Heath, 2008; Walker and Abbas, 2002). 
Tolerant cells do not typically acquire effector functions (Hernandez et al., 2001), and 
are ultimately prevented from participating in future immune responses by either 
undergoing apoptotic death (Davey et al., 2002) or persisting in a hypofunctional 
state, termed anergy, which is characterised by TCR signaling deficiencies 
(Schwartz, 2003). 
 
A longstanding and unresolved question within the field has been to what extent 
similar molecular pathways control anergy and exhaustion. While exhaustion, and 
peripheral tolerance processes such as anergy, occur at different points within the 
immune response, there are a number of similarities between these differentiation 
states. Both processes are programmed by persistent TCR signaling (Redmond et 
al., 2003; Shin et al., 2007), are maintained by the inhibitory receptor PD-1 (Barber et 
al., 2006; Goldberg et al., 2007; Keir et al., 2007; Probst et al., 2005; Tsushima et al., 
2007), can be disrupted by IL-2 treatment (Blattman et al., 2003; Waithman et al., 
2008), show deficiencies in TCR signaling (Schwartz, 2003; Staron et al., 2014), and 
both differentiation states exhibit a significant overlap in their gene expression 
profiles (Parish et al., 2009; Schietinger et al., 2016). These observations raise the 
possibility that the TCR-induced molecular pathways that limit effector functions 
during exhaustion and anergy are largely overlapping. Understanding whether these 
states are molecularly distinct has important clinical implications. Autoimmune 
adverse events are observed within a subset of cancer patients downstream of 
immune checkpoint blockade (Postow et al., 2018). Therapies such as PD-1 
blockade disrupt both peripheral tolerance and exhaustion, which likely contributes to 
these autoimmune side-effects. However, if the pathways enforcing peripheral 
tolerance and exhaustion can be molecularly separated, it may be possible to 
develop more refined therapies that disrupt exhaustion within tumour-specific effector 
cells while leaving the peripheral tolerance process intact. 
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A key regulator of T cell anergy is the transcription factor EGR2. EGR2 inhibits T cell 
function during anergy through direct induction of factors that diminish TCR 
signalling, such as Cblb, Dgka and Dgkz (Zheng et al., 2012; Zheng et al., 2013), and 
Egr2-/- T cells are resistant to anergy induction (Safford et al., 2005; Zheng et al., 
2012). Previous gene expression profiling studies have demonstrated that Egr2 is 
also selectively up-regulated during CD8+ T cell exhaustion (Doering et al., 2012), 
suggesting that the EGR2-induced anergy program could contribute to impaired TCR 
signaling and diminished T cell function during exhaustion. In support of this idea, 
key EGR2 gene targets during anergy, such as Cblb and Lag3 (Zheng et al., 2012; 
Zheng et al., 2013), are also induced during exhaustion (Blackburn et al., 2009; Man 
et al., 2017), and both Cblb and Lag3 functionally contribute to the exhausted state 
(Blackburn et al., 2009; Ou et al., 2008).  
 
Here, we directly examined the role of EGR2 in the exhaustion process. We found 
that persistent antigen recognition drove higher EGR2 expression within CD8+ T cells 
during chronic relative to acute lymphocytic choriomeningitis virus (LCMV) infection. 
EGR2 was transiently expressed within the TCF1+ memory-like exhausted T cell 
population, and promoted terminal differentiation of these cells. RNA-seq analysis 
revealed a broad loss of the terminal exhaustion program in EGR2-deficient T cells, 
with ChIP-seq analysis indicating that EGR2 directly induced key exhaustion genes, 
such as Pdcd1 and Tigit, while directly repressing genes associated with a less 
terminally exhausted state, such as Bcl6 and Bach2. Strikingly, there was little 
overlap between the gene targets bound by EGR2 in the context of exhaustion and 
those previously identified during anergy. Collectively, these data suggest that 
exhausted CD8+ T cells repurpose the function of an antigen-induced tolerance 
regulator to promote terminal exhaustion rather than the anergy gene program. 
 
 
4.3: Methods 
 
4.3.1: Mouse strains, adoptive transfer and infections 
C57BL/6 (B6), B6.129S7-Rag1tm1Mom/J (Rag1-/-) and B6.SJL-PtprcaPep3b/BoyJ 
(CD45.1) mice were purchased from the Australian Phenomics Facility, ANU, 
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Australia or the Walter and Eliza Hall Institute Kew Animal Facility, VIC, Australia. 
P14 transgenic (Pircher et al., 1989), Egr2-GFP (Williams et al., 2017) and C57BL/6 
backcrossed CD4-cre+ Egr2 floxed (Ramon et al., 2010) mice have all been 
described previously. Mice were infected with 2x105 pfu LCMV-Arm virus by 
intraperitoneal (i.p.) injection, or with 2x106 pfu LCMV-Cl13 or LCMV-Cl13-V35A 
(Puglielli et al., 2001) virus by intravenous (i.v.) injection. LCMV viral plaque assays 
were conducted as described previously (Ahmed et al., 1984). For CD4 depletion, 
mice were injected with 200µg GK1.5 antibody (BioXCell) on days -1 and +1 of the 
infection. For P14 transfer experiments, 2x103 CD45.1+ P14 cells were transferred 
i.v. into CD45.2+ B6 mice one day prior to infection. All animal work was in 
accordance with protocols approved by the ANU and Peter MacCallum Cancer 
Centre Animal Experimentation Ethics Committees, and current guidelines from the 
Australian Code of Practice for the Care and Use of Animals for Scientific Purposes. 
 
4.3.2: Bone marrow chimeras 
Bone marrow was prepared by flushing the bone marrow cells out of mouse femurs 
using a 26G needle. Rag1-/- recipient mice were irradiated with 5 Gy, and 
reconstituted with 2x106 bone marrow cells consisting of a 50:50 mixture of wild-type 
B6.CD45.1+ bone marrow and B6.CD45.2+ CD4-cre+ Egr2f/f or CD4-cre+ Egr2+/+ bone 
marrow. Mice were allowed to reconstitute for at least 8 weeks prior to use. To 
account for reconstitution differences between mice, the %CD45.2+ cells in the 
tetramer+ CD8+ T cell subset measured after infection was divided by the %CD45.2+ 
cells in all CD8+ T cells measured in the same mouse bled before infection, and then 
multiplied by 100 and divided by 2 to set the pre-infection %CD45.2+ at 50%. 
 
4.3.3: CTV labeling, flow cytometric analysis and cell sorting 
Single cell suspensions were prepared from lymphoid organs for flow cytometry and 
CTV labeling by passing the cells through a 70µm cell strainer. Cells were CTV 
labelled in RPMI (Life Technologies) containing 10% Foetal Calf Serum with 10 µM 
CTV (Invitrogen) at room temperature for 5 min. For MHCII I-AbGP66-77 tetramer 
staining, cells were stained at 37oC for 1.5h in RPMI prior to staining for other 
markers. For all other surface flow cytometric staining, cell suspensions were stained 
in PBS containing 2.5% Foetal Calf Serum and 0.1% Azide on ice for 30 min. For 
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CXCR5 staining, cells were stained with CXCR5 antibody for 45 min. at room 
temperature prior to staining on ice for other markers. To eliminate dead cells from 
the analysis, cells were also stained with Fixable Viability Stain 620 (BD Biosciences) 
or LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Life Technologies) according to 
manufacturer’s instructions. For intracellular staining, cells were fixed, permeabilised 
and stained using the Foxp3 Transcription Factor Staining Buffer Set (eBioscience) 
according to manufacturer’s instructions. Samples were collected on a BD LSRII, 
Fortessa, X20 or Symphony flow cytometer (BD Biosciences), with data analysed 
using FlowJo Software (Tree Star). 
 
4.3.4: Phosphoflow and cytokine staining experiments 
For phosphoflow analysis, splenocytes were restimulated with plate-bound anti-CD3 
(clone 500A2, BD Biosciences; coated using 1µg/ml antibody in PBS) in a flat-
bottomed 96 well plate for 30 min. Cells were then fixed and permeabilised using the 
BD Phosflow Fix Buffer I and Perm Buffer III according to manufacturer’s instructions. 
Cells were stained with the appropriate surface and phosphoflow antibodies for 1h at 
room temperature in PBS containing 2.5% Foetal Calf Serum and 0.1% Azide. For 
cytokine staining, cells were restimulated with 0.1µg/ml of the appropriate 
synthesised viral peptide (Biomolecular Resource Facility, ANU) in the presence of 
3µg/ml Brefeldin A (eBioscience) and CD107a antibody for 6h, prior to surface 
staining then fixation with Biolegend Fixation Buffer, and intracellular cytokine 
staining in eBioscience Permeabilisation Buffer according to manufacturer’s 
instructions. 
 
4.3.5: Antibodies and tetramers used for flow cytometric analysis 
The following antibodies were used for staining (purchased from Biolegend unless 
otherwise stated): CD8a (clone 53-6.7), CD4 (clone RM4-5), CD44 (clone IM7), 
CD107a (clone 1D4B), IFNg (clone XMG1.2), TNFa (clone MP6-XT22), IL-2 (clone 
JES6-5H4), CD45.1 (clone A20), CD45.2 (clone 104), Ly6C (clone AL21; BD 
Biosciences), PSGL1 (clone 4RA10; BD Biosciences), PD-1 (clone RMP1-30), Tim3 
(clone RMT3-23), 2B4 (clone 2B4; BD Biosciences), Lag3 (clone C9B7W), CD160 
(clone 7H1), Egr2 (clone erongr2; eBioscience), TCF1 (clone C63D9; Cell Signaling 
Technologies), CXCR5 (clone 2G8; BD Biosciences), Eomes (clone Dan11mag, 
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eBioscience), T-bet (clone eBio4B10, eBioscience), ppErk1/2 (clone 197G2; Cell 
Signaling Technologies), and pS6 (clone D57.2.2E; Cell Signaling Technologies). 
MHCI LCMV tetramers were purchased from the Biomolecular Resource Facility, 
JCSMR, ANU. The MHCII I-AbGP66-77 tetramer was obtained from the NIH tetramer 
core facility (Emory University, Atlanta, GA). 
 
4.3.6: RNAseq analysis 
CD4 depleted WT or cKO mice were infected with LCMV-Cl13 (~5 mice per genotype 
per sort). At day 20 p.i., CD8+CD44int-hi H-2DbGP33-41-tetramer stained cells were 
isolated by fluorescence activated cell sorting, with 2 separate sorts conducted per 
genotype (ie. 4 samples in total), and ~1x105-2x105 cells recovered per sort. Total 
RNA was isolated using Trizol LS (Thermo Fisher Scientific) according to 
manufacturer’s instructions, and RNA-seq libraries were prepared at the Molecular 
Genomics Core Facility, Peter MacCallum Cancer Centre, using the Illumina TruSeq 
Stranded mRNA Library Prep Kit. Samples were sequenced on an Illumina 
NextSeq500 instrument with 75bp single-end reads. All reads were aligned to the 
mouse genome reference (GRCm38/mm10) sequence using HiSat2 (Kim et al., 
2015) with default parameters. Read counts were then generated for each gene in 
each sample using FeatureCounts from the Subread package (v1.5.0-p3) (Liao et al., 
2014) by using annotated gene locations. Differential expression analysis was 
performed using LIMMA (v3.32.4). An adjusted p-value threshold of 0.05 was used to 
identify significantly differentially-regulated genes. Pheatmap (v1.0.8) and ggplot2 
(v2.2.1) were used for generation of volcano plots and annotated heatmaps. Gene 
Set Enrichment Analysis (Subramanian et al., 2005) was conducted by searching the 
fold change ranked cKO versus WT RNA-seq dataset against the genes from a 
published LCMV exhaustion signature (Man et al., 2017) or published signature of 
CXCR5+ T cells during chronic LCMV (Im et al., 2016). For the Man et al dataset, a 
published gene list was filtered to only include genes with a FC of either >2 or <0.5 in 
the following 4 comparisons of WT RNAseq datasets: d8 Chronic vs d8 Acute, d8 
Chronic vs Naïve, d30 Chronic vs d30 Acute and d30 Chronic vs Naïve. The resulting 
gene list was then split into genes up or down at d30 Chronic vs d30 Acute for the 
respective Exhaustion Up and Down signatures. For the Im et al dataset, genes with 
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a logFC of >2 (CXCR5- signature) or <-2 (CXCR5+ signature) in the CXCR5- vs 
CXCR5+ comparison were included. 
 
4.3.7: ChIP-seq analysis 
B6 mice were infected with LCMV-Cl13, and at day 20 p.i. Spleen and lymph nodes 
were isolated from the mice and pooled. CD8+ T cells were then isolated by MACS 
enrichment (Miltenyi) according to manufacturer’s instructions to yield ~93% purity of 
CD8+ T cells. Briefly, cells were labelled with CD8-PE antibody then enriched with 
anti-PE beads. Bulk CD8+ T cells were used in this analysis as we had previously 
confirmed by flow cytometry that, within total CD8+ T cells during LCMV-Cl13 
infection, EGR2 protein is only expressed within PD-1+ CD44int-hi exhausted CD8+ T 
cells. After enrichment, ~60x106 CD8+ T cells from ~8 mice were then used for 
subsequent ChIP-seq analysis. Cells were resuspended in PBS and crossed-linked 
with fresh formaldehyde solution (Table 4.S4; 1X final concentration) for 30 min at 
room temperature. Excess formaldehyde was quenched with 125mM Glycine for 5 
min before cells were washed once with ice-cold PBS. Cells were incubated 3 times 
with nuclear extraction buffer (Table 4.S4) containing Roche cOmplete protease 
inhibitors (MERCK, 04693159001) on ice for 5 min. Nuclear extracts were 
resuspended in sonication buffer (Table 4.S4) containing protease and Pierce 
phosphatase inhibitors (ThermoFisher Scientific, A32957) and sonicated using the 
Covaris S220 Focused Ultrasonicator for 18 min. Sheared lysates were diluted with 1 
volume of ChIP dilution buffer (Table 4.S4) containing protease and phosphatase 
inhibitors. Protein A and Protein G Dynabeads (ThermoFisher Scientific, 10002D and 
10004D) were mixed 1:1 (50µl total per IP) and washed in blocking buffer (Table 
4.S4) containing protease inhibitors at 4oC. Protein A/G beads were resuspended in 
ChIP IP buffer (Table 4.S4; ~0.5mL/IP) containing protease and phosphatase 
inhibitors and added to diluted lysates with 20µg of a previously validated polyclonal 
anti-EGR2 ChIP antibody (ab43020, Abcam) (Jang et al., 2010) and 0.45% bovine 
serum albumin (BSA). IP samples were incubated overnight at 4oC while tumbling. 
Protein A/G beads were washed twice with ChIP IP buffer on ice, before washing 
once with ChIP Wash Buffer 1 and Wash Buffer 2 (Table 4.S4), each containing 
protease and phosphatase inhibitors, and washing twice with Tris-EDTA buffer 
(10mM Tris-HCl pH 7.5, 1mM EDTA). Washed beads were incubated with Reverse 
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Crosslinking Buffer (Table 4.S4) containing 45µg Proteinase K at 55oC for 1h and the 
supernatant was then isolated and incubated at 65oC overnight. DNA was isolated 
using the ChIP DNA Clean & Concentrator Kit (Zymo Research, D5205). Indexed 
libraries were prepared using KAPA Hyper Prep Kit for Illumina platforms (Kapa 
Biosystems) and the SeqCap Adapter Kit (Roche) following vendor’s instructions. 
Library QC and quantification was performed using D1000 high-sensitivity screen 
tape with a 4200 TapeStation Instrument (Agilent Technologies) and size selected for 
between 200 bp and 500 bp using a Pippin Prep system (Sage Science). Libraries 
were pooled and sequenced with 75 bp single-end sequencing to a depth of 15–
20x106 reads per sample on a NextSeq500 (Illumina). bcl2fastq (v2.17.1.14) was 
used for de-multiplexing. The Fastq files were then aligned to the mouse reference 
genome (GRCm38/mm10) using bowtie2 (v2.3.3). Samtools (v1.4.1) was used for 
manipulation of SAM and BAM files. MACS (v2.1.1) was used for peak-calling, and 
significant peaks (FDR<0.05) were then associated with the closest gene TSS using 
Bedtools (v2.26). Motif analysis was performed with Homer (v4.8). Browser viewable 
TDF files were generated using IGVTools (v2.3.95) and ChIP-Seq tracks were 
visualized using IGV (v2.3.55). Graphics were generated using deeptools (v2.5.3). 
 
4.3.8: Statistical analysis 
Data analysis was conducted using Prism Software (Version 7.0, GraphPad 
software). P values were calculated using a 2-tailed unpaired T test or a 2-tailed 
Mann–Whitney test when data failed normality tests. Where indicated in the text, a 
Chi-square test with Yate’s correction or Fisher’s Exact test was used to calculate 
enrichment P values. 
 
 
4.4: Results 
 
4.4.1: EGR2 expression is elevated in chronic relative to acute LCMV infection 
During mouse infection with chronic LCMV Clone 13 (Cl13), virus-specific CD8+ T 
cells adopt an exhausted state and fail to rapidly clear infection. In contrast, antigen-  
 
0 10 20 30 40
0
2
4
6
days post infection 
E
G
R
2 
(R
el
at
iv
e 
M
FI
)
TCF1+
TCF1-**
* ** ** **
Na
ive
CX
CR
5+
CX
CR
5-
0
1
2
3
4
5
lo
g 2
R
PK
M
0 10 20 30
0
2
4
6
8
10
days post infection 
lo
g 2
R
P
K
M
0 10 20 30 40
0
1
2
3
days post infection 
E
G
R
2 
(R
el
at
iv
e 
M
FI
) ***
***
*** ***
0 102 103 104 105
0
20
40
60
80
100
EGR2 
Armstrong 
Clone 13 
Naïve cells 
a b 
0 103 104 105
0
102
103
104
105
TCF1 
E
G
R
2 
c d Gated on GP33-41+ 
Gated on GP33-41+ 
123 
 124 
 
 
 
 
 
 
 
 
Figure 4.1. EGR2 expression is elevated within TCF1+ memory-like exhausted 
cells. (A) Expression levels of Egr2 transcript within virus-specific CD8+ T cells 
during chronic (blue) versus acute (black) LCMV infection extracted from RNAseq 
data from a published dataset (Man et al., 2017). n=2-4 replicates per time point. (B) 
EGR2 protein levels assessed by flow cytometry within splenic H2-DbGP33-41 tetramer 
stained CD8+ T cells from B6 mice infected with LCMV-Arm (black) or Cl13 (blue) for 
the indicated times. Representative histogram (left) shows data from day 8 p.i., with 
naïve T cell staining included from polyclonal CD44loCD8+ T cells from uninfected B6 
mice. Right graph shows EGR2 expression relative to naïve levels (as defined 
above). n=11-15 mice per group per time point from 2-3 independent experiments. 
(C) Expression levels of Egr2 transcript within CXCR5+ and CXCR5- virus-specific 
CD8+ T cells during chronic LCMV infection, or within naïve CD8+ T cells, extracted 
from RNAseq data from a published dataset (Leong et al., 2016). n=2-3 replicates 
per condition. (D) EGR2 protein levels assessed as in (B) within TCF1+ and TCF1- 
tetramer-stained CD8+ T cells from B6 mice infected with LCMV-Cl13 for the 
indicated times. Representative plot (left) shows data from day 20 p.i. Right graph 
shows EGR2 expression relative to naïve levels (as defined above). n=5-6 mice per 
group per time point from 2 independent experiments. Error bars depict SEM, * = 
p<0.05, ** = p<0.01, *** = p<0.001. 
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specific CD8+ T cells during acute LCMV Armstrong (Arm) infection form non-
exhausted effector cells that clear infection and differentiate into memory cells. Data 
obtained from a recent RNAseq analysis of virus-specific CD8+ T cells during chronic 
relative to acute LCMV infection (Man et al., 2017) indicated that Egr2 transcript 
levels are elevated during chronic versus acute LCMV infection at both day 8 and 
day 30 post-infection (p.i.) (Fig. 4.1A). To confirm that this translated to an increase 
in EGR2 protein levels, we examined EGR2 levels by flow cytometry within tetramer 
stained H-2DbGP33-41-specific CD8+ T cells isolated from the spleens of C57BL/6 (B6) 
mice infected with either LCMV-Cl13 or Arm. During acute LCMV-Arm infection, 
EGR2 levels initially spiked above naïve CD8+ T cell levels at day 5 p.i. before 
dropping below naïve levels from day 8 p.i. onwards (Fig. 4.1B). In contrast, EGR2 
remained elevated in antigen-specific CD8+ T cells compared to naïve cells at all time 
points measured during chronic LCMV-Cl13 infection, and was significantly higher 
than in LCMV-Arm infection from day 8 p.i. onwards. Thus, EGR2 expression is 
elevated in antigen-specific CD8+ T cells in chronic relative to acute LCMV infection. 
 
4.4.2: EGR2 is selectively expressed within TCF1+ memory-like exhausted T 
cells 
We next examined the dynamics of EGR2 expression during the exhaustion 
differentiation process. A small population of exhausted T cells with memory 
characteristics maintains CD8+ T cell responses during chronic stimulation. These 
“exhausted memory” cells, characterised by expression of the chemokine receptor 
CXCR5 and diminished expression of TIM3, self-renew and continuously give rise to 
terminally exhausted progeny (He et al., 2016; Im et al., 2016; Leong et al., 2016; Wu 
et al., 2016). Results extracted from previously published RNAseq data (Leong et al., 
2016) indicated that Egr2 transcript expression was restricted to this less 
differentiated CXCR5+ exhausted CD8+ T cell population (Fig. 4.1C). Exhausted 
memory cells express the transcription factor TCF1, which is required for the 
maintenance of this population (Im et al., 2016; Leong et al., 2016; Utzschneider et 
al., 2016; Wu et al., 2016). Notably, among antigen-specific CD8+ T cells, EGR2 
expression was limited to the TCF1+ population at all time-points examined p.i. (Fig. 
4.1D). Thus, EGR2 expression is enriched within less differentiated TCF1+ exhausted 
cells. 
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Figure 4.2. Egr2 expression is lost as cells undergo terminal exhaustion. (A) 
Experimental outline. Egr2-GFP reporter mice were infected with LCMV-Cl13, and 
at day 20 p.i. spleens were isolated and CTV labeled splenocytes, transferred into 
infection-matched CD45.1+ hosts (5x105 cells per mouse), and CD45.2+ cells were 
analysed at day 6 post transfer. (B,C) CTV and GFP expression within total CD8+ 
CD45.2+ cells (B) or H2-DbGP33-41 tetramer-stained CD8+CD45.2+ cells (C). Left 
plots show representative profiles from mice that received GFP+ or GFP- cells, right 
graph shows pooled data from GFP MFI within undivided (CTV+) or divided (CTV-) 
populations. n=5-14 mice per group from 2 independent experiments. * = p<0.05, ** 
= p<0.01, *** = p<0.001. 
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The absence of EGR2 expression within TCF1- cells suggests that EGR2 expression 
is lost as cells differentiate during exhaustion. To formally test this idea, we 
conducted lineage-tracing experiments using GFP knock-in Egr2 reporter (Egr2-
GFP) mice (Williams et al., 2017). Egr2-GFP mice were infected with LCMV-Cl13, 
and at day 20 p.i. Egr2 expressing GFP+ and Egr2 non-expressing GFP- polyclonal 
exhausted (CD44hiPD-1int-hi) CD8+ T cells were sorted into Egr2/GFP+ and GFP- 
populations and labeled with the Cell Trace Violet (CTV) division dye. 5x105 CTV 
labeled GFP+ or GFP- cells were then transferred into infection-matched 
congenically marked CD45.1+ mice. 6 days later, proliferation and GFP expression 
was assessed both within the total transferred CD45.2+ CD8+ T cells, as well as in H-
2DbGP33-41-specific cells within this transferred population (Fig. 4.2A). After adoptive 
transfer, both polyclonal and GP33-41 tetramer+ GFP+ cells that hadn’t divided 
retained GFP expression, while GFP+ cells that diluted CTV and divided lost GFP 
expression (Fig. 4.2B,C). In contrast, GFP- cells remained GFP- after division (Fig. 
2B,C). Collectively, these data support a model whereby TCF1+ cells transiently 
express EGR2 prior to terminal exhaustion. 
 
4.4.3: EGR2 expression is maintained by chronic antigen encounter 
During anergy induction, EGR2 is directly induced downstream of TCR signaling via 
the transcription factor NFAT (Martinez et al., 2015). We thus speculated that EGR2 
expression is maintained within exhausted CD8+ T cells by chronic antigen 
encounter. To test this idea, 2x103 CD45.1+ H-2DbGP33-41-specific CD8+ TCR 
transgenic (P14) T cells were transferred into B6 mice that were subsequently 
infected with LCMV-Cl13 or LCMV-Arm. At day 8 p.i., when differential EGR2 
expression is first observed between chronic and acute LCMV (Fig. 4.1A,B), 5x105 
splenic CD45.1+ P14 cells were isolated from these mice and transferred into either 
LCMV-Arm or LCMV-Cl13 infected-matched B6 recipients. As LCMV-Arm infected 
mice clear virus by day 8 p.i., this meant that the P14 cells were effectively 
transferred into mice that did or didn’t contain virus. 7 days later (day 15 p.i.), EGR2 
expression was assessed within the transferred CD45.1+ P14 cells (Fig. 4.3A). 
Transfer of P14 cells from LCMV-Arm infection into LCMV-Cl13 infected hosts lead to 
increased EGR2 expression relative to P14 cells transferred into control LCMV-Arm 
infected mice (Fig. 4.3B). In the reciprocal experiment, transfer of P14 cells from 
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LCMV-Cl13 infection into LCMV-Arm infected hosts caused loss of EGR2 expression 
relative to cells transferred into control LCMV-Cl13 infected mice (Fig. 4.3C). Thus, 
active infection is required to maintain EGR2 expression. 
 
Active infection could maintain EGR2 expression via antigen or inflammatory signals. 
To discriminate between these possibilities, the above experiment was repeated, 
except that P14 cells derived from LCMV-Cl13 infection were transferred into 
infection-matched recipients given either LCMV-Cl13, or a mutant form of Cl13 
bearing a single point mutation (V35A) within the GP33-41 epitope that abolishes 
peptide binding to H-2Db, thereby depriving P14 cells of antigen (Fig. 4.3D) (Puglielli 
et al., 2001). Transfer of P14 cells into V35A infected recipients lead to loss of EGR2 
expression relative to cells transferred into Cl13 infected control mice, despite 
persistent infection in both hosts. Thus, persistent antigen engagement is required to 
sustain EGR2 expression during chronic LCMV infection. 
 
4.4.4: EGR2 ablation cell intrinsically disrupts CD8+ T cell exhaustion 
To assess the role of Egr2 in the CD8+ T cell exhaustion process, we utilised Egr2 
floxed mice crossed to a CD4-cre transgene to delete the Egr2 gene within all T cells 
(Ramon et al., 2010). CD4-cre+ Egr2f/f mice (cKO), or CD4-cre+ Egr2+/+ littermates 
(WT), were infected with LCMV-Cl13 and the response to infection was assessed. 
The number of virus-specific cells, as assessed by both tetramer staining and by 
enumerating IFNγ+ cells after peptide restimulation, was similar between WT and 
cKO mice across the course of infection (Fig. 4.S1A and data not shown). 
Dysregulated T cell responses during LCMV-Cl13 increase morbidity due to 
immunopathology, but there was no increase in morbidity within cKO mice as 
assessed by weight loss during infection (Fig. 4.S1B) and viral control was similar to 
WT controls (Fig. 4.S1C,D). However, GP33-41 and, to a lesser extent, GP276-286-
specific IFNγ+CD8+ T cells exhibited elevated IL-2 production at day 20 p.i. onwards 
that was not accompanied by a significant increase in TNFα production (Fig. 
4.S1E,F). Inhibitory receptor expression was largely unchanged within tetramer+ 
CD8+ T cells (data not shown), but diminished expression of the exhaustion-
associated transcription factor EOMES (Paley et al., 2012) was observed within cKO 
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Figure 4.3. EGR2 expression is maintained by chronic antigen. (A) Experiment 
outline for (B,C). 2x103 CD45.1+ P14 cells were transferred into B6 mice 
subsequently infected with LCMV-Arm or LCMV-Cl13. At day 8 p.i., splenocytes were 
isolated and the equivalent of 5x105 P14 cells were transferred into LCMV-Cl13 or 
LCMV-Arm infection matched B6 mice. 7 days later (day 15 p.i.), EGR2 protein levels 
were assessed within the transferred P14 cells. (B,C) EGR2 levels within cells 
transferred from LCMV-Arm (B) or LCMV-Cl13 (C) donors into Arm or Cl13 infected 
recipients. Left histograms show representative plots, with naïve CD44loPD-1lo cells 
from Cl13 infected mice also shown in grey. Right graphs show EGR2 MFI relative to 
the above naïve population. n=9-15 mice per group from 2-3 independent 
experiments. (D) Experiment outline for (E). Experiment was conducted as in (A) 
except that P14 cells derived from Cl13 infected donors were transferred into 
recipients infected with wild-type Cl13 or GP V35A mutant Cl13. (E) EGR2 levels 
within cells transferred from Cl13 donors into Cl13 or V35A recipients. Plots and data 
representation is as in (B,C). n=15-18 mice per group from 3 independent 
experiments. *** = p<0.001. 
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cells at day 20 p.i. (Fig. 4.S1G, data not shown). This was not associated with an 
increase in expression of markers associated with a memory-like exhausted state, 
with no alteration in the proportions of CXCR5+TIM3- or CXCR5-TIM3+ cells, and no 
change in expression of T-BET and TCF1 (Fig. 4.S1H, and data not shown). 
Collectively, these data suggest that EGR2 deletion alters exhausted CD8+ T cells 
differentiation during chronic infection. This phenotype appeared restricted to CD8+ T 
cells, with virus-specific CD4+ T cell numbers, differentiation into Th1 
(PSGL1hiLy6Chi) and Tfh (PSGL1lo) subsets (Marshall et al., 2011; Parish et al., 
2014), and cytokine function largely unaltered in cKO mice (Fig. 4.S2). 
 
To determine whether the observed phenotypes were CD8+ T cell intrinsic, an 
irradiation mixed bone marrow (BM) chimera approach was employed. Lethally 
irradiated Rag1-/- mice were reconstituted with a 50:50 mix of CD45.1+ BM and 
CD45.2+ WT or cKO BM, and subsequently infected with LCMV-Cl13. We failed to 
observe any consistent change in the proportion of cKO derived tetramer+ cells within 
the blood or spleen over the course of infection, suggesting that EGR2 does not 
intrinsically influence tetramer+ cell numbers (Fig. 4.S3A,B). However, a cell intrinsic 
decrease was observed in EOMES levels within tetramer+ cKO cells, consistent with 
observations in cKO mice (Fig. 4.S3C). Furthermore, in the competitive environment 
of a mixed BM chimera, cKO cells also displayed decreased PD-1 levels (Fig. 4.S3D) 
although TIM3 levels were unchanged (Fig. 4.S3E). Similar to observations in cKO 
mice, cKO cells within mixed BM chimeras had unaltered levels of TCF1 (data not 
shown). Collectively, these results suggest that EGR2 loss causes a cell intrinsic 
defect in differentiation during exhaustion that is exacerbated in a competitive 
environment. 
 
4.4.5: EGR2 controls inhibitory receptor expression and terminal exhaustion  
The mixed BM chimera experiments above suggested that the differentiation block 
upon EGR2 loss could be exacerbated when cKO cells were further challenged. As 
depletion of CD4+ T cells from mice prior to LCMV-Cl13 infection exacerbates 
exhaustion (Zajac et al., 1998), we next asked whether CD4-depleted cKO mice 
would exhibit a more pronounced phenotype. CD4-depleted WT or cKO mice were 
thus LCMV-Cl13 infected and the CD8+ T cell response to infection was monitored. 
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Similar to infection of non-depleted cKO mice, there was little alteration in the number 
of virus-specific CD8+ T cells in cKO mice aside from a slight ~2 fold decrease in 
GP33-41 and GP276-286-specific cells at day 20 p.i. (Fig. 4.S4A). However, in the 
absence of CD4 help, EGR2 loss diminished expression of multiple inhibitory 
receptors (PD-1, 2B4 and TIM3) within tetramer+ CD8+ T cells over the course of 
infection, although CD160 and LAG3 were either unchanged or even elevated in 
expression within cKO cells (Fig. 4.4A). This lead to a reduced overall load of 
inhibitory receptor expression, with a significant reduction in the proportion of cKO 
cells with 5 or more inhibitory receptors, and a corresponding expansion in cells with 
2-3 inhibitory receptors (Fig. 4.4B). While we again observed a trend towards 
increased IL-2 production within virus-specific CD8+ T cells, coupled with no 
alteration in TNFα production, the increase in IL-2 was more variable and not 
significant in this more severe model of exhaustion (Fig. 4.S4B,C), and viral control 
was again unchanged in this model (Fig. 4.4C). However, we did observe a 
pronounced block in differentiation in CD4-depleted cKO mice. EOMES was 
diminished in expression within cKO tetramer+ CD8+ T cells at every time-point 
examined, and this was coupled with an increase in the proportion of TCF1+TIM3- 
cells from day 20 p.i. onwards (Fig. 4.4D,E). This was coupled with elevated 
expression of the memory cell marker CD127 from day 20 p.i. onwards (Fig. 4.4F). 
Interestingly, other aspects of terminal exhaustion remained intact. CXCR5 down-
regulation still occurred in cKO cells, with overall CXCR5 expression actually lower 
than in WT cells (Fig. 4.S4D,E). Thus, EGR2 plays a prominent non-redundant role in 
promoting terminal exhaustion in a more severe exhaustion model. 
 
4.4.6: EGR2 broadly controls the terminal exhaustion gene program 
To more broadly assess how EGR2 impacts upon the exhaustion gene program, 
RNAseq analysis was performed at day 20 p.i. on sorted, splenic H-2DbGP33-41-
specific CD8+ T cells isolated from CD4-depleted, LCMV-Cl13 infected WT or cKO 
mice. 415 differentially expressed genes were identified (Table 4.S1; FDR<0.05), 
with diminished expression of a number of key genes associated with terminal 
exhaustion evident (Eomes, Pdcd1, Tigit, Batf, Tox, Tox2, Cd200r1, Cd200r4), 
coupled with an increase in memory-like cell associated genes (Bcl6, Satb1, Bach2, 
Fos, Il7r) (Fig. 4.5A). Indeed, a previously published exhaustion signature (Man et al., 
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2017) was depleted from cKO cells as assessed by Gene Set Enrichment Analysis 
(GSEA), with a concurrent increase in genes associated with acute infection (Fig. 
4.5B,D). Similarly, cKO cells exhibited an enrichment of a published CXCR5+ 
memory-like cell signature (Im et al., 2016), and a corresponding loss of a CXCR5- 
signature (Fig. 4.5C,D). However, consistent with our data suggesting an arrest at an 
intermediate differentiation state, a few gene changes opposed this trend, including 
diminished expression of Cxcr5 and increased expression of the exhaustion 
promoting transcription factors Nr4a1 and Nr4a3 (Fig. 4.5A) (Chen et al., 2019; Liu et 
al., 2019). Nevertheless, collectively, our RNAseq data were reflective of a less 
differentiated state and suggest that EGR2 globally controls the CD8+ T cell 
exhaustion differentiation process. 
 
4.4.7: EGR2 is re-routed away from anergy gene targets during T cell 
exhaustion to directly regulate exhaustion-associated genes 
To identify genes directly controlled by EGR2, we next conducted ChIP-seq analysis 
of EGR2 binding within exhausted CD8+ T cells. CD8+ T cells were enriched from 
LCMV-Cl13 infected B6 mice at day 20 p.i., and the genome-wide pattern of EGR2 
binding was assessed. A total of 2259 EGR2 binding peaks were identified 
(FDR<0.05). To identify peaks associated with open chromatin regions within 
exhausted CD8+ T cells, we cross-referenced our ChIPseq data with a previously 
published ATAC-seq dataset (Sen et al., 2016). Notably, 1983 peaks (87.8%, 
associated with 1643 genes) were found to localise to open chromatin regions, with 
EGR2 peak signal strength broadly correlating with binding site accessibility (Fig. 
4.S5A). Unbiased de novo motif analysis identified a highly significant enrichment of 
an EGR2 motif within these ChIP-seq peaks (Table 4.S2), with the identified motif 
closely matching the consensus EGR2 motif (Fig. S5B). We observed a highly 
significant enrichment of promoters and 5’UTRs within the EGR2 binding sites 
(p<0.0001 for both, Chi-square test with Yate’s correction)(Fig. S5C). 78 genes were 
bound by EGR2 and differentially expressed within cKO cells (Fig. 4.6A, Table 4.S3; 
50 repressed and 28 induced by EGR2), which represents a significant enrichment 
over background (p=0.035, Fisher’s exact test). In particular, binding peaks were 
observed in the open chromatin regions around key genes induced (Pdcd1, Tigit, 
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Figure 4.4. Egr2 loss blocks terminal exhaustion in the absence of CD4+ T cell 
help. WT or cKO mice were depleted of CD4+ T cells then infected with LCMV-Cl13 
and the response tracked over time. (A) Inhibitory receptor MFI within H2-DbGP33-41 
tetramer stained CD8+ T cells over time (right; normalized to WT mean at each 
timepoint) with representative day 20 p.i. histograms (left). (B) Summary of data in 
(A) expressed as the proportion of cells expressing 0-5 of the listed inhibitory 
receptors at day 20 p.i. n=7-13 mice per group per time point from 2 independent 
experiments. (C) Viral titres in serum, liver and kidney over time. n=5-13 mice per 
group per time point from 2-3 independent experiments. (D) EOMES levels within 
tetramer+ cells over time (bottom; normalized to WT mean at each timepoint) with 
representative day 20 p.i. histogram (top). n=7-13 mice per group per time point from 
2 independent experiments. (E) Representative (top; day 20 p.i.) and pooled (bottom) 
proportions of tetramer+ cells that were TIM3-TCF1+ or TIM3+TCF1- over the course 
of infection. n=7-13 mice per group from 2 independent experiments. (F) CD127 
levels within tetramer+ cells over time (bottom; normalized to WT mean at each 
timepoint) with representative day 20 p.i. histogram (top). n=7-13 mice per group per 
time point from 2 independent experiments. Error bars depict SEM, * = p<0.05, ** = 
p<0.01, *** = p<0.001. 
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Tox2) and repressed (Bach2, Bcl6, Tcf7) by EGR2 (Fig. 4.6B,C). Notably, the open 
chromatin region downstream of the Pdcd1 gene bound by EGR2 has previously 
been shown to contribute to PD-1 expression (Sen et al., 2016). 
 
Having defined the direct targets regulated by EGR2 during exhaustion, we were now 
able to directly examine the overlap between the genes directly regulated by EGR2 
during exhaustion versus anergy. A high confidence set of 50 genes directly induced 
by EGR2 during anergy has previously been defined (Zheng et al., 2013). Strikingly, 
only 4 of these genes were shared direct targets during exhaustion (Egr2, Bach2, 
Ryr1, Cd74) (Fig. 4.6A). Moreover, with the exception of Egr2 (which was deleted in 
both studies), the direction in which these genes were regulated in exhaustion versus 
anergy was opposing (Bach2, Ryr1 and Cd74 are induced by EGR2 in anergy, but 
repressed by EGR2 during exhaustion; Table 4.S3). Notably, functionally important 
genes that were identified as EGR2-induced anergy targets in other studies, 
including Cblb, Dgka, Dtx1, Ndrg1, Rnf128, Tob1 and Itch (Oh et al., 2015; Zheng et 
al., 2012) were not differentially expressed within cKO cells, and none were EGR2 
bound with the exception of Cblb (Fig. 4.S5D,E, and data not shown). Finally, we 
examined whether EGR2 is regulating the same fundamental processes in the 
context of exhaustion and anergy. In the context of anergy, EGR2 induces a set of 
genes that collectively inhibit TCR signaling (Zheng et al., 2012). As exhausted cells 
also have TCR signaling deficiencies, we assessed whether TCR signaling was 
rescued in exhausted cKO CD8+ T cells. WT or cKO splenocytes isolated at day 20 
p.i. from CD4-depleted LCMV-Cl13 infected mice were restimulated with anti-CD3 in 
vitro for 30 min, after which ERK1/2 phosphorylation (ppERK) and mTOR signaling 
(pS6) was assessed within CD44hiPD-1hi CD8+ T cells by flow cytometry. Egr2 loss 
failed to rescue either the proportion of ppERK+ and pS6+ cells, or the degree of 
phosphorylation within the ppERK+ and pS6+ cells (as assessed by MFI) (Fig. 
4.6D,E). Similar results were obtained from CD8+ T cells isolated from LCMV-Cl13 
infected CD4-replete mice (data not shown). Collectively, these data suggest that, 
although EGR2 promotes terminal exhaustion, it targets a fundamentally different 
gene program during exhaustion versus anergy. 
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Figure 4.5. Global block in the terminal exhaustion gene program within EGR2 
deficient cells. WT or cKO mice were depleted of CD4+ T cells and infected with 
LCMV-Cl13, then H2-DbGP33-41 tetramer-stained CD8+ T cells were sorted at day 20 
p.i. and subjected to RNAseq analysis (n=2 per genotype). (A) Volcano plot denoting 
differentially expressed genes in cKO versus WT cells. (B-D) GSEA (B,C) and 
heatmap analysis (D) examining expression in cKO vs WT cells of a set of genes 
previously published to be selectively up or down within virus-specific CD8+ T cells in 
chronic versus acute LCMV infection (Man et al., 2017) (B,D) or genes differentially 
expressed within CXCR5+ vs CXCR5- virus-specific CD8+ T cells isolated from 
chronic LCMV infection (Im et al., 2016) (C,D). GSEA plots in (B) examine 
enrichment of genes selectively up (left; red) or down (right; blue) in exhaustion, 
while plots in (C) examine enrichment of published gene signatures associated with 
CXCR5+ (left; red) or CXCR5- (right; blue) cells. Heatmaps in (D) shows significantly 
differentially expressed genes (p<0.05) from these two signatures, with genes up or 
down in the respective gene sets indicated in red or blue in the left column. 
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4.5: Discussion 
 
In this study, we investigated whether the negative regulatory pathways triggered by 
TCR engagement are conserved in the context of exhaustion and anergy. We 
demonstrate that expression of the anergy-associated transcription factor EGR2 is 
sustained in the context of T cell exhaustion in an antigen-dependent manner, and 
that EGR2 promotes terminal exhaustion by direct regulation of a number of key 
differentiation-linked genes. However, the genes directly regulated by EGR2 in the 
context of exhaustion differ fundamentally from those regulated by EGR2 during 
anergy. Thus, although a TCR-induced upstream negative regulator (EGR2) is 
similarly induced in the context of exhaustion and anergy, it triggers distinct 
differentiation outputs. 
 
Our data identify EGR2 as a previously unappreciated regulator of exhaustion. 
During exhaustion, antigen-induced EGR2 expression peaks within TCF1+ cells 
before being lost as cells proliferate and terminally differentiate. It is unclear why 
EGR2 expression is lost as cells terminally differentiate given that TCF1- cells will still 
encounter antigen, which is the trigger for Egr2 expression during LCMV. It may 
either be related to diminishing TCR signal strength as terminally exhausted cells up-
regulate inhibitory receptors, or increased access of TCF1- cells to inflammatory 
signals that are known to inhibit Egr2 expression (Miao et al., 2017) within the red 
pulp of the spleen where there are higher viral loads (Im et al., 2016). Regardless, 
this wave of EGR2 expression plays an important role in promoting terminal 
exhaustion. Given that EGR2 expression is not maintained within TCF1- cells, we 
speculate that EGR2 plays roles in initiating the terminal differentiation process, but 
is unlikely to sustain this process once TCF1 down-regulation occurs. Additionally, 
only a subset of TCF1+ cells expresses EGR2 (Fig. 4.1D), and we hypothesise that 
these cells have recently encountered differentiation signals and represent the 
subset of TCF1+ cells en route to terminal exhaustion. EGR2 does not appear to 
control differentiation by initiating proliferation of TCF1+ cells, as we saw no alteration 
in Ki67 expression within cKO vs WT cells (data not shown), and we failed to observe 
any change in cKO virus-specific CD8+ T cell numbers. EGR2 likely operates in 
parallel to other NFAT-induced factors that promote exhaustion, such as IRF4, BATF  
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Figure 4.6. EGR2 directly regulates a non-overlapping set of genes in 
exhaustion versus anergy. CD8+ T cells were isolated from B6 mice at day 20 p.i. 
with LCMV-Cl13 and subjected to EGR2 ChIP-seq analysis. (A) Venn diagram 
summarizing the overlap between genes identified as EGR2 bound by ChIP-seq 
within CD8+ T cells isolated from LCMV-Cl13 infection (Exh. bound), genes 
differentially expressed within exhausted cKO vs WT cells from Fig. 4.5 (Exh. DE), 
and genes previously identified (Zheng et al., 2013) as directly induced by EGR2 
during anergy (Anergy target). (B,C) Representative profiles of EGR2 ChIP-seq 
peaks within genes induced (B) or repressed (C) by EGR2 from Figs 4.4 and 4.5. 
Traces show EGR2 Ab signal, Total input signal, and published ATAC-seq 
accessibility within day 27 exhausted virus-specific CD8+ T cells from LCMV-Cl13 
infection (Sen et al., 2016). Red boxes (and arrows) denote significant peaks. (D,E) 
WT or cKO mice were depleted of CD4+ T cells and infected with LCMV-Cl13, then 
splenocytes were isolated at day 20 p.i. and restimulated with anti-CD3 for 30 min. 
CD44hiPD-1hi CD8+ T cells were then analysed for ppERK and pS6 staining. n=9-10 
mice per group from 2 independent experiments. 
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and the NR4A family (Chen et al., 2019; Liu et al., 2019; Man et al., 2017; Martinez et 
al., 2015; Quigley et al., 2010) . Compensatory induction of some of these factors in 
cKO cells, in particular Nr4a1Compensatory induction of some of these factors in 
cKO cells, in particular Nr4a1 and Nr4a3 (Fig. 4.5A), combined with elevated LAG3 
and CD160 (Fig. 4.4A), could explain why the block in terminal exhaustion in cKO 
mice is only partial, and why EGR2 loss fails to durably rescue exhausted T cell 
function or impact upon cell persistence. 
 
The dichotomy between EGR2 function in exhaustion and anergy logically aligns with 
the likely disparate roles of these differentiation states in immunoregulation. 
Peripheral tolerance processes such as anergy play important roles in completely 
inactivating self-reactive T cell clones so that they are unable to differentiate into 
productive effector cells. In contrast, exhaustion aids persistence of effector cells in a 
tempered state able to contain infection without causing immunopathology. We 
hypothesise that this is the reason why EGR2 is rerouted to a gene program aimed at 
promoting terminal differentiation during exhaustion, as opposed to simply preventing 
differentiation as it does during anergy. Interestingly, a few functionally important 
direct EGR2 anergy gene targets, namely Lag3 and Cblb, are still induced during 
exhaustion and play roles in enforcing the exhausted state (Blackburn et al., 2009; 
Man et al., 2017; Ou et al., 2008). However, in the context of exhaustion, both genes 
are induced in an EGR2-independent manner, suggesting that the regulatory 
networks controlling expression of these genes in the context of exhaustion are 
distinct from those that operate during anergy. These data are in line with recent 
observations in tumour-infiltrating CD8+ T cells, where Lag3 expression early during 
the response was EGR2-dependent, but became EGR2-independent at later time-
points (Williams et al., 2017). Overall, these data suggest that the pathways that 
induce key negative regulators to limit TCR signaling during exhaustion versus 
anergy are molecularly distinct. 
 
Previous network analysis has suggested that other exhaustion-associated 
transcription factors, such as EOMES, are repurposed during exhaustion to target a 
distinct gene program (Doering et al., 2012) but our data provide direct evidence of 
this concept in the context of EGR2. This concept will now be important to revisit in 
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the context of other transcription factors. In particular, NR4A1, NR4A2 and NR4A3, 
another NFAT-induced transcription factor family, have recently been linked to both 
tolerance and exhaustion (Chen et al., 2019; Liu et al., 2019), and it will be important 
to determine whether they undergo similar context-dependent repurposing. The 
mechanism underlying this redirecting of EGR2 function is still unclear, but it does 
not appear due to exhaustion-associated chromatin accessibility changes. We have 
examined whether chromatin accessibility increases at exhaustion-specific EGR2 
binding sites in naïve vs exhausted cells using a published dataset (Sen et al., 2016), 
but 73 of the 74 exhaustion-specific EGR2 gene targets showed no change in 
accessibility (the exception was Tox2). Thus, another mechanism, such as altered 
binding partners or cofactors, must underlie this shift in function. Finally, our finding 
that the TCR-induced negative regulatory circuitry may be differentially wired during 
exhaustion versus anergy could have practical applications. In particular, this finding 
may ultimately open avenues for designing more targeted immunotherapies that 
disrupt exhaustion while leaving peripheral tolerance intact, thereby limiting immune-
related adverse events. 
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Figure 4.S1: CD8+ T cell phenotype in LCMV-Cl14 infected WT vs cKO mice. 
Related to Figure 4.4. WT or cKO mice were infected with LCMV-Cl13 and the 
response tracked over time. (A) The number of CD8+IFNγ+ T cells recovered over 
time upon stimulation of splenocytes with the indicated LCMV peptides. n=6-14 mice 
per group per time point from 2-4 independent experiments. (B) Weight loss over 
time, with weight expressed as % of starting weight pre-infection. n=4-16 mice per 
group per time point from 2-4 independent experiments. (C,D) Plaque forming units 
(p.f.u.) of virus determined by plaque assay in the serum over time (C) or at day 20 
p.i. in the liver and kidney (D). n=4-15 mice per group per time point from 2-4 
independent experiments. (E,F) IL-2 (E) and TNFα (F) production by IFNγ+CD8+ T 
cells upon restimulation with LCMV GP33-41 or GP276-286 peptides. Representative 
plots (left, GP33-41 peptide) are shown from day 20 p.i. alongside pooled data over 
time (right). n=6-14 mice per group per time point from 2-4 independent experiments. 
(G,H) Representative (left) and pooled (right) EOMES (G) and T-BET (H) levels 
assessed by flow cytometry at day 20 p.i. within H2-DbGP33-41 tetramer stained CD8+ 
T cells. n=7-11 mice per group from 2-3 independent experiments. MFI data were 
normalized to the WT mean. All error bars depict SEM. * = p<0.05, ** = p<0.01, *** = 
p<0.001.  
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Figure 4.S2. The virus-specific CD4+ T cell response within LCMV-Cl13 infected 
WT versus cKO mice. Related to Figure 4.4. In the experiment outlined in Figure 
4.S1, the virus-specific CD4+ T cell response was analysed. (A) The number of 
CD4+IFNγ+ T cells recovered over time upon splenocyte stimulation with the 
immunodominant CD4+ T cell LCMV peptide GP61-80. n=6-14 mice per group per time 
point from 2-3 independent experiments. (B,C) Representative (B) and pooled (C) 
proportions of PSGL1+Ly6C+, PSGL1+Ly6C- and PSGL1-Ly6C- MHCII I-AbGP66-77 
tetramer+ CD4+ T cells at day 20 p.i. n=11-12 mice per group from 3 independent 
experiments. (D,E) Representative (left) and pooled (right) TNFα (E) and IL-2 (D) 
production within the CD4+IFNγ+ T cells from (A) over time. n=6-14 mice per group 
per time point from 2-3 independent experiments. All error bars depict SEM. * = 
p<0.05, ** = p<0.01. 
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Figure 4.S3. Disruption of CD8+ T cell exhaustion by Egr2 loss is cell intrinsic. 
Related to Figure 4.4. Lethally irradiated Rag1-/- mice were reconstituted with a 
50:50 mix of CD45.1+ BM and CD45.2+ WT or cKO BM, and allowed to reconstitute 
for 8 weeks prior to infection with LCMV-Cl13. (A,B) The percentage of CD45.2+ cells 
within H2-DbGP33-41 tetramer stained blood (A) or splenic (B; day 20 p.i.) CD8+ T cells 
in WT or cKO mixed BM chimeras. The % CD45.2+ cells was normalized to the pre-
infection % CD45.2+ cells within blood CD8+ T cells (with this starting percentage set 
to 50%). (C-E) Representative (left) and pooled (right) MFI values for EOMES (C), 
PD-1 (D) and TIM3 (E) within splenic H2-DbGP33-41 tetramer+ CD8+ T cells at day 20 
p.i. MFI values are expressed as relative to the MFI values of the CD45.1+ tetramer+ 
cells within the same mouse. n=13-15 mice per group per time point from 3 
independent experiments. All error bars depict SEM. * = p<0.05, ** = p<0.01, *** = 
p<0.001.  
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Figure 4.S4. CD8+ T cell expansion and phenotype in CD4 depleted, LCMV-Cl13 
infected WT vs cKO mice. Related to Figure 4.4. WT or cKO mice were depleted 
of CD4+ T cells then infected with LCMV-Cl13 and the response tracked over time. 
(A) The number of CD8+IFNγ+ T cells recovered over time upon stimulation of 
splenocytes with the indicated LCMV peptides. n=7-13 mice per group per time point 
from 2-3 independent experiments. (B,C) Representative (left; day 20 p.i.) and 
pooled (right) TNFα (C) and IL-2 (B) production within the GP33-41 peptide-specific 
CD8+IFNγ+ T cells from (A) over time. (D,E) Representative (left) and pooled (right) 
data showing the proportions of CXCR5+TIM3-, CXCR5-TIM3+ and CXCR5-TIM3- 
cells (D) and overall CXCR5 MFI (E) in tetramer+ cells from WT and cKO mice at day 
40 p.i. n=7 mice per group from 2 independent experiments. All error bars depict 
SEM. * = p<0.05, ** = p<0.01, *** = p<0.001. 
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Figure 4.S5. EGR2 ChIP-seq analysis of CD8+ T cells isolated from LCMV-Cl13 
infection. Related to Figure 4.6. CD8+ T cells were isolated from LCMV-Cl13 
infected B6 mice at day 20 p.i. and subjected to ChIP-seq analysis. (A) Association 
between EGR2 peak signal (left) and chromatin accessibility at the binding site 
(right), ranked from most (top) to least (bottom) accessible EGR2 binding site. Each 
row represents a single gene, and the X-axis depicts signal strength in the genomic 
regions up to 1Kb either side of the centre of the binding site (labeled “0”). (B) 
Consensus EGR2 motif within the HOMER database (top), and the de novo EGR2 
motif extracted from the ChIP-seq peaks (bottom). (C) Proportions of EGR2 binding 
within different genomic regions (top) relative to the proportion of those regions within 
the whole genome (bottom). (D,E) Expression levels of Cblb from the RNAseq data 
in Fig. 4.5 (D) and EGR2 binding peaks identified within the Cblb locus (E). Traces 
show EGR2 Ab signal, Total input signal, and published ATAC-seq accessibility 
within day 27 exhausted virus-specific CD8+ T cells from LCMV-Cl13 infection as in 
Fig. 4.6. Red boxes denote significant peaks. 
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Table 4.S1- significantly differentially expressed genes within Egr2 cKO CD8+ T 
cells relative to WT control cells (FDR<0.05) 
 
Gene logFC 
AveEx
pr t P.Value adj.P.Val B 
Gm11168 2.637 8.825 18.520 5.49E-13 5.30E-09 19.364 
Ifitm1 2.566 3.127 5.146 7.25E-05 6.63E-03 1.665 
Gm21738 2.269 11.449 15.914 6.86E-12 3.31E-08 17.208 
Cadm1 2.218 4.395 8.811 7.22E-08 3.87E-05 8.130 
Prex2 2.166 2.569 4.331 4.22E-04 2.01E-02 0.123 
Itgae 2.161 4.940 8.221 1.95E-07 9.42E-05 7.376 
Unc79 2.137 2.282 5.279 5.47E-05 5.68E-03 1.827 
Clec9a 2.092 3.891 7.924 3.27E-07 1.26E-04 6.812 
Mycl 2.028 3.571 6.743 2.87E-06 6.02E-04 4.672 
Gm10717 2.024 9.587 14.120 4.87E-11 1.42E-07 15.407 
Gm10718 2.016 7.106 13.306 1.27E-10 1.76E-07 14.437 
Dnase1l3 2.015 5.940 10.528 5.06E-09 4.44E-06 10.908 
Gm10719 2.011 7.597 13.765 7.37E-11 1.42E-07 14.982 
Hrnr 2.009 4.809 7.901 3.40E-07 1.26E-04 6.807 
Gm10721 1.993 6.518 12.354 4.17E-10 5.04E-07 13.277 
Gm10801 1.964 9.909 13.433 1.09E-10 1.76E-07 14.659 
Flt3 1.955 4.170 7.270 1.06E-06 2.93E-04 5.719 
Gm10722 1.940 9.329 13.806 7.02E-11 1.42E-07 15.068 
Plbd1 1.926 6.031 9.688 1.78E-08 1.43E-05 9.743 
Adam23 1.921 4.573 8.038 2.68E-07 1.08E-04 7.024 
Anpep 1.895 4.317 7.105 1.44E-06 3.48E-04 5.459 
Zfp366 1.894 3.074 6.183 8.57E-06 1.45E-03 3.671 
Shtn1 1.865 3.984 6.283 7.03E-06 1.23E-03 3.945 
Reln 1.833 3.369 5.437 3.93E-05 4.78E-03 2.267 
Gm10720 1.829 4.906 8.825 7.06E-08 3.87E-05 8.327 
Ttn 1.827 6.926 11.637 1.07E-09 1.04E-06 12.472 
Itgax 1.787 5.818 8.948 5.77E-08 3.48E-05 8.612 
Gm10800 1.766 13.918 12.064 6.08E-10 6.52E-07 13.060 
Xcr1 1.763 4.464 7.558 6.28E-07 2.09E-04 6.264 
Tbc1d9 1.734 4.393 6.646 3.45E-06 7.09E-04 4.654 
Dbn1 1.725 3.738 5.602 2.79E-05 3.74E-03 2.654 
Notch4 1.661 3.693 5.238 5.97E-05 5.88E-03 1.960 
Apol7c 1.659 4.025 6.407 5.50E-06 1.04E-03 4.182 
Pbx1 1.658 3.601 5.307 5.16E-05 5.51E-03 2.068 
Nav1 1.656 4.095 5.264 5.65E-05 5.80E-03 2.025 
Cbfa2t3 1.656 4.185 5.775 1.96E-05 2.95E-03 3.012 
Naaa 1.655 6.380 7.857 3.68E-07 1.32E-04 6.831 
Nr4a3 1.647 4.700 7.328 9.56E-07 2.71E-04 5.866 
Dnm3 1.638 3.288 4.786 1.57E-04 1.15E-02 1.042 
Fnip2 1.634 4.211 5.711 2.23E-05 3.17E-03 2.894 
 161 
Fos 1.621 3.988 5.736 2.12E-05 3.10E-03 2.919 
Gm6377 1.621 4.217 4.133 6.51E-04 2.53E-02 -0.274 
Cd74 1.614 10.164 7.252 1.10E-06 2.95E-04 5.721 
Rab7b 1.609 3.670 5.218 6.22E-05 5.95E-03 1.934 
Mroh2a 1.599 4.785 7.340 9.35E-07 2.71E-04 5.897 
Hydin 1.598 3.503 4.985 1.02E-04 8.44E-03 1.446 
Abca13 1.592 3.943 5.416 4.11E-05 4.84E-03 2.314 
Trpm2 1.587 4.711 6.316 6.59E-06 1.20E-03 4.057 
Cxcl9 1.584 3.906 5.808 1.83E-05 2.80E-03 3.075 
Fbn1 1.582 2.796 4.160 6.13E-04 2.44E-02 -0.186 
Il12rb2 1.579 3.616 5.158 7.08E-05 6.57E-03 1.792 
Mpeg1 1.579 7.269 5.645 2.55E-05 3.52E-03 2.608 
Sh3pxd2b 1.572 2.629 4.371 3.86E-04 1.89E-02 0.231 
Kit 1.570 4.269 5.935 1.41E-05 2.31E-03 3.322 
Fmnl2 1.570 3.812 5.343 4.79E-05 5.37E-03 2.178 
Olfm1 1.567 3.537 4.744 1.72E-04 1.22E-02 0.992 
Tlr3 1.565 3.922 4.626 2.22E-04 1.41E-02 0.727 
Dnah7a 1.564 3.185 4.472 3.10E-04 1.62E-02 0.435 
Duxf3 1.564 4.461 6.569 4.01E-06 8.07E-04 4.506 
Lrp1b 1.559 3.118 4.317 4.35E-04 2.04E-02 0.130 
Wdfy4 1.554 7.706 7.045 1.62E-06 3.72E-04 5.345 
Sostdc1 1.554 4.395 6.390 5.69E-06 1.06E-03 4.175 
Aif1 1.553 3.440 4.880 1.28E-04 1.03E-02 1.255 
Lima1 1.551 3.312 4.716 1.82E-04 1.27E-02 0.920 
Dnah10 1.549 3.351 4.596 2.37E-04 1.45E-02 0.685 
Gpr55 1.546 6.212 8.167 2.14E-07 9.72E-05 7.360 
Nav2 1.540 3.775 5.145 7.27E-05 6.63E-03 1.777 
H2-Eb1 1.519 8.371 5.925 1.44E-05 2.32E-03 3.164 
Plcb4 1.514 3.411 4.530 2.73E-04 1.50E-02 0.564 
Ank2 1.505 3.703 5.040 9.10E-05 7.57E-03 1.570 
Cst3 1.491 8.194 7.219 1.17E-06 3.05E-04 5.665 
Astn1 1.487 2.751 3.852 1.21E-03 3.62E-02 -0.779 
Igf1r 1.482 3.457 4.648 2.11E-04 1.39E-02 0.794 
Treml4 1.475 3.894 4.760 1.66E-04 1.18E-02 1.025 
H2-Ab1 1.474 9.070 5.675 2.40E-05 3.36E-03 2.652 
Obscn 1.466 4.099 5.592 2.85E-05 3.77E-03 2.659 
Dnah6 1.466 2.791 3.804 1.34E-03 3.75E-02 -0.868 
Specc1 1.454 3.944 5.294 5.30E-05 5.57E-03 2.078 
Fras1 1.433 3.336 4.303 4.48E-04 2.07E-02 0.115 
Fam186a 1.432 3.129 3.845 1.23E-03 3.62E-02 -0.785 
Myh2 1.428 2.980 3.923 1.03E-03 3.32E-02 -0.635 
Hba-a2 1.423 8.964 9.581 2.11E-08 1.56E-05 9.624 
Gm26992 1.423 3.747 4.527 2.75E-04 1.50E-02 0.539 
Ciita 1.420 5.817 5.538 3.19E-05 4.05E-03 2.464 
Hba-a1 1.419 9.013 9.343 3.06E-08 2.11E-05 9.259 
 162 
Egr3 1.411 3.648 4.117 6.75E-04 2.59E-02 -0.259 
Zbtb46 1.405 3.958 4.849 1.37E-04 1.07E-02 1.200 
Csf2rb2 1.402 3.307 4.205 5.55E-04 2.34E-02 -0.077 
Slc4a1 1.401 5.416 7.503 6.95E-07 2.24E-04 6.219 
Asb2 1.397 4.643 6.290 6.93E-06 1.23E-03 4.008 
Itga1 1.395 4.044 5.251 5.81E-05 5.85E-03 1.997 
Pag1 1.394 5.021 5.364 4.58E-05 5.20E-03 2.185 
Csf2rb 1.386 4.404 4.565 2.53E-04 1.46E-02 0.605 
Tifab 1.379 4.061 4.786 1.57E-04 1.15E-02 1.071 
Gcsam 1.379 3.868 5.106 7.90E-05 6.94E-03 1.712 
Ccnd1 1.378 3.621 4.326 4.26E-04 2.02E-02 0.161 
Gm2a 1.378 7.159 7.051 1.60E-06 3.72E-04 5.362 
AW822073 1.375 4.089 5.054 8.81E-05 7.47E-03 1.611 
Jaml 1.359 4.494 5.184 6.69E-05 6.34E-03 1.856 
Ank3 1.352 4.249 4.845 1.38E-04 1.08E-02 1.185 
H2-Aa 1.350 8.351 5.257 5.74E-05 5.83E-03 1.787 
Dnah2 1.346 3.197 3.916 1.05E-03 3.35E-02 -0.647 
Grk3 1.333 3.595 4.134 6.49E-04 2.53E-02 -0.224 
Gm13698 1.333 3.720 4.496 2.94E-04 1.57E-02 0.499 
Apobr 1.326 5.004 6.429 5.27E-06 1.04E-03 4.268 
Wdfy3 1.326 3.831 4.542 2.66E-04 1.48E-02 0.590 
Adgrv1 1.319 3.345 4.021 8.32E-04 2.92E-02 -0.440 
Fam196b 1.314 4.032 4.553 2.60E-04 1.46E-02 0.600 
Ryr1 1.314 4.178 4.971 1.05E-04 8.62E-03 1.441 
Fat4 1.313 3.075 3.753 1.51E-03 4.03E-02 -0.965 
Ccr2 1.312 5.590 4.761 1.66E-04 1.18E-02 0.863 
Sbf2 1.291 3.317 3.882 1.13E-03 3.47E-02 -0.716 
AC133103.1 1.282 4.845 5.740 2.10E-05 3.10E-03 2.943 
Zfp600 1.280 3.450 4.072 7.44E-04 2.76E-02 -0.341 
Atp8a2 1.279 3.291 3.894 1.10E-03 3.43E-02 -0.691 
Vwf 1.279 3.354 3.956 9.62E-04 3.17E-02 -0.571 
Nhsl2 1.275 3.666 4.286 4.65E-04 2.10E-02 0.080 
Zan 1.264 3.651 4.179 5.89E-04 2.40E-02 -0.135 
Spta1 1.252 3.786 4.585 2.42E-04 1.45E-02 0.673 
Sfi1 1.250 7.427 8.523 1.17E-07 5.93E-05 7.947 
Arhgef11 1.248 3.705 4.193 5.71E-04 2.36E-02 -0.110 
Adam8 1.247 5.594 7.121 1.40E-06 3.47E-04 5.536 
Mctp1 1.244 3.579 4.080 7.32E-04 2.74E-02 -0.335 
Gm17535 1.243 7.449 8.133 2.27E-07 9.72E-05 7.292 
Gm10715 1.240 7.332 8.122 2.31E-07 9.72E-05 7.273 
Itgad 1.237 4.019 4.628 2.21E-04 1.41E-02 0.755 
Tns3 1.236 4.583 4.047 7.87E-04 2.84E-02 -0.509 
Trio 1.225 4.703 5.634 2.61E-05 3.55E-03 2.739 
Ryr2 1.208 3.715 4.140 6.40E-04 2.51E-02 -0.217 
Hs3st3b1 1.207 3.926 4.465 3.15E-04 1.63E-02 0.428 
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Itsn1 1.190 4.142 4.451 3.25E-04 1.66E-02 0.385 
Pdzd2 1.189 3.684 4.072 7.45E-04 2.76E-02 -0.354 
Snca 1.184 3.392 3.624 2.00E-03 4.82E-02 -1.235 
Akap2 1.184 3.482 3.838 1.25E-03 3.63E-02 -0.813 
Alas2 1.183 4.985 5.506 3.41E-05 4.27E-03 2.466 
Sdc3 1.179 5.367 4.854 1.35E-04 1.07E-02 1.079 
Tbc1d8 1.172 4.147 3.663 1.83E-03 4.63E-02 -1.262 
Acss2 1.164 4.439 5.061 8.69E-05 7.42E-03 1.609 
Plekho1 1.162 4.655 5.137 7.40E-05 6.67E-03 1.745 
Satb1 1.157 6.482 6.819 2.48E-06 5.44E-04 4.938 
Afdn 1.155 3.958 4.216 5.42E-04 2.32E-02 -0.082 
Rxra 1.154 3.866 3.742 1.54E-03 4.07E-02 -1.048 
Hbb-bt 1.149 8.160 7.359 9.02E-07 2.71E-04 5.922 
Cd36 1.141 4.366 3.748 1.52E-03 4.03E-02 -1.103 
Rasgrp3 1.138 4.210 4.449 3.26E-04 1.66E-02 0.372 
March1 1.138 4.905 4.298 4.53E-04 2.08E-02 -0.030 
Myo9a 1.136 5.071 5.428 4.01E-05 4.78E-03 2.296 
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Rik 1.133 3.517 3.699 1.70E-03 4.36E-02 -1.097 
Rasa4 1.125 3.770 3.848 1.22E-03 3.62E-02 -0.817 
Il18r1 1.120 6.992 6.854 2.32E-06 5.21E-04 4.994 
Dst 1.116 5.316 6.212 8.09E-06 1.40E-03 3.835 
Ryr3 1.101 4.355 4.685 1.95E-04 1.32E-02 0.845 
Irf8 1.095 7.520 5.431 3.98E-05 4.78E-03 2.158 
Gabbr1 1.090 4.701 4.617 2.26E-04 1.42E-02 0.658 
Nr4a1 1.086 4.426 4.493 2.96E-04 1.57E-02 0.442 
Slc8b1 1.080 4.501 4.559 2.56E-04 1.46E-02 0.549 
Kctd12 1.067 4.782 4.537 2.69E-04 1.49E-02 0.486 
Pkib 1.055 4.220 4.076 7.39E-04 2.75E-02 -0.402 
Ppt1 1.052 7.418 5.329 4.93E-05 5.47E-03 1.949 
Ece1 1.050 5.951 5.239 5.95E-05 5.88E-03 1.823 
Psap 1.046 9.220 5.304 5.19E-05 5.51E-03 1.882 
Med12l 1.045 3.646 3.608 2.07E-03 4.89E-02 -1.295 
Slco3a1 1.044 4.516 4.576 2.47E-04 1.45E-02 0.597 
Tmcc2 1.037 3.922 4.025 8.26E-04 2.92E-02 -0.509 
Tanc1 1.035 4.273 3.837 1.25E-03 3.63E-02 -0.906 
Marcksl1 1.022 4.050 3.986 9.00E-04 3.04E-02 -0.568 
H2-DMb1 1.002 4.673 4.021 8.32E-04 2.92E-02 -0.586 
Zbtb20 0.977 5.151 5.306 5.18E-05 5.51E-03 2.034 
Rara 0.976 4.844 4.401 3.62E-04 1.81E-02 0.184 
Bach2 0.975 5.179 5.314 5.09E-05 5.51E-03 2.047 
Tsc22d1 0.954 4.208 3.613 2.05E-03 4.86E-02 -1.368 
Ifi205 0.951 6.386 4.259 4.94E-04 2.19E-02 -0.300 
Diaph2 0.949 4.192 3.883 1.13E-03 3.47E-02 -0.804 
A530032D1 0.939 4.771 4.632 2.19E-04 1.41E-02 0.678 
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Galnt10 0.935 4.747 3.628 1.98E-03 4.80E-02 -1.435 
Apol11b 0.926 4.167 3.894 1.10E-03 3.43E-02 -0.796 
Ly6c2 0.922 7.552 5.557 3.06E-05 3.94E-03 2.417 
Slc7a5 0.916 4.679 3.988 8.96E-04 3.04E-02 -0.662 
Pld4 0.916 5.222 3.754 1.50E-03 4.03E-02 -1.252 
St6gal1 0.916 5.094 4.255 4.98E-04 2.19E-02 -0.162 
Cacna1e 0.912 4.908 4.163 6.09E-04 2.44E-02 -0.332 
Rgs10 0.911 5.115 4.677 1.98E-04 1.32E-02 0.724 
Jun 0.905 4.945 4.613 2.28E-04 1.42E-02 0.614 
Hivep3 0.902 4.909 4.587 2.41E-04 1.45E-02 0.566 
Fosl2 0.902 4.432 4.014 8.47E-04 2.94E-02 -0.570 
Tiam1 0.887 5.018 4.610 2.29E-04 1.42E-02 0.597 
Prkd3 0.878 5.578 5.124 7.59E-05 6.79E-03 1.609 
Hbb-bs 0.867 8.250 4.312 4.40E-04 2.05E-02 -0.232 
Btla 0.859 6.258 3.958 9.57E-04 3.16E-02 -0.950 
Iqgap2 0.855 6.442 3.902 1.08E-03 3.41E-02 -1.085 
Ctnna1 0.847 5.037 4.445 3.28E-04 1.67E-02 0.242 
Alms1 0.840 5.115 4.574 2.48E-04 1.45E-02 0.505 
Plcg2 0.839 5.812 4.014 8.46E-04 2.94E-02 -0.765 
Plekhm3 0.838 4.872 4.213 5.46E-04 2.32E-02 -0.226 
AC125149.1 0.835 4.609 3.604 2.09E-03 4.91E-02 -1.466 
Ly6c1 0.829 5.875 4.852 1.36E-04 1.07E-02 1.004 
Bcl6 0.828 4.864 4.230 5.26E-04 2.26E-02 -0.188 
Mdn1 0.825 6.806 5.376 4.46E-05 5.13E-03 2.055 
Kmt2d 0.823 8.786 4.736 1.75E-04 1.23E-02 0.679 
Csprs 0.820 4.610 3.709 1.66E-03 4.30E-02 -1.243 
Rab43 0.819 6.639 4.820 1.46E-04 1.10E-02 0.888 
Lrrk2 0.818 5.542 4.161 6.13E-04 2.44E-02 -0.428 
Atrn 0.807 4.594 3.617 2.03E-03 4.85E-02 -1.435 
Aldh2 0.803 4.713 3.643 1.92E-03 4.71E-02 -1.410 
Arrb1 0.803 4.983 4.048 7.85E-04 2.84E-02 -0.597 
Egr1 0.802 6.069 5.117 7.71E-05 6.83E-03 1.548 
Ptprs 0.798 4.684 3.720 1.62E-03 4.24E-02 -1.243 
Vav2 0.797 4.741 3.814 1.31E-03 3.72E-02 -1.050 
D1Ertd622e 0.797 5.371 4.581 2.44E-04 1.45E-02 0.483 
Apoe 0.795 5.027 4.252 5.01E-04 2.19E-02 -0.168 
Sipa1l3 0.793 5.303 4.407 3.57E-04 1.80E-02 0.122 
Sh2b3 0.792 5.522 3.924 1.03E-03 3.32E-02 -0.943 
Cln3 0.786 4.847 4.006 8.61E-04 2.98E-02 -0.663 
Marcks 0.785 5.012 3.672 1.80E-03 4.57E-02 -1.404 
Parp8 0.780 5.152 4.108 6.88E-04 2.62E-02 -0.496 
Plxnc1 0.780 5.298 3.872 1.16E-03 3.52E-02 -1.021 
Runx2 0.773 6.108 4.898 1.23E-04 1.00E-02 1.082 
Zeb2 0.772 5.771 4.713 1.83E-04 1.27E-02 0.717 
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Atp8b4 0.764 6.622 4.406 3.58E-04 1.80E-02 -0.004 
Il18rap 0.763 7.038 5.048 8.93E-05 7.50E-03 1.359 
Gusb 0.748 5.599 4.172 5.98E-04 2.42E-02 -0.424 
Cmah 0.747 5.694 4.034 8.10E-04 2.90E-02 -0.732 
Unc93b1 0.744 6.929 4.087 7.21E-04 2.72E-02 -0.702 
Vim 0.743 9.229 4.231 5.25E-04 2.26E-02 -0.413 
Rreb1 0.740 5.114 3.882 1.13E-03 3.47E-02 -0.976 
Tsc22d2 0.736 5.085 3.811 1.32E-03 3.73E-02 -1.121 
Patj 0.722 5.374 4.200 5.62E-04 2.35E-02 -0.335 
Ahnak 0.722 10.738 4.685 1.95E-04 1.32E-02 0.558 
Tep1 0.715 5.384 3.973 9.25E-04 3.09E-02 -0.823 
Stx16 0.712 5.172 3.941 9.95E-04 3.25E-02 -0.859 
Jchain 0.710 6.119 4.119 6.71E-04 2.58E-02 -0.523 
Nfat5 0.710 6.659 4.822 1.45E-04 1.10E-02 0.892 
Kdm6b 0.709 5.682 3.887 1.12E-03 3.47E-02 -1.050 
Prrc2c 0.708 9.111 4.258 4.95E-04 2.19E-02 -0.354 
Grn 0.707 5.661 4.181 5.86E-04 2.40E-02 -0.413 
Atp11a 0.704 5.101 3.858 1.19E-03 3.58E-02 -1.025 
Utrn 0.703 8.854 4.381 3.78E-04 1.87E-02 -0.086 
Ubn2 0.703 5.985 4.494 2.95E-04 1.57E-02 0.225 
Klrd1 0.693 5.554 4.052 7.78E-04 2.83E-02 -0.677 
Tmem131 0.683 6.394 4.601 2.34E-04 1.44E-02 0.424 
Zbtb37 0.679 5.123 3.739 1.55E-03 4.08E-02 -1.282 
Slc7a1 0.676 5.628 4.065 7.57E-04 2.79E-02 -0.661 
Macf1 0.676 9.516 4.062 7.60E-04 2.79E-02 -0.780 
Hectd4 0.675 6.658 4.614 2.27E-04 1.42E-02 0.443 
Ifngr1 0.674 7.402 4.457 3.20E-04 1.65E-02 0.087 
Huwe1 0.664 8.505 4.551 2.60E-04 1.46E-02 0.284 
Smg1 0.654 8.264 4.188 5.77E-04 2.38E-02 -0.501 
Gvin1 0.652 10.217 4.282 4.70E-04 2.11E-02 -0.310 
Ssh2 0.650 6.993 4.135 6.48E-04 2.53E-02 -0.602 
Kdm7a 0.647 6.355 4.353 4.02E-04 1.94E-02 -0.109 
Ppp1r15a 0.646 5.685 3.607 2.08E-03 4.89E-02 -1.652 
Gm4070 0.644 10.198 4.255 4.98E-04 2.19E-02 -0.368 
Clcn3 0.641 5.879 3.887 1.12E-03 3.47E-02 -1.074 
Rnf213 0.641 9.680 4.510 2.85E-04 1.54E-02 0.188 
Zfp407 0.639 5.636 3.619 2.02E-03 4.85E-02 -1.620 
Itpr1 0.635 6.788 3.867 1.17E-03 3.53E-02 -1.177 
Mtmr4 0.635 5.626 3.748 1.52E-03 4.03E-02 -1.344 
Kmt2a 0.633 8.311 4.330 4.23E-04 2.01E-02 -0.195 
Sgk1 0.621 5.578 3.761 1.48E-03 3.98E-02 -1.308 
Mki67 0.614 8.687 3.904 1.08E-03 3.40E-02 -1.118 
Klrc2 0.614 6.048 3.751 1.51E-03 4.03E-02 -1.384 
Cit 0.613 5.471 3.655 1.87E-03 4.68E-02 -1.523 
Zfp36l1 0.612 7.401 3.871 1.16E-03 3.52E-02 -1.181 
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Dnajc15 0.610 5.860 3.800 1.36E-03 3.77E-02 -1.260 
Ubr4 0.603 8.313 4.187 5.79E-04 2.38E-02 -0.504 
Srrm2 0.600 9.453 4.097 7.04E-04 2.68E-02 -0.704 
Map4k4 0.595 7.950 3.986 9.00E-04 3.04E-02 -0.937 
Zfc3h1 0.593 6.511 3.655 1.87E-03 4.68E-02 -1.623 
Smad3 0.592 6.042 3.827 1.28E-03 3.65E-02 -1.222 
Plec 0.581 9.353 3.748 1.52E-03 4.03E-02 -1.458 
Mib1 0.580 5.707 3.592 2.15E-03 4.99E-02 -1.688 
Cad 0.570 6.049 3.719 1.62E-03 4.24E-02 -1.456 
Dock5 0.565 6.793 3.799 1.36E-03 3.77E-02 -1.323 
Klrk1 0.564 6.430 3.612 2.05E-03 4.86E-02 -1.714 
Golgb1 0.560 6.611 3.686 1.74E-03 4.46E-02 -1.562 
Fbxw7 0.554 6.117 3.650 1.89E-03 4.69E-02 -1.611 
Birc6 0.549 8.673 3.698 1.70E-03 4.36E-02 -1.562 
Luc7l2 0.546 7.870 3.644 1.91E-03 4.71E-02 -1.675 
Mycbp2 0.543 8.169 3.649 1.89E-03 4.69E-02 -1.666 
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3Rik 0.538 7.883 3.633 1.96E-03 4.78E-02 -1.699 
Sema4a 0.533 6.458 3.617 2.03E-03 4.85E-02 -1.704 
Hist1h4d -0.511 9.747 -3.642 1.92E-03 4.71E-02 -1.690 
Hist1h2br -0.512 9.512 -3.593 2.14E-03 4.99E-02 -1.794 
Hist1h4b -0.514 8.964 -3.638 1.94E-03 4.74E-02 -1.693 
Hist1h2ak -0.516 9.077 -3.632 1.96E-03 4.78E-02 -1.706 
Sub1 -0.525 8.548 -3.701 1.69E-03 4.35E-02 -1.555 
Hist1h2be -0.525 8.578 -3.665 1.83E-03 4.63E-02 -1.633 
Cxcr5 -0.527 6.578 -3.617 2.03E-03 4.85E-02 -1.717 
Trim14 -0.535 7.357 -3.751 1.51E-03 4.03E-02 -1.444 
Cox17 -0.540 6.482 -3.709 1.66E-03 4.30E-02 -1.516 
Hist1h2bf -0.544 8.452 -3.828 1.27E-03 3.65E-02 -1.280 
Dnajc9 -0.547 6.981 -3.603 2.10E-03 4.91E-02 -1.759 
Batf -0.552 6.659 -3.772 1.44E-03 3.94E-02 -1.388 
Hist1h4j -0.552 8.678 -3.817 1.31E-03 3.71E-02 -1.306 
Casp3 -0.553 6.659 -3.614 2.04E-03 4.86E-02 -1.727 
Nab1 -0.558 7.457 -3.908 1.07E-03 3.38E-02 -1.104 
Smpdl3a -0.559 6.878 -3.808 1.33E-03 3.74E-02 -1.315 
Hist1h4a -0.562 8.991 -3.971 9.31E-04 3.10E-02 -0.974 
Glipr1 -0.563 6.256 -3.797 1.36E-03 3.77E-02 -1.314 
Pfdn5 -0.567 8.101 -3.787 1.40E-03 3.83E-02 -1.368 
Hist1h4k -0.576 9.079 -4.000 8.72E-04 2.99E-02 -0.911 
Hist1h4i -0.577 8.337 -4.027 8.22E-04 2.92E-02 -0.849 
Hist1h4h -0.578 9.378 -4.039 8.00E-04 2.87E-02 -0.829 
Fcgr3 -0.581 6.348 -3.953 9.69E-04 3.18E-02 -0.983 
Hist1h4m -0.581 8.405 -3.984 9.04E-04 3.04E-02 -0.943 
Gpr65 -0.583 6.391 -3.822 1.29E-03 3.68E-02 -1.267 
Dhrs7 -0.583 5.487 -3.595 2.13E-03 4.99E-02 -1.682 
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Rab27a -0.584 7.291 -4.051 7.79E-04 2.83E-02 -0.794 
Tox -0.585 8.526 -3.681 1.77E-03 4.50E-02 -1.599 
Gm21987 -0.596 5.896 -3.844 1.23E-03 3.62E-02 -1.194 
Hist1h4c -0.597 8.739 -4.085 7.24E-04 2.72E-02 -0.726 
Prkch -0.597 8.442 -3.879 1.14E-03 3.48E-02 -1.170 
1810009A1
5Rik -0.599 5.642 -3.836 1.25E-03 3.63E-02 -1.186 
Cd3d -0.602 8.393 -3.796 1.37E-03 3.77E-02 -1.350 
Tmem9b -0.603 5.720 -3.648 1.90E-03 4.69E-02 -1.598 
Zfp827 -0.604 6.136 -3.991 8.89E-04 3.03E-02 -0.888 
Tma7 -0.606 7.225 -4.147 6.31E-04 2.49E-02 -0.586 
Hist1h4f -0.609 8.750 -4.287 4.64E-04 2.10E-02 -0.288 
Hist1h4n -0.611 8.442 -4.198 5.65E-04 2.35E-02 -0.480 
Hist1h2bl -0.618 8.389 -4.317 4.34E-04 2.04E-02 -0.221 
Gm20388 -0.621 7.484 -3.913 1.06E-03 3.36E-02 -1.095 
Adap1 -0.625 5.975 -3.764 1.47E-03 3.98E-02 -1.369 
Dut -0.625 6.544 -3.763 1.47E-03 3.98E-02 -1.401 
Galnt2 -0.635 7.483 -4.015 8.45E-04 2.94E-02 -0.874 
Iqcg -0.638 5.760 -3.833 1.26E-03 3.65E-02 -1.203 
Ddx3y -0.641 5.617 -3.896 1.10E-03 3.43E-02 -1.041 
S100a11 -0.644 6.954 -4.479 3.05E-04 1.61E-02 0.136 
Cetn2 -0.651 5.677 -4.093 7.12E-04 2.69E-02 -0.637 
Rgs1 -0.653 7.599 -4.582 2.44E-04 1.45E-02 0.353 
Tecr -0.654 6.052 -4.368 3.89E-04 1.90E-02 -0.071 
Pglyrp1 -0.660 5.663 -4.154 6.21E-04 2.46E-02 -0.501 
Tmem135 -0.664 6.058 -3.709 1.66E-03 4.30E-02 -1.492 
Fasl -0.665 6.721 -3.961 9.51E-04 3.16E-02 -0.980 
Hist4h4 -0.669 7.187 -4.563 2.54E-04 1.46E-02 0.315 
2410015M2
0Rik -0.670 5.161 -3.846 1.23E-03 3.62E-02 -1.093 
Ndufb4 -0.679 6.086 -4.294 4.57E-04 2.08E-02 -0.232 
Vamp8 -0.690 6.068 -4.553 2.60E-04 1.46E-02 0.327 
Ap1s2 -0.702 5.660 -4.380 3.79E-04 1.87E-02 -0.015 
Ctsc -0.708 7.055 -3.828 1.27E-03 3.65E-02 -1.274 
Gimap7 -0.714 8.561 -4.031 8.16E-04 2.91E-02 -0.843 
Hist3h2ba -0.722 4.612 -3.658 1.85E-03 4.66E-02 -1.396 
Pet100 -0.729 6.135 -4.636 2.17E-04 1.40E-02 0.502 
Stard3nl -0.747 5.097 -3.868 1.17E-03 3.53E-02 -1.033 
Glmn -0.788 4.355 -3.658 1.85E-03 4.66E-02 -1.339 
Suox -0.792 4.600 -3.861 1.18E-03 3.56E-02 -0.958 
Eif2s3y -0.793 5.080 -4.351 4.04E-04 1.94E-02 0.003 
Rgs16 -0.796 4.813 -4.171 5.99E-04 2.42E-02 -0.338 
Lgalsl -0.817 4.960 -4.005 8.63E-04 2.98E-02 -0.717 
Map2 -0.832 5.243 -4.802 1.51E-04 1.13E-02 0.941 
Chn2 -0.843 6.048 -3.642 1.92E-03 4.71E-02 -1.635 
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Cyth3 -0.846 5.029 -4.508 2.86E-04 1.54E-02 0.346 
Ift27 -0.857 4.539 -4.197 5.66E-04 2.35E-02 -0.236 
Eomes -0.863 7.782 -5.448 3.85E-05 4.76E-03 2.187 
Smpdl3b -0.866 4.794 -4.573 2.48E-04 1.45E-02 0.520 
Sh2d1a -0.873 6.671 -6.023 1.18E-05 1.97E-03 3.373 
Cd5 -0.876 7.147 -5.899 1.52E-05 2.40E-03 3.116 
Slc27a4 -0.877 6.064 -5.394 4.31E-05 5.01E-03 2.107 
Mrpl10 -0.881 4.859 -4.575 2.47E-04 1.45E-02 0.515 
Tigit -0.888 6.965 -4.820 1.46E-04 1.10E-02 0.870 
Cst7 -0.892 7.279 -5.233 6.03E-05 5.88E-03 1.741 
Pdcd1 -0.917 8.138 -4.697 1.90E-04 1.30E-02 0.598 
Ephx1 -0.924 5.491 -4.673 2.00E-04 1.32E-02 0.636 
Gm28778 -0.966 3.979 -3.931 1.02E-03 3.29E-02 -0.700 
Slc37a2 -0.988 4.812 -5.070 8.53E-05 7.36E-03 1.557 
Lrig1 -0.995 3.881 -3.626 1.99E-03 4.82E-02 -1.319 
Ctla2a -1.012 7.422 -6.784 2.65E-06 5.69E-04 4.852 
Rpa3 -1.013 3.819 -3.623 2.00E-03 4.82E-02 -1.310 
Immp1l -1.020 3.824 -3.931 1.02E-03 3.29E-02 -0.677 
Abcb9 -1.022 5.867 -4.829 1.43E-04 1.10E-02 0.934 
Insl6 -1.049 3.834 -3.916 1.05E-03 3.35E-02 -0.709 
Cd6 -1.050 7.411 -7.183 1.25E-06 3.17E-04 5.600 
Sec14l1 -1.054 6.687 -5.726 2.16E-05 3.11E-03 2.772 
Mien1 -1.065 4.659 -5.229 6.09E-05 5.88E-03 1.905 
Galm -1.074 3.852 -3.653 1.88E-03 4.68E-02 -1.255 
Adrb1 -1.095 3.600 -4.055 7.73E-04 2.83E-02 -0.409 
Prmt2 -1.101 3.814 -3.765 1.46E-03 3.98E-02 -1.020 
Borcs5 -1.106 3.509 -3.705 1.67E-03 4.33E-02 -1.100 
Cd200r4 -1.111 5.094 -3.779 1.42E-03 3.88E-02 -1.219 
Cd200r1 -1.138 5.108 -3.791 1.38E-03 3.81E-02 -1.198 
Plekhf1 -1.151 3.337 -3.847 1.22E-03 3.62E-02 -0.802 
Sept4 -1.181 5.116 -4.636 2.17E-04 1.40E-02 0.612 
Nanos1 -1.186 3.314 -3.830 1.27E-03 3.65E-02 -0.828 
Izumo1r -1.188 4.273 -5.078 8.38E-05 7.29E-03 1.636 
Vamp5 -1.198 3.243 -3.839 1.24E-03 3.63E-02 -0.809 
Penk -1.199 4.114 -4.159 6.14E-04 2.44E-02 -0.243 
Polr2h -1.222 3.354 -3.811 1.32E-03 3.73E-02 -0.870 
Adgrg1 -1.227 6.959 -4.311 4.41E-04 2.05E-02 -0.225 
Tbx1 -1.265 3.431 -4.244 5.11E-04 2.22E-02 -0.005 
Tnfrsf9 -1.285 6.999 -5.561 3.04E-05 3.94E-03 2.427 
Gzmk -1.289 7.383 -7.331 9.50E-07 2.71E-04 5.872 
Pak6 -1.309 2.940 -3.691 1.72E-03 4.41E-02 -1.089 
Cisd3 -1.318 3.235 -4.231 5.25E-04 2.26E-02 -0.026 
Tox2 -1.325 5.846 -7.565 6.20E-07 2.09E-04 6.317 
Mob3c -1.343 2.926 -3.981 9.10E-04 3.05E-02 -0.519 
Itga9 -1.383 7.049 -9.097 4.53E-08 2.92E-05 8.875 
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Pfn2 -1.399 3.225 -3.923 1.03E-03 3.32E-02 -0.636 
Gm15013 -1.399 3.561 -4.392 3.69E-04 1.84E-02 0.289 
Ccrl2 -1.437 4.304 -3.950 9.74E-04 3.19E-02 -0.703 
Rnf135 -1.438 3.043 -4.208 5.52E-04 2.34E-02 -0.073 
Cela1 -1.456 4.148 -3.844 1.23E-03 3.62E-02 -0.893 
Clgn -1.461 3.426 -4.362 3.94E-04 1.91E-02 0.234 
Uxt -1.523 2.985 -4.259 4.93E-04 2.19E-02 0.025 
Taco1 -1.525 2.789 -4.130 6.56E-04 2.53E-02 -0.238 
Pcbd2 -1.616 3.101 -4.791 1.55E-04 1.15E-02 1.056 
Gm4950 -1.634 2.827 -4.469 3.12E-04 1.63E-02 0.412 
Prr7 -1.709 2.756 -4.296 4.55E-04 2.08E-02 0.090 
Pcgf1 -1.714 2.609 -4.001 8.72E-04 2.99E-02 -0.498 
Rpp25l -1.739 2.910 -4.717 1.82E-04 1.27E-02 0.890 
Snai3 -1.753 2.809 -4.680 1.97E-04 1.32E-02 0.813 
Apobec2 -1.755 3.157 -4.771 1.62E-04 1.18E-02 1.022 
Mrc2 -1.770 4.120 -3.804 1.34E-03 3.75E-02 -0.979 
Sgpp2 -1.925 2.814 -5.174 6.84E-05 6.41E-03 1.712 
Ociad2 -2.238 3.931 -6.418 5.39E-06 1.04E-03 4.175 
P2ry10b -2.324 2.282 -4.535 2.70E-04 1.49E-02 0.488 
Egr2 -2.337 3.149 -5.818 1.79E-05 2.79E-03 2.975 
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Table 4.S2 - HOMER de novo TF binding motifs identified within EGR2 ChIP-
seq binding peaks 
 
P-value % of Targets % of Background Best Match 
1.00E-206 38.77% 11.80% Etv2(ETS) 
1.00E-92 17.21% 4.73% RUNX1(Runt) 
1.00E-65 31.45% 15.87% Egr2(Zf) 
1.00E-43 16.20% 6.97% Atf1(bZIP) 
1.00E-32 0.86% 0.01% PB0099.1_Zfp691_1 
1.00E-30 0.81% 0.01% MF0009.1_TRP(MYB)_class 
1.00E-30 0.81% 0.01% ZBTB7B 
1.00E-29 6.87% 2.20% IRF2(IRF) 
1.00E-28 1.11% 0.03% KLF10(Zf) 
1.00E-27 0.76% 0.01% PB0117.1_Eomes_2 
1.00E-27 4.39% 1.04% GFX(?) 
1.00E-25 0.76% 0.01% PB0056.1_Rfxdc2_1 
1.00E-22 0.56% 0.00% HINFP 
1.00E-21 18.02% 10.71% NRF(NRF) 
1.00E-20 0.50% 0.00% GCM2 
1.00E-20 0.50% 0.00% CEBPA 
1.00E-20 0.50% 0.00% SP4 
1.00E-19 0.56% 0.01% PB0091.1_Zbtb3_1 
1.00E-18 5.65% 2.14% FOSL1 
1.00E-17 0.45% 0.00% Maz(Zf) 
1.00E-17 7.47% 3.40% NFY(CCAAT) 
1.00E-17 0.71% 0.02% EKLF(Zf) 
1.00E-17 0.76% 0.03% PB0022.1_Gata5_1 
1.00E-16 8.68% 4.35% Mef2c(MADS) 
1.00E-15 6.51% 2.93% NFY(CCAAT) 
1.00E-15 0.40% 0.00% CRX(Homeobox) 
1.00E-15 0.81% 0.04% PB0196.1_Zbtb7b_2 
1.00E-14 5.50% 2.39% NFAT(RHD) 
1.00E-13 0.45% 0.01% PH0017.1_Cux1_2 
1.00E-10 4.09% 1.78% PB0176.1_Sox5_2 
1.00E-09 0.30% 0.01% SPI1 
1.00E-08 0.76% 0.10% PB0179.1_Sp100_2 
1.00E-05 4.90% 2.97% YY2/MA0748.1 
1.00E-03 1.41% 0.71% Ap4(bHLH) 
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Table 4.S3 - Directly bound EGR2 targets during CD8+ T cell exhaustion 
 
Gene Up or down in KO during exhaustion? EGR2 anergy target? 
Nr4a3 Up No 
Cd74 Up Yes (down in KO in anergy) 
Cst3 Up No 
Il18r1 Up No 
Satb1 Up No 
Cbfa2t3 Up No 
Ly6c2 Up No 
Irf8 Up No 
Bach2 Up Yes (down in KO in anergy) 
Il12rb2 Up No 
Ryr1 Up Yes (down in KO in anergy) 
Rab43 Up No 
Kmt2d Up No 
Zeb2 Up No 
Ahnak Up No 
Jun Up No 
Hivep3 Up No 
D1Ertd622e Up No 
Nr4a1 Up No 
Rara Up No 
Utrn Up No 
Kdm7a Up No 
Kmt2a Up No 
Gvin1 Up No 
Gm4070 Up No 
Bcl6 Up No 
Ubr4 Up No 
Ssh2 Up No 
Egr3 Up No 
Parp8 Up No 
Srrm2 Up No 
Btla Up No 
Sh2b3 Up No 
Iqgap2 Up No 
Diaph2 Up No 
Zfp36l1 Up No 
Itpr1 Up No 
Smad3 Up No 
Dnah6 Up No 
Plec Up No 
Mtmr4 Up No 
Birc6 Up No 
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Marcks Up No 
Fbxw7 Up No 
Mycbp2 Up No 
Luc7l2 Up No 
Atrn Up No 
Klrk1 Up No 
Med12l Up No 
Ppp1r15a Up No 
Tox2 Down No 
Egr2 Down* Yes (down in KO in anergy)* 
Izumo1r Down No 
Abcb9 Down No 
Tigit Down No 
Pdcd1 Down No 
Ephx1 Down No 
Rgs1 Down No 
Prr7 Down No 
Ift27 Down No 
Gimap7 Down No 
Hist1h4i Down No 
Galnt2 Down No 
Hist1h4k Down No 
Fasl Down No 
Nab1 Down No 
Prkch Down No 
Hist1h2bf Down No 
Ctsc Down No 
Gpr65 Down No 
Glipr1 Down No 
Cd3d Down No 
Adap1 Down No 
Sub1 Down No 
Hist1h2be Down No 
Chn2 Down No 
Cxcr5 Down No 
Hist1h2br Down No 
 
* In both datasets Egr2 was knocked out, meaning that Egr2 expression was reduced in KO cells in 
both datasets due to gene deletion rather than differential expression 
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Table 4.S4 – Buffers for ChIP-seq analysi 
Buffer Name Recipe 
10X Formaldehyde Cross-Linking Buffer 50mM HEPES-KOH (pH 7.5) 
100mM NaCl 
1mM EDTA 
11% Formaldehyde 
Nuclear Extraction Buffer 20mM Tris-HCl (pH 8.0) 
10mM NaCl 
2mM EDTA 
0.5% IGEPAL CA-630 
ChIP Sonication Buffer 20mM Tris-HCl (pH 7.5) 
150mM NaCl 
2mM EDTA 
1% IGEPAL CA-630 
0.3% SDS 
ChIP Dilution Buffer 20mM Tris-HCl pH 8.0 
150mM NaCl 
2mM EDTA 
1% TritonX-100 
ChIP IP Buffer 20mM Tris-HCl (pH 8.0) 
150M NaCl 
2mM EDTA 
1% TritonX-100 
0.15% SDS 
ChIP Blocking Buffer ChIP IP Buffer 
0.1% BSA 
ChIP Wash Buffer 1 20mM Tris-HCl pH 8.0 
500mM NaCl 
2mM EDTA 
1% TritonX-100 
0.1% SDS 
ChIP Wash Buffer 2 20mM Tris-HCl pH 8.0 
250mM LiCl 
2mM EDTA 
0.5% IGEPAL CA-630 
0.1% SDS 
0.5% Sodium Deoxycholate 
Reverse Crosslinking Buffer 1% SDS 
100mM NaHCO3 
200mM NaCl 
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CHAPTER 5- FINAL DISCUSSION  
 
5.1: Introduction 
 
Molecular checkpoints responsible for limiting the activity of CD8+ T cells are crucial 
in protecting the host from autoimmune disease and immunopathology. In 
comparison to effector-memory differentiation, the molecular pathways that regulate 
CD8+ T cell tolerance and exhaustion are not as well characterised. Furthermore, 
despite the phenotypic similarities between tolerance and exhaustion, the extent of 
overlap between the molecular pathways driving these fates remains unclear. 
Understanding these molecular intricacies is increasingly crucial in the rapidly 
evolving landscape of cancer immunotherapy. While checkpoint blockade has shown 
remarkable clinical efficacy for cancer treatment (478), several autoimmune 
conditions arise as side effects of therapy due to the targeting of molecular 
regulators shared by both tolerance and exhaustion (479). As immunotherapy may 
proceed to becoming the first line of treatment for certain cancers (480), it is 
important to further characterise any potential novel molecular pathways that could 
be exclusively required for CD8+ T cell exhaustion and not in self-tolerance 
processes. Exhaustion-specific pathways would represent better targets for more 
refined therapy approaches that reinvigorate exhausted tumour-specific T cells 
without triggering autoimmune disease. This thesis aimed to characterise the specific 
roles of the TFs FOXO3 and EGR2, and the ubiquitin ligase adaptor molecule 
NDFIP1, in CD8+ T cell tolerance and exhaustion. The results from these studies 
have revealed several new insights into these differentiation states.  
 
Chapter 2 explored the requirement of the TF FOXO3 in the induction of apoptosis in 
self-reactive CD8+ T cells undergoing peripheral deletion. Despite its 
dephosphorylated and thus activated state during tolerance induction, FOXO3 was 
dispensable for inducing apoptosis in CD8+ T cells undergoing deletional tolerance, 
in contrast to its role in effector and exhausted CD8+ T cells. This result supports the 
concept that, at the level of cell survival pathways, cells undergoing tolerance and 
immunity are molecularly separable. Results from Chapter 3 further confirmed this 
concept, as loss of the ubiquitin ligase adaptor protein NDFIP1 did not affect CD8+ T 
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cell effector differentiation during acute infection despite playing an indispensable 
role in the induction of CD8+ T cell anergy. The reasons for these differences in the 
function of FOXO3 and Ndfip1 in tolerance versus immunity are discussed further in 
section 5.2.  
 
Chapter 3 aimed to shed light on the unexplored role of ubiquitin ligases in CD8+ T 
cell tolerance induction given their well-established role in the induction and 
maintenance of CD4+ T cell anergy. The results of this study revealed a previously 
unappreciated antigen dose-dependent role of NDFIP1 in CD8+ T cell tolerance 
induction. Collectively, these data provide the first evidence for the differential control 
of anergy versus deletion of CD8+ T cells at the molecular level. Thus, NDFIP1 acts 
as a checkpoint that prevents responses against high levels of tolerogenic antigen in 
the periphery. As will be discussed later within this chapter, this finding could be 
utilised to create better experimental models to specifically test the contribution of 
anergy to peripheral self-tolerance.  
 
Chapter 4 investigated the role of the TCR-induced TF EGR2, which is critically 
required for anergy induction, in CD8+ T cell exhaustion. The results indicated that 
while EGR2 expression in exhaustion was driven by chronic antigen, possibly in a 
similar manner to anergy, the gene program regulated by EGR2 was distinct 
between exhaustion and anergy. EGR2 was repurposed to play a unique role in 
promoting terminal exhaustion, with these results bearing similarities to the 
repurposing of other effector-linked TFs during exhaustion. Surprisingly, this 
repurposing was not due to chromatin changes in the binding sites of anergy genes, 
indicating that other factors may contribute to altered EGR2 function in exhaustion 
versus tolerance. These results suggest that chronic antigen signals are differentially 
processed into transcriptional outputs in different contexts, even though the proximal 
factors downstream of chronic TCR signals may be shared. These distinctions may 
exist because tolerance and exhaustion likely evolved for fundamentally different 
purposes. We argue that these data collectively highlight important distinctions 
between tolerance and exhaustion, and suggest that these terms should not be used 
interchangeably. The importance of clarifying these definitions is discussed within 
this chapter, along with the implications of the thesis findings for immunotherapy.  
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5.2: Context-specific roles of molecular checkpoints in tolerance versus 
immunity 
 
There is some evidence supporting the notion that tolerance and effector 
differentiation are unique differentiation states utilizing separate molecular pathways 
(234,268,481). Results from this thesis suggested that there are differential functions 
for FOXO3 and NDFIP1 in tolerance and effector differentiation. There are a number 
of potential underlying factors that could have led to these differences.  
 
FOXO3 is differentially required for cell death in tolerance versus immunity despite 
being dephosphorylated and presumably transcriptionally active within tolerant OT-I 
cells (Fig. 2.1). Although it remains controversial whether FOXO3 binds to the Bim 
locus and directly controls apoptosis (137), another possibility for its lack of effect in 
tolerance versus immunity may be the presence of tolerance-specific cell death 
pathways that render FOXO3-dependent Bim induction redundant. Some candidate 
transcription factors that could directly induce Bim include HELIOS and NUR77. 
NUR77 is proposed to play a role in thymic tolerance of CD8+ T cells (482) and both 
TFs are upregulated in CD8+ T cells undergoing deletional tolerance (268). Although 
the involvement of these factors in inducing apoptosis is controversial (483–485), the 
presence of different factors could explain the redundant functions of FOXO3 in 
tolerance versus immunity. Conversely, perhaps specific co-factors or chromatin 
accessibility changes that are only induced during effector differentiation are required 
for FOXO3 to induce apoptotic cell death. Finally, we have not examined the levels of 
total FOXO3 protein during tolerance, so it is possible that there is less FOXO3 
protein present during tolerance. 
 
Results from Chapter 3 indicated that Ndfip1 plays little role in restraining effector 
differentiation during acute LM-OVA and LCMV infections (Figure 3.S4 and 3.S5) 
despite its indispensable role in the maintenance of T cell anergy in response to high 
antigen doses. This difference is particularly surprising given that strong antigen 
signals will also be encountered by differentiating effector T cells in response to 
these systemic infections. One possibility is that NDFIP1 expression is dampened in 
an inflammatory environment. Previous in vitro experiments have indicated that 
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NDFIP1 expression is induced by CD3 and CD28 signaling (344), however it is 
possible that signaling from cytokine receptors such as IL-12R or IFN receptors 
could override these signals and shut down NDFIP1 expression in effector cells in 
vivo. While there are no reliable antibodies to detect NDFIP1 expression by flow 
cytometry, NDFIP1 reporter mice (344) could be used to address the above 
hypothesis. An alternative explanation may be that the function of NDFIP1 is 
irrelevant in immunity. In the peptide anergy model, lack of Ndfip1 resulted in 
increased mTOR and pERK signaling. These pathways are normally impaired in 
anergic cells, and hence augmented signaling via these pathways results in a break 
in tolerance. In the context of effector differentiation, multiple pathways, including co-
stimulatory and cytokine receptors, signal through and activate the mTOR pathway 
(82). As such, loss of NDFIP1 may not influence the magnitude of signalling by these 
pathways since they are already “maxed out” during infection.  
 
Given the antigen-dose dependent role of Ndfip1 in T cell tolerance, it will be 
important to discern whether NDFIP1 regulates CD8+ T cell exhaustion. In the 
context of exhaustion, cells are exposed to sustained high levels of antigen relative 
to cells responding to an acute infection, meaning NDFIP1 may play an 
immunoregulatory role in this context. Furthermore, exhausted cells have 
deficiencies in mTOR signaling that contribute to the exhausted state(393,409), so it 
is possible that NDFIP1 deficiency could rescue mTOR signaling during exhaustion 
in a manner that could influence differentiation. The NDFIP1 deficient krusty mouse 
strain develops systemic inflammation (344) and this would confound any study of 
CD8+ T cell exhaustion. However, Ndfip1 could be conditionally deleted from effector 
CD8+ T cells using GranzymeB-Cre (486) or E8I-Cre (93) (E8I-Cre mice specifically 
express Cre within peripheral CD8+ T cells), and the response to chronic LCMV 
infection could be studied as in the LCMV Cl13 experiments performed in Chapter 4. 
In particular, it would be interesting to assess whether Ndfip1-deficient exhausted 
CD8+ T cells would respond in a similar manner to the anergic counterparts through 
excessive expansion and potentially clearing the infection. Alternatively, NDFIP1 
may regulate exhaustion in a differential manner to its role in tolerance. These future 
studies would help to further understand whether tolerance-specific factors are re-
engaged during exhaustion.  
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5.3: The response to chronic antigen is plastic and context dependent 
 
Chronic antigen engagement is a common feature of multiple states of negative 
regulation. Tolerant cells rely on persistent antigen encounter for durable tolerance 
induction. In particular, removal of cells from antigen results in a failure in peripheral 
deletion (270), although some studies have shown transcriptional and epigenetic 
commitment to a tolerant phenotype that is maintained even after withdrawal from 
antigen (474,481). Similarly, withdrawal from antigen can lead to a restoration of 
function within exhausted CD8+ T cells early during the response, although the cells 
ultimately become committed to an exhausted fate at later time-points (423,453). 
Hence, chronic antigen is a crucial determining factor in the establishment of both 
tolerance and exhaustion. The link between chronic antigen and negative regulation 
is likely because chronic antigen is almost always a signal of a problem with the 
immune response. Chronic antigen will mainly be encountered in two situations. 
First, chronic antigen could arise because the immune response is unable to clear an 
infection. In this situation, maintaining the immune response against the infection 
could lead to fatal immunopathology. Thus, negative regulatory pathways would 
likely evolve in this context to temper the response, such that immunopathology was 
averted but the infection was still contained. Alternatively, chronic antigen encounter 
by the immune system could suggest that the antigen being targeted is either a self-
antigen, or a harmless environmental antigen. In this context, maintaining a 
response against the antigen could lead to autoimmunity or chronic inflammation, 
and in this situation it would be preferable to completely inactivate the response. 
While it may be difficult to distinguish between these two possibilities during 
infection, any antigen chronically encountered during the steady state is almost 
certainly a self-antigen or harmless environmental antigen. We reason that this is 
why tolerance induction to steady-state antigens typically leads to complete 
inactivation of responding cells by either peripheral deletion or anergy. Thus, we 
would speculate that tolerance and exhaustion ultimately evolved for different 
reasons and thus have different end goals. 
 
Our study of EGR2 function within exhaustion represented an opportunity to test 
whether the response to chronic antigen evolves depending on context. The results 
from Chapter 4 indicated that EGR2 expression was indeed sustained by chronic 
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antigen in exhausted virus-specific CD8+ T cells, however its target genes were 
vastly different from those previously identified during anergy. The results from this 
chapter indicated that during exhaustion EGR2 fails to bind to the majority of direct 
EGR2 anergy targets, and even when EGR2 binding still occurs to anergy targets 
(eg. Cblb) it fails to influence gene expression (Figure 4.S6). Thus chronic antigen 
signals possibly engage different downstream pathways in different contexts and 
differentiation states.  
 
The context-dependent role of Egr2 makes sense given that the evolutionary 
purposes of tolerance versus exhaustion are likely different. Egr2 promotes genes 
that drive terminal exhaustion in effector CD8+ T cells. The exhaustion process, 
despite leading to diminished inflammatory function, still contributes to control of 
infections or tumours. On the other hand, Egr2 actively inhibits T cell differentiation in 
anergy through the induction of negative regulators of T cell signaling, such as Dgka 
and Cblb. In contrast to exhaustion, this inactivation process prevents these cells 
from acquiring any effector function to prevent the likely self-reactive responding 
cells from causing autoimmunity. Hence, possibly as a result of these differential end 
goals, chronic antigen signals are processed in a context-dependent manner in 
tolerance and exhaustion as depicted in Figure 5.1. In exhaustion, EGR2 has been 
shown to bind to Pdcd1, Tigit, Bach2 and Bcl6 possibly resulting in its differential 
effect in exhaustion. 
 
 
5.4: Building better mouse models to address unresolved questions in 
tolerance 
 
The peripheral tolerance processes that control self-reactive CD8+ T cells have thus 
far predominantly been explored using transgenic mouse models. While these 
models, where model antigens are expressed under the control of tissue-specific 
promoters, have helped us to understand the peripheral tolerance mechanisms that 
operate upon self-reactive transgenic CD8+ T cell in vivo (233), it is unclear to what 
extent these mechanisms are responsible for controlling endogenous populations of 
those around them are a li                                          
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Tcf7 
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Figure 5.1. Differential downstream functions of transcription factor EGR2 in 
CD8+ T cell tolerance and exhaustion: EGR2 is induced downstream of chronic 
antigen signals in both CD8+ T cell tolerance and exhaustion. EGR2 is crucial in 
driving T cell tolerance by targeting genes such as Cbl-b and Dgkz, which limit TCR 
signaling. However, EGR2 is repurposed in exhaustion, and binds to different gene 
targets such as Pdcd1, Tigit and Tcf7 which drive exhausted cells towards terminal 
differentiation. 
EGR2 
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polyclonal self-reactive T cells. Mouse models that have a genetic predisposition to 
autoimmunity, such as Non Obese Diabetic (NOD) mice (487), can help to identify 
the specific genetic pathways that might normally allow certain populations of self- 
reactive cells to escape tolerance and cause pathology. However, as these mouse 
models typically harbor multiple genetic lesions that disrupt both peripheral and 
central tolerance, it is difficult to use these models to assess the specific contribution 
of peripheral tolerance pathways to the prevention of autoimmune disease. The rapid 
inflammatory disease that ensues upon Treg depletion is arguably one of the few 
pieces of evidence that peripheral tolerance pathways constitutively prevent 
autoinflammatory disease, although it is unclear whether Tregs predominantly 
function in restraining existing effectors or enforcing peripheral tolerance in this 
context (316). While deficiency in cell intrinsic regulators of peripheral tolerance, such 
as PD-1 and CBL-B (294,488), also results in autoimmunity, it is again unclear in this 
model whether this affect is due to the influence of these factors on peripheral 
tolerance alone, or on peripheral and central tolerance (and/or other regulatory 
processes). 
 
Due to the potential caveats of existing data, there are thus a number of key 
unanswered questions within the CD8+ T cell peripheral tolerance field. First, what 
role (if any) do peripheral tolerance processes play in preventing autoimmune 
disease? Did peripheral tolerance mainly evolve to limit responses against harmless 
environmental antigens, or to only serve as a back-up pathway in the event that an 
inherited mutation caused thymic selection deficiencies? Second, what are the 
relative contributions of peripheral deletion and anergy to tolerance maintenance? 
Finally, what types of self-reactive cells (if any) are the main targets of peripheral 
tolerance pathways? Does peripheral tolerance mainly restrain low affinity self-
reactive cells, or does it target high affinity cells specific for antigens not expressed 
in the thymus? Answering these questions requires experimental mouse models 
where the cell intrinsic pathways that regulate peripheral tolerance are selectively 
disrupted in peripheral CD8+ T cells. 
 
The results from Chapter 3 indicated that NDFIP1 is selectively required for CD8+ T 
cell anergy to high dose self-antigens, while being largely dispensable for peripheral 
deletion. Thus, mice in which Ndfip1 is conditionally deleted within peripheral CD8+ T 
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cells (such as could be achieved with an E8I-cre transgene) should have a selective 
defect in peripheral anergy, at least as defined by the peptide anergy model. These 
mice could then be aged to examine whether a defect in peripheral anergy results in 
autoimmune disease, and/or expansion of self-reactive T cells clones (as assessed 
by TCR repertoire profiling). This proposed mouse model would provide, to our 
knowledge, the first opportunity to directly test how anergy contributes to CD8+ T cell 
self-tolerance within an endogenous repertoire. If no autoimmune phenotype is 
observed in these mice, then further work could be done to determine whether 
anergy instead contributes to tolerance in other situations, such as tolerance to food 
or environmental antigens, or fetomaternal tolerance. We suggest that targeted 
models such as this are needed to determine the physiological contributions of 
peripheral tolerance processes to immune homeostasis. 
 
 
5.5: A question of semantics: is there a need to develop better 
nomenclature around T cell exhaustion and tolerance? 
 
There is currently a plethora of definitions used to describe the differentiation states 
that T cells adopt when they lose effector functions. These include terms such as 
hyporesponsive, dysfunctional, senescent and sub-optimal, in addition to existing 
terms used in this thesis such as tolerance, anergy and exhaustion. A major 
challenge for the field is that these terms are often poorly defined and/or have 
different meanings within the scientific community. The net result is that these terms 
are either used interchangeably, or the same terms are used to describe different 
states in different studies. The original papers describing the exhausted state 
(351,352), where the terms “exhaustion” and “anergy” were used interchangeably, 
perhaps best exemplify this problem. There is thus a need to develop a standardized 
system of classifying states of negative regulation. Part of the complication 
surrounding definitions is that even for established terms such as anergy and 
exhaustion, which have both existed for almost 30 years, their definitions have 
evolved over time. Exhaustion initially was used to describe the disappearance of 
virus-specific CTLs during chronic LCMV infection (351), but later evolved to 
describe the persistence of virus-specific T cells with diminished effector functions 
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during chronic LCMV infection (352). Similarly, classical in vitro “anergy” was 
subsequently extended to describe in vivo models of tolerance and tolerant human 
self-reactive T cells (273). Can these terms be extrapolated for use in other contexts 
of CD8+ T cell restraint? There is now evidence that tumour-reactive cells display 
similar phenotypic features to exhausted cells during LCMV infection, with 
functionally and phenotypically similar “exhausted memory” and “terminally 
exhausted” subsets also evident within tumour-reactive T cells (377,461). 
Nevertheless, there are still clear differences between the transcriptional profile of 
exhausted cells and TILs (489,490), suggesting that there are at least some 
differences between these states. Thus, there needs to be a consensus on how 
these states can be defined and further extended to accommodate all scenarios 
where diminished CD8+ T cell function may occur.  
 
Any new system of nomenclature would have to first create new terminology with 
carefully constructed definitions to replace existing terms. Similar approaches to 
revise classification and nomenclature of cell subsets have been successful within 
the ILC and DC fields (50,491). As in these two examples, the creation of this 
nomenclature system would have to be a collaborative process, involving consensus 
from leaders within the field. New terminology is important, as simply redefining 
existing terms is unlikely to remove the ambiguity that would continue to be attached 
to them due to their long and complicated history (eg. anergy and exhaustion). 
 
Second, the classification system would have to be carefully considered to avoid 
future ambiguity. For example, defining a state of negative regulation based on the 
specificity of the responding cells would be problematic given that self-reactive cells 
can be restrained by exhaustion (492) and that cells specific for foreign antigens 
(such as food and commensal antigens) can undergo peripheral tolerance (214,215). 
Molecular similarities and differences between states could be used as a starting 
point for reclassification, although as this is somewhat of a continuum, relying solely 
on molecular signatures may also ultimately cause problems. Perhaps the simplest 
classification system would be based on the point during the immune response at 
which responding T cells lose effector function (ie. the kinetics of negative 
regulation). For example, perhaps cells that fail to differentiate into effector cells 
and/or only minimally and transiently acquire effector functions early during 
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the”immune response prior to being rapidly shutdown (such as occurs within 
peripheral tolerance models) would be classified as undergoing “Class I negative 
regulation” or a “Class I checkpoint”. In these situations, cells would also typically 
never acquire the capacity to infiltrate inflamed tissues. This checkpoint could be 
subdivided into cells that persist in an “anergic” state (Class Ia) or undergo apoptotic 
death (Class Ib). In contrast, cells that undergo negative regulation after initial 
relatively normal effector differentiation over the first 5-7 days of the response prior to 
a gradual and progressive loss of inflammatory function would be said to undergo a 
“Class II checkpoint”. This would encompass exhausted cells within tumours and 
during chronic viral infection. It may be possible to sub-divide this checkpoint into 
“Class IIa” and “Class IIb” based on phenotypic markers that distinguish exhausted 
cells in responses against chronic infections and tumours.  
 
This classification system would largely align with both the published molecular 
profiles associated with these states, and the functional distinctions highlighted by 
this thesis (Figure 5.2). Nevertheless, ambiguities still exist even within this proposed 
system. Where is the dividing line between when something is classified as “Class I” 
and “Class II”, and will defining a specific point during the immune response 
ultimately cause further problems? Moreover, a recent study within a transfer 
tolerance model suggested that persistent anergic CD8+ T cells adopt a gene 
signature with similarity to TILs (474). How would these cells be classified? Perhaps 
additional information on the epigenetic state of the cells would better help classify 
cells, given the strong similarities between TILs and exhausted cells from LCMV in 
this regard (467). Either way, overhauling the current nomenclature system is an 
important priority for the field. 
 
 
5.6: Significance of thesis findings and implications in the clinic.   
 
As mentioned earlier, targeting molecular checkpoints in exhaustion during cancer 
immunotherapy has led to remarkable efficacy against multiple cancer types (368). 
Many of these therapies are thought to work by releasing the “brakes” on exhausted 
T cell differentiation state  
Naïve T cell  
CLASS I 
Effector T cell  
CLASS II 
Anergy 
Class Ia 
Deletion 
Class Ib 
? 
Class IIa 
?  
Class IIb 
Figure 5.2. Proposed nomenclature system for negatively regulated CD8+ T 
cell differentiation states: The proposed system suggests that negatively 
regulated processes should initially be classified depending on the target T cell 
differentiation state. If the target CD8+ T cell population is a naïve cell, then it will be 
classified as Class I immunoregulation, while if the target population is an effector 
cell, the process will be classified as Class II immunoregulation. Both of these 
classes can be further categorised into a and b subdivisions based on the specifics 
of the cell phenotype. For example, anergy can be classified as Class Ia while 
peripheral deletion will be classified as Class Ib. Similar classification in Class II 
could also be based on phenotypic outcomes of the cells in the tumor environment 
or in chronic infections. However the current understanding of phenotypic variation 
between exhaustion responses to different viruses and tumor types is limited, 
although a classification based on phenotypic outcomes could be used in the future.  
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CD8+ T cells and thereby “reinvigorating” the anti-tumour response. However to 
avoid autoimmune side effects downstream of therapy (479), it is important to find 
therapeutic targets that disrupt exhaustion within tumour-specific CD8+ T cells while 
leaving self-tolerance processes intact. The data from this thesis indicates that 
tolerance is molecularly separable from effector differentiation as seen from the 
unique roles of FOXO3 and NDFIP1 in these states. Furthermore, results from 
Chapter 4 indicate that the manner in which negative regulatory pathways are 
“wired” during tolerance and exhaustion may be fundamentally different. Hence, 
given that there is evidence of molecular differences between these two states, 
future research on new molecular targets for immunotherapy should examine the 
feasibility and efficacy of targeting pathways that only operate in the exhaustion 
setting. Nevertheless, it is unclear whether this would prevent autoimmune disease. 
It has been shown that exhaustion likely acts as a “last resort” checkpoint to prevent 
autoimmune disease in some patients. It is thus possible that disrupting exhaustion 
rather than peripheral tolerance processes is the reason for the autoimmune side 
effects of therapy. In this scenario, autoimmune disease would only be triggered 
within patient subsets that already have peripheral tolerance defects that result in 
sub-clinical disease associated with an existing pool of self-reactive exhausted T 
cells. 
 
Another potential problem with an exhaustion-targeted therapeutic approach is that 
disruption of peripheral tolerance to tumour antigens could contribute to the efficacy 
of current immunotherapy approaches. Clinical data identifying patients that respond 
to immunotherapy have suggested that exhausted CD8+ T cell infiltration of the 
tumour is required for treatment efficacy (493,494). Given that tolerant cells often fail 
to infiltrate target tissues, this suggests that therapies are more likely to operate 
through disruption of exhaustion rather than tolerance. Nevertheless, peripheral 
tolerance to tumour antigens has been observed within the tumour draining lymph 
nodes in mouse models (494) raising the possibility that disrupting this pathway may 
amplify the response and contribute to efficacy. Furthermore, a recent case study 
indicated that the pathways that contribute to autoimmunity and anti-tumour 
responses may in fact be shared during checkpoint blockade. While most 
autoimmune adverse events are treated with a standard therapy of short-term 
immunosuppression, treating therapy-induced colitis in a colorectal cancer patient 
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with an anti-IL-17 monoclonal antibody resulted in relapse of the cancer (496). Thus, 
there is a need to further define the degree to which disrupting peripheral tolerance 
versus exhaustion contributes to treatment efficacy in the context of cancer 
immunotherapy. Models such as Ndfip1 deletion within peripheral CD8+ T cells could 
be used to examine whether peripheral anergy contributes to tumour control. 
 
Apart from shedding light on the potential molecular overlap between tolerance and 
exhaustion, results from this thesis could be applied in the genetic engineering of 
immune adoptive cell therapy approaches for cancer treatment, such as the recently 
approved Chimeric Antigen Receptor (CAR)-T cells. CARs are engineered to be 
modified immune receptors that couple extracellular antibody-mediated recognition of 
an antigen to the intracellular signaling domain of both the TCR and co-stimulatory 
receptors (497). When cancer patients are treated with CAR T cells, cultured T cells 
from patients are transduced with plasmids containing a CAR that redirects the T 
cells towards a surface protein on the cancer (498). As these cells are already 
manipulated genetically during CAR insertion, there is scope for concurrently 
introducing other genetic manipulations (via, for example, CRISPR/Cas9 gene 
editing) that enhance CAR T cell function against the cancer. This is an area of active 
research, as while CAR T cells have demonstrated efficacy against blood cancers 
(498), they have not worked well against solid tumours (499). 
 
While the reasons for this lack of efficacy are likely multifactorial, exhaustion of the T 
cell response likely contributes to lack of efficacy (499). A number of future questions 
relevant to CAR T cells are raised by the results within this thesis. First, would Ndfip1 
deletion in CAR T cells result in increased proliferation and improved efficacy against 
solid tumours? Could deletion of Egr2 in CAR T cells boost the proportion of TCF1+ 
cells, thereby augmenting the CAR T cell response to checkpoint blockade? On the 
other hand, it is also crucial to understanding immune tolerance mechanisms and 
how they affect treatment of autoimmune disease treatment. Is it really possible to 
restore tolerance in autoreactive T cells? These questions are becoming more 
relevant as the there is an increase in the incidence of autoimmune disease from 
immunotherapies. Answering these questions could reveal practical therapeutic 
applications for the results from this thesis. 
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